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Abstract: Malaria is an ancient vector-borne disease that still has a 
huge impact on global health. Malaria pathogenesis is developed during 
the asexual intraerythrocytic stage where P. falciparum modifies the host 
erythrocytes by exporting repertoires of parasite proteins on to the 
surface of infected erythrocytes. PfEMP1 is one of these proteins that 
mediate different functions including the adhesion of IEs to the host 
receptors such as CD36, ICAM-1 and EPCR. The current study has 
characterised the adhesion of infected erythrocytes with different 
PfEMP1 variants to CD36, ICAM-1 and primary endothelial cells. The 
characterisation was carried using static protein and flow endothelial 
adhesion assays. First, the characterisation involved an analysis of the 
binding of recently selected ICAM-1 binding P. falciparum patient isolates 
on different ICAM-1 variants. The results showed that different isolates 
have variant-specific binding phenotypes suggesting that there might be 
variable contact residues on ICAM-1 being used by different parasite 
PfEMP1 variants. This observation was more emphasised by the 
adhesion of isogenic isolates that has been confirmed to express ICAM-1 
binding domain from IT4 parasites. The second part of the study has 
characterised the adhesion of IEs with upsC PfEMP1 isolates from HB3 
and IT4 isolates on CD36, ICAM-1 and endothelial cells. Three upsC IT4 
isolates bound to CD36 and one of these isolates bound to ICAM-1 
because it expresses DBLβ-ICAM-1 binding domain. In contrast, HB3 
upsC isolates did not show preferential binding to CD36, ICAM-1 and the 
endothelial cells despite showing cross reactivity with adult hyperimmune 
sera. Finally, the adhesion of IEs with different length PfEMP1s was 
analysed. It was concluded that long PfEMP1 adapted to bind efficiently 
the short, but this might be due to the lack of variety of DBLs for 
adhesion in the short forms. Therefore, it is suggested that it is the 
domain constitution rather than size that seems to be important.  
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1. Malaria: 
1.1 Disease overview:  
Malaria is an ancient vector-borne disease that still has a huge impact on 
global health. It is one of the leading causes of death in countries with 
limited resources.  It was described historically in a Chinese document 
from about 2700 BC. Also, there are other early documents describing 
malaria after that, but these need extra care when dealing with them 
(Cox, 2010). However, Hippocrates, in about 400 BC, was able to 
differentiate between “tertian” malaria fevers and “quartan” fevers on the 
basis of disease severity (Haldar et al., 2007).  
Historically, the reason behind the word “malaria” derives from the Italian 
“mal ’ aria” meaning “bad air” because it used to be thought that the 
cause  of  malaria was miasmas  arising  from  marshes. However, this 
was controversial until significant advancements in malaria research 
permitted the identification of the causative agent and the transmission 
vector at the end of 19th century. The identification of malaria parasites 
was by Charles Laveran, a French army surgeon, in 1880, and the 
identification of mosquitoes as transmission vectors was by Ronald Ross 
in 1897 (Cox, 2010). The evolutionary worldwide symbiotic relationship 
between humans and malaria parasites is estimated to have begun in 
Africa about ten thousand years ago (Hay et al., 2004). 
There are six species that cause human malaria;  P. falciparum, P. vivax, 
P. malariae, two distinct forms of P. ovale (Sutherland et al., 2010) and 
recently P. knowlesi has been found increasingly infecting humans 
especially in Malaysia (William et al., 2013). P .falciparum accounts for 
90% of mortality caused by malaria worldwide.  
World Health Organisation (WHO) estimated 3.2 billion people are at risk 
of malaria and  198 million cases of malaria occurred overall the world in 
2013 (WHO, 2014). However, there is a discrepancy about malaria 
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mortality and morbidity reports most likely due to the measurement tools. 
In 2013, WHO estimated 584,000 deaths worldwide. In contrast, a 
systematic review in The Lancet reported deaths cases were about twice 
as much as stated by WHO in 2010 (Murray et al., 2012, Lozano et al., 
2012). Most malaria deaths occur in children under five years old in 
Africa.  
However, most cases were asymptomatic carriers that cause a major 
concern for malaria elimination programmes by facilitating continuous 
transmission by the mosquitoes. Along these lines, it has been noticed 
that malaria burden is shifting from the typical susceptible populations of 
young children and pregnant women to older children and adults (Cotter 
et al., 2013).  
Considering the huge efforts towards malaria elimination programmes 
(Figure: 1.1), malaria mortality rate was reduced by about 47%, and 
incidence rate was decreased by 30% around the globe between 2000 
and 2013 (WHO, 2014). Four countries have been certified as malaria 
free by the WHO since 2007 (WHO, 2013). Nowadays, many countries 
are trying to be certified as “malaria eliminated country” , including the 
Kingdom of Saudi Arabia (KSA) (Cotter et al., 2013). Saudi governmental 
efforts to control malaria started about 20 years after the foundation of 
the KSA in 1932. In 1963, KSA joined the WHO malaria eradication 
programme. KSA has succeeded to restrict malaria to its two main 
southern regions, Aseer and Jazan, which share borders with Yemen. 
Since 1990, Saudi government started to categorise the cases as 
indigenous or imported. There were outbreaks in the late 1990s, the 
worst in 1998. In 2004, the Kingdom re-established malaria control 
programme towards elimination status in 2015. Since then, the 
endogenous cases have continued decreasing to very low number, for 
instance, just 82 cases in 2012. However, this target is faced by many 
challenges, first of which is the imported cases, particularly with the 
current political disturbance taking place in Yemen, which is closed to the 
Saudi border. It is not surprising that local cases did increase in 2011 and 
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2012. The second problem is the rise of vivax malaria cases, which are 
less responsive to control than falciparum infections. It is believed that 
the economic development and improved health system have contributed 
to the current status of malaria in KSA (Coleman et al., 2014).  
 
Figure 1.1: Classification of countries by stages of malaria elimination, as of 
December 2013. The map was created using WHO global malaria mapper. 
Lastly accessed on October 17, 2014 http://worldmalariareport.org/ 
1.2 Important clinical definitions: 
Individuals infected by malaria experience different clinical outcomes. In 
early life, it usually starts with severe symptoms; approximately 10% of 
children develop symptoms of severe malaria with different pathological 
effects. Then, as individuals develop immunity to the severe 
manifestations they only suffer from mild disease or even can be as 
asymptomatic hosts, especially in highly endemic areas such as Sub-
Saharan Africa.  
1.2.1 Uncomplicated malaria (UM):  
Generally, signs range from fever followed by headache, fatigue, muscle 
pains, and abdominal discomfort. Vomiting, nausea, and orthostatic 
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hypotension are also commonly associated with malaria (White et al., 
2014).  
1.2.2 Severe malaria (SM): 
Generalised seizures in severe malaria caused by P. falciparum are 
associated with age dependent manifestations, especially in areas of 
high- transmission. It is worth clarifying that for concepts of SM there is 
unlikely to be a simple association between the clinical syndromes and 
the pathogenic mechanisms (Miller et al., 2002, White et al., 2014).  For 
example, SM in children involves three overlapping syndromes: cerebral 
malaria, metabolic acidosis/ respiratory distress and severe anaemia. In 
adults, jaundice, acute renal injury and acute pulmonary oedema are 
more common and cerebral malaria and acidosis also occur. In the 
absence of early and proper clinical management death can result from 
severe manifestations and about 0.1% of the uncomplicated falciparum 
malaria cases die eventually (White et al., 2014, WHO, 2013).  
1.2.2.1 Severe anaemia: 
Malaria is the major cause of severe anaemia of in young children, 
particularly in high transmission areas. It is defined as haemoglobin 
concentration < 5 g/dl in the presence of P. falciparum parasitemia (Calis 
et al., 2008). Malarial anaemia results from the lysis of infected 
erythrocytes (IEs) to release new generations of merozoites, destruction 
of uninfected erythrocytes by unknown mechanism and reduced 
erythrocyte production and/or inadequate erythropoietic response. This is 
often followed by fever and chills, and the typical description of fever 
based on the cycle of the parasites may not be valid in the case of P 
.falciparum, which is usually asynchronous at least during the first days 
of illness (White et al., 2014).  
1.2.2.2 Acidosis and hypoglycaemia: 
Acidosis is one of the lethal manifestations associated with severe 
malaria. The acidotic breathing is considered as a bad prognosis 
5 
 
indicator in severe malaria patients. It is caused by the accumulation of 
organic acids, mainly lactic acid. Lactic acidosis is usually connected with 
hypoglycaemia, in children and pregnant women particularly (White et al., 
2014).  
1.2.2.3 Cerebral malaria:  
Cerebral malaria (CM) is a complication of severe malaria. It is identified 
as the patient being in a coma, parasitaemia, Blantyre coma score ≤ 2 
with the absence of other coma causes. Recent clinical observations 
have shown that infected humans with CM have marked retinopathy that 
has facilitated the diagnosis of this syndrome, reaching 95% sensitivity 
and 90% specificity in comparison with previous results using the gold 
standard examining autopsy samples (Beare et al., 2006). CM is often 
associated with a high mortality rate in malaria among other malaria 
outcomes (WHO, 2013).  
1.3 Life Cycle: 
1.3.1 Mosquito stage:  
Female Anopheles mosquitoes transmit malaria during feeding on hosts’ 
blood to use proteins for egg synthesis (Figure: 1.2). In malaria 
transmission regions individuals often carry the sexual forms of the 
parasites, gametocytes. During the blood feed, IEs with the gametocytes 
move into mosquitoes’ gut where the erythrocytes are digested, and 
gametocytes released and developed into male and female gametes. 
Then, both gametes fuse to form diploid zygotes, which turn into  motile 
forms called ookinetes that travel into the mosquito midgut wall and 
transform into oocysts. Inside the oocysts the human infectious forms, 
sporozoites, are formed. Once the oocysts rupture, sporozoites invade 
the body cavity of the mosquito and migrate to the salivary glands, 
whereby, they  infect humans during another feed on a human blood 
meal. The life cycle inside the mosquito has been recently reviewed by 
(Smith et al., 2014).  
6 
 
 
 
Figure 1.2: The life cycle of P. falciparum in human and mosquito. 
1.3.2 Pre-erythrocytic stage:  
In humans, injected sporozoites transform into merozoites, the 
erythrocyte invading form, in a growth phase known as the pre-
erythrocytic stage. After a mosquito blood feed, sporozoites pass through 
the skin layer into either the blood stream, and thereby hepatocytes, 
where they multiply, or local lymph nodes where most of them probably 
die (Amino et al., 2006). In fact, recent studies showed that sporozoites 
in mice can stay at the bite sites for a few hours and can transform into 
merozoites in the epidermis and dermis and are able to invade 
erythrocytes (Gueirard et al., 2010). In P. falciparum, sporozoites invade 
hepatocytes and can produce thousands of daughter merozoites within a 
week in a hepatic schizont. However, non-falciparum species, such as P. 
vivax malaria parasites, can stay longer in the liver as a dormant form 
known as a hypnozoite (Wells et al., 2010). Once the hepatic schizonts 
rupture, released merozoites invade erythrocytes to start the erythrocytic 
cycle. 
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1.3.3 Erythrocytic stage: 
The erythrocytic stage begins when the merozoites invade erythrocytes 
and develop into ring forms, mature trophozoites, and develop into 
schizonts before releasing a new generation of infective merozoites. 
Erythrocytic stage duration varies depending on the transmitted species; 
it takes 48 hours for P. falciparum, P. vivax, and P. ovale, 72 hours for P. 
malariae, and 24 hours for P. knowlesi. The clinical signs and symptoms 
of malaria become detectable during this stage (White et al., 2014). 
However, some IE differentiate into gametocytes, the vector transmission 
stage.  The signal for development to gametocytes is not understood (Liu 
et al., 2011) but may involve density dependent mechanisms.  Indeed, 
preventing disease symptoms is one of the targets for malaria 
management programmes. Different studies have been extensively 
conducted to explore proper targets for alternative therapeutic 
interventions due to the spread of drug resistance to the available drugs 
in the field and lack of effective vaccines (Miller et al., 2013). Targeting 
the erythrocytic stage is essential not only to prevent the disease but 
possibly to inhibit transmission (or at least the production of 
gametocytes) as well. Therefore, the focus of the following sections is to 
highlight some alterations occuring to erythrocytes upon infection with P. 
falciparum and the contribution of these alterations to malaria 
pathogenesis.   
 
1.3.3.1 Erythrocytes: 
An erythrocyte is about 7-8 µm diameter, often considered as a simple 
cell that lacks organelles and transports oxygen and carbon dioxide by 
haemoglobin that occupies most of the cell (Fowler, 2013). In addition, it 
has a plasma membrane with uniform structure across the whole surface. 
The erythrocyte plasma membrane is strong and flexible to allow the 
movement smoothly through blood vessels (Mohandas and An, 2012, 
Fowler, 2013). The plasma membrane is supported by the membrane 
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skeleton, which is a network of long strands of α1 and β1 spectrin 
tetramers , interconnected by actin filaments forming a 2D hexagonal 
array (Fowler, 2013). Erythrocytes are regularly filtered in the spleen, 
thus, they are removed from the circulation often when they are over age 
of the life span of about 120 days, or the membrane loses its ability to 
move in the circulation (Mebius and Kraal, 2005). 
1.3.3.2 Infected Erythrocytes (IEs):  
Changes to the erythrocyte membrane are thought to take place soon 
after the initial contact between an erythrocyte and parasites (Hanssen et 
al., 2010b). The time estimated between the released merozoites to 
come in contact with erythrocytes is in the order of a few seconds. 
Merozoites have apical organelles that secrete products to promote host-
cell invasion (Sam-Yellowe, 1996). Erythrocyte invasion by Plasmodium 
merozoites involves multi-step interactions between the parasite and 
erythrocytes by specific proteins. Initially, merozoites adhere to the 
erythrocyte plasma membrane in a reversible process. The adherence 
involves different receptors on erythrocytes and parasites; proteins on 
parasites at this stage are termed Merozoite Surface Proteins (MSPs) 
(Farrow et al., 2011). For example, Erythrocyte Binding Antigen (EBA) 
and Rhoptry (Rh) families are the most important families among MSP 
families. In two studies in 2010, EBA175 was found to bind sialic acid 
residues of Glycophorin A on the erythrocyte surface but sialic acid was 
not involved in binding between PfRh4 and complement receptor 1 (CR1) 
(Spadafora et al., 2010, Tham et al., 2010). After the initial binding, the 
merozoite reorients itself so that the apical tip points towards the 
erythrocyte. Then, the tight junction between merozoites and 
erythrocytes is formed and the attachment becomes irreversible at this 
stage. This process is facilitated by the interactions of two proteins 
MTRAP and AMA1. This stage is completed by a fully enveloped 
merozoite within a parasitophorous vacuole inside the erythrocyte, but it 
is still attached to the erythrocyte plasma membrane. The final step is the 
migration of the tight junction complex towards the erythrocyte. It is 
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assumed that the orthologous myosin, PfMyoA, is responsible for entry of 
P. falciparum merozoite into the erythrocyte (Farrow et al., 2011). Then, 
the parasite develops within a parasitophorous vacuole (PV) and it is 
freely motile inside the vacuole. After 12 hours, the parasites differentiate 
to the ring form and can be seen in peripheral blood (Langreth et al., 
1978, Bannister et al., 2000, Tilley et al., 2011).  
1.3.4 Intraerythrocytic Developmental Cycle of P. falciparum: 
During the cycle, the parasite needs to consume nutrients and then 
discard waste substances. This is not easily carried out inside 
erythrocytes that lack essential organelles. The parasite has to fulfil its 
growth requirements by exporting numerous proteins to the host cell 
cytoplasm and subsequently, in later stages, to the membrane (Bannister 
et al., 2004, Hanssen et al., 2010b). Several proteins are exported 
including kinases, lipases, proteases, chaperone-like proteins, and 
adhesins. This eventually remodels the IE and in turn reduces the IE 
membrane deformability and increases the permeability of the host cell 
membrane (Goldberg and Cowman, 2010, Glenister et al., 2002, Maier et 
al., 2009).  
1.4 Host cell remodelling: 
IEs remodelling is mediated by an array of diverse parasite-encoded 
export proteins that traffic within IE. These remodelling proteins 
extensively modify the cytoskeleton and membrane of IE and help in the 
formation of parasite-induced novel organelles such as 'Maurer's Cleft, 
tubulovesicular network, and parasitophorous vacuole membrane (PVM); 
these organelles have been called exomembrane system (Hanssen et 
al., 2010a). Of these organelles, Maurer’s Clefts have been described to 
have a role in the export of virulence proteins (Tilley and Hanssen, 2008).  
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 Figure 1.3: The membrane skeleton in uninfected and Plasmodium falciparum- 
infected red blood cells. a) Uninfected erythrocytes. Spectrin dimer repeat units 
form tetramers by joining actin and are stabilised by protein 4.1R and other 
molecules and anchored vertically by two junctions. b) Infected erythrocyte. In 
the early stage, RESA is linked with spectrin to stabilise the membrane 
skeleton. In later stage, KAHRP interacts with spectrin with other molecules that 
might be involved in PfEMP1 exportation to surface of IEs, which is 
demonstrated in the next figure. The figure is cited from (Maier et al., 2009). 
1.4.1 Maurer’s Clefts: 
One of the the major components of the exomembrane system is Golgi-
like organelles called Maurer's Clefts. The Maurer’s Clefts were first 
characterised by Georg Maurer, using light microscopy in 1902 
(Mundwiler-Pachlatko and Beck, 2013). Maurer's Clefts bud from PV 
membrane into the IE cytoplasm, and they attach to IE membrane by 
specialised tubular structures (Hanssen et al., 2010a). Although little is 
known about the function of Maurer’s Clefts, they transiently localise 
some surface proteins prior to the arrival to their final (often membrane) 
destinations. There is an array of surface exported proteins forming 
protrusions that are called knobs that mediate significant roles for 
parasites development, survival and pathogenesis. 
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1.4.2 Knobs: 
The remodelling proteins of P. falciparum specifically bind and modify 
natural interactions of the erythrocyte cytoskeleton proteins. The major 
remodelling proteins of P. falciparum are ring exported surface antigen 
(RESA), knob-associated histidine rich protein (KAHRP), Plasmodium 
falciparum erythrocyte membrane protein-3 (PfEMP3), mature-parasite-
infected erythrocyte surface antigen (MESA) and Plasmodium falciparum 
erythrocyte membrane protein-1 (PfEMP1).  
Once the merozoite occupies the erythrocyte, it produces immediately 
Pf155 protein also called ring-infected erythrocyte surface antigen 
(RESA). It interacts with spectrin to bind the erythrocyte membrane 
(Deloron et al., 1987, Aikawa et al., 1990). It has been found that RESA 
strengthens erythrocyte membrane (Silva et al., 2005, Pei et al., 2007). 
Several findings suggested different roles for RESA. It was suggested to 
have a role in enabling the flow of ring infected erythrocytes (RIEs) 
through capillaries, and can protect IEs from damage caused by fever 
(Pei et al., 2007). Also, it can protect RIEs from new invasion by other 
merozoites and some chemicals including antimalarial drugs (Orjih and 
Cherian, 2013). RESA can be detected by specific antibodies in infected 
individuals with P. falciparum (Kabilan et al., 1994, Genton et al., 2003).  
The plasma membrane of IE is interrupted by protrusions known as 
knobs. One of the main components of the knobs is knob-associated 
histidine-rich protein (KAHRP). KAHRP interacts with the RBC 
membrane skeleton to form the knobs (Aikawa et al., 1985, Waller et al., 
1999). KARHP alters IE cytoskeleton by interacting with spectrin and 
actin (Kilejian et al., 1991, Chishti et al., 1992) and also with ankyrin. 
KAHRP binds to repeat 4 of α-spectrin. Although KAHRP–α-spectrin 
association has no effect on the membrane mechanical properties, 
interaction of KAHRP with spectrin is required for the proper assembly of 
KAHRP into the knob complex found at the erythrocyte membrane (Pei et 
al., 2005). Recently, the interaction with ankyrin R was found to be 
necessary for the attachment of KAHRP to the host cell membrane 
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(Weng et al., 2014). KAHRP accumulates on the cytoplasmic face of the 
membrane. KAHRP is required for knob formation and thus for efficient 
IE cytoadherence (Crabb et al., 1997).  
1.4.3 PfEMP3:  
It is a protein linked to the cytoplasmic face of the RBC membrane in the 
trophozoite stage of the IE. PfEMP3 interacts with spectrin adjacent to 
the actin–protein 4.1R junction, disturbing the spectrin–actin–4.1R 
complex, and it may well contribute to deformability loss in mature IE. It 
was shown that PfEMP3 and KAHRP account for major rigidity of IE with 
51% of lost deformability dependent on these proteins (Glenister et al., 
2002).   
There are other proteins included in IE remodelling and several reviews 
have updated the recent findings about IE remodelling (Maier et al., 
2009). Although PfEMP3 has no impact for PfEMP1 surface expression, 
higher expression of a truncated form of PfEMP3 changes the form of 
Maurer's cleft and subsequently prevents PfEMP1 trafficking (Maier et 
al., 2009). 
1.5 PfEMP1: 
The uniqueness of P. falciparum virulence among other Plasmodium 
species that infect humans is thought to be due to the expression of 
Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1). It 
was identified in 1984, through the use of radioiodination and 
immunoprecipitation with isolate specific immune sera (Leech et al., 
1984). PfEMP1 is a variable, high molecular weight and trypsin sensitive 
protein. PfEMP1 was immunoprecipitated by strain specific sera from a 
homologous strain but not from others. Moreover, the binding of 
homologous IE to endothelial cells was blocked by strain specific sera as 
reviewed by (Sherman et al., 2003, Kraemer and Smith, 2006). From 
these observations, it was concluded that PfEMP1 is an immunogenic 
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molecule that mediates antigenic variation and sequestration (details 
about these PfEMP1 roles found in section 1.7, 1.8 and 1.9).  
PfEMP1 features are summarised in box 1. It should be noted that there 
are several proteins exported to IE surface including RIFINs and 
STEVORs, but their roles in malaria pathogenesis are less understood (a 
brief description about them can be found in later sections). 
PfEMP1: 
 The most extensively studied of variant surface antigen (VSA). 
 A high-MW protein (200-350 kDa) 
 Sensitive to trypsin treatment. 
 Immunogenic, (immunoprecipitated with immune sera). 
 Encoded by highly diverse var gene family members. 
 Expressed as a single member as commonly known on the IE 
surface at a given time through mutually exclusive transcription. 
 Mediate sequestration in the vital organs. 
   Box 1: Summary of PfEMP1 key features.  
1.5.1 PfEMP1 export to the IE membrane: 
There are several alterations that occur in the IE including changes in ion 
channel behaviour (Decherf et al., 2004, Bouyer et al., 2006), and the 
development of new channels to enable nutrient delivery to the parasite 
(Saliba et al., 1998, Biagini et al., 2004), however, these alterations are 
beyond the theme of this thesis. Changes of interest include cell 
deformability due to the membrane rigidity (Glenister et al., 2002, Cooke 
et al., 2014) and the effect on the microcirculation (Diez-Silva et al., 
2012, Boddey and Cowman, 2013).  
The parasite’s proteins have many membranes to cross to reach the 
surface of IE (Marti and Spielmann, 2013). Two export pathways have 
been suggested: one is channel mediated and the other vesicle 
mediated, with the latter thought to mediate PfEMP1 export although the 
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evidence for this is incomplete. Protein export starts in the parasite 
endoplasmic reticulum (ER), crossing the parasitophorous vacuole 
membrane (PVM) approaching two destinations; IE cytosol and 
cytoskeleton or to membranous structures such as Maurer's Clefts and 
its outer surface (Prajapati et al., 2014).  
Recently, one potential trafficking pathway to the cytosol of IE and its 
components has been identified and called Plasmodium translocon of 
exported proteins (PTEX) (de Koning-Ward et al., 2009) (Elsworth et al., 
2014b). It is responsible for the export of many proteins, although there 
are other proteins that are transported independently of PTEX and this 
group is known as PTEX negative exported proteins (PNEPs), among 
which is PfEMP1 (Boddey and Cowman, 2013).  
The export processes are not fully understood but we know several 
details. It initiates at about 16 h post-invasion. Vesicular budding from 
Maurer's clefts followed by PfEMP1 fusion with the IE membrane are 
proposed mechanisms (Boddey and Cowman, 2013). The Maurer's 
Clefts are generated at an early stage in the erythrocytic cycle and are 
highly mobile before attaching under the IE membrane by 16 - 20 h after 
invasion (Gruring et al., 2011, McMillan et al., 2013). It is thought that 
electron dense filaments called tethers lead to this attachment between 
the Maurer's Clefts and the IE membrane (Hanssen et al., 2010a, 
Elsworth et al., 2014a). Also, as mentioned above, alteration of host actin 
contributes to Maurer's Clefts immobilization. One tether protein is called 
MAHRP2 and there may be some other unidentified proteins contributing 
to this process (McMillan et al., 2013). The trafficking of PfEMP1, KAHRP 
and PfEMP3 come through the Maurer's Clefts to the IE adhesive knobs 
(Wickham et al., 2001). Some reports have found some Maurer's Clefts 
proteins including PfEMP1 are soluble before the membrane 
localizations. It was supported by the time course between the Maurer's 
Clefts synthesis and the expression of PfEMP1. The solubility of the 
exported proteins to Maurer's Clefts suggests a role for chaperones to 
keep them in this state (Papakrivos et al., 2005, Gruring et al., 2011), for 
15 
 
instance, Hsp40 proteins and Hsp70-x which is only found in 
P. falciparum and the closely related P. reichenowi (Kulzer et al., 2012, 
Elsworth et al., 2014a).  
Other Maurer's Clefts proteins have been proposed as essential for 
correct PfEMP1 transport including PfSBP1 and MAHRP1; two integral 
membrane proteins (Gruring et al., 2011, McMillan et al., 2013). 
MAHRP1 is required for correct PfEMP1 entrance to the Maurer's Clefts 
and also shows a structural function for the Maurer's Clefts (Spycher et 
al., 2008). Parasites with a SBP knockout mutation failed to traffic 
PfEMP1 to the IE surface and it is not clear yet whether this caused 
PfEMP1 not to enter the Maurer's Clefts or disturbed the delivery from 
Maurer's Clefts to the surface (Cooke et al., 2006, Maier et al., 2007). 
REX1 and Pf332 are Maurer's Clefts proteins and likewise they are 
crucial for appropriate localization of Maurer's Clefts and the transport of 
PfEMP1. Upon their deletion, it has been noticed that Maurer's Clefts 
were stacked and PfEMP1 transport was decreased (Elsworth et al., 
2014a). 
 
Figure 1.4 PfEMP1 exportation to the surface of infected erythrocytes. The 
figure demonstrates the structural organelle called Maurer's Clefts (MC), and 
several proposed proteins that play a role in PfEMP1 exportation to the IE 
surface; P. falciparum skeleton binding protein 1 (PfSBP1), Membrane-
Associated Histidine-Rich Protein-1 (MAHRP-1), Ring exported protein 1 
(REX1), Pf332, knob-associated histidine rich protein (KAHRP), PfEMP1-
trafficking proteins (PTP), Proteins encode Plasmodium helical interspersed 
subtelomeric (PHIST) domains and others. 
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Proteins encoding Plasmodium helical interspersed subtelomeric 
(PHIST) domains were also involved in PfEMP1 trafficking and IE 
membrane rigidity (Maier et al., 2008). Mayer et al (2012) showed that a 
single PHIST protein interacts with the ATS domain of PfEMP1 (Mayer et 
al., 2012), and it was thought that PHIST proteins were involved in 
delivery of parasite proteins to the IE membrane (Prajapati et al., 2014). 
Six PEXEL proteins were also recognized as important for PfEMP1 
trafficking called PfEMP1-trafficking proteins 1–6 (PTP1–6). Disruption 
and inactivation of some PTPs disrupted PfEMP1 export (Rug et al., 
2014).  
To conclude, it has been shown that a minimal structure is needed for 
PfEMP1 export and display on IE. This involves; semiconserved head 
region, a transmembrane domain and cytoplasmic tail (Melcher et al., 
2010). Rask et al. (2010) predicted that the N-terminus of PfEMP1 is 
myristoylated in the cytoplasm of the parasite; therefore, this might assist 
protein trafficking and anchoring the protein in the IE membrane (Rask et 
al., 2010). 
1.6 Var genes: 
After almost a decade from the molecular identification of PfEMP1, the 
genes encoding this protein were identified in 1995, and called var (for 
variant), by three research groups (Baruch et al., 1995, Su et al., 1995, 
Smith et al., 1995). Each parasite genome encodes about 50-60 different 
var genes, that are expressed in a (mainly) mutually exclusive fashion 
(Gardner et al., 2002, Scherf et al., 1998, Chen et al., 1998, Guizetti and 
Scherf, 2013). The var genes are large (6–13 kb), with extreme 
sequence diversity so that in theory they could encode proteins of 
around 200–500 kDa. Most of the var genes are located in subtelomeric 
regions of all 14 chromosomes where the other variant antigen-
encoding genes are located, such as the rif and stevor gene families, 
with a smaller group located in central regions of the chromosomes 
(Gardner et al., 2002). Figure 1.5 shows that var genes encode 
structurally typical PfEMP1 that have intracellular exon of one domain, and 
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multi-domains extracellular exon composed of DBL-α and CIDRα (known 
as the head structure) and followed by different classification and numbers 
of DBL and CIDR domains (Smith, 2014, Gardner et al., 2002).
 
Figure 1.5: PfEMP1 structure: Typical PfEMP1 showing the intracellular exon of 
one domain followed by the extracellular exon composed of multi-domains: 
DBL-α and CIDRα known as the head structure followed by different 
classification and numbers of DBL and CIDR domains. The figure modified from 
(Smith, 2014). 
The most important feature describing var genes is the significant sequence 
diversity. Var gene repertoires are virtually unlimited due to extreme 
levels of var gene polymorphism observed over the entire globe 
(Chookajorn et al., 2007a). Var gene evolution has been described as 
extremely rapid. It was proposed that they do not show stable positions in 
the genome (Kraemer et al., 2007). Thus, var genes sequences are 
extremely diverse (Barry et al., 2007). The great diversity is due to the 
ability of individual var genes to recombine with other repertoires during 
the sexual stage in the mosquito abdomen (Babiker et al., 1994, Paul et 
al., 1995, Su et al., 1999). In addition, there are reports suggesting 
ectopic recombination events between var genes of the same genome 
during both meiosis and mitosis (Freitas-Junior et al., 2000, Taylor et al., 
2000b). 
It has been well established that the most highly conserved domain is 
DBL-α, and it is found in nearly all PfEMP1s. Based on DBL-α, primers 
were designed (Kyes et al., 1997) and optimized (Taylor et al., 2000a) to 
explore the diversity of var genes. It was generally found that PfEMP1s 
are highly diverse in parasites locally as well as from overall the world, 
thus, underlining the repertoire complexity of the var genes (Kyes et al., 
1997, Taylor et al., 2000a). More recent work in Indonesia has 
emphasised this diversity (Sulistyaningsih et al., 2013).  
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Many reports showed several sequences appeared more frequently than 
others within individual patients (Kyriacou et al., 2006, Kirchgatter and 
Portillo Hdel, 2002, Fowler et al., 2002, Conway et al., 1999, Taylor et al., 
2000b, Mugasa et al., 2012). In Tanzania, for example, isolates from 
children with asymptomatic infections and severe malaria were examined 
to study the var gene expression profiles. The findings showed that there 
is a dominant expression of one particular var gene for each isolate with 
unique sequences. Nevertheless, these dominant sequences were 
different between isolates. Therefore, Mugasa et al (2012) suggested 
that each parasite retains its individual var gene variants and this 
explains the reason of having multi-exposure does not always protect 
from disease in subsequent infections (Fowler et al., 2002, Trimnell et al., 
2006). Overall various reports emphasised minimal overlaps in the var 
gene repertoires in Africa (Chen et al., 2011) and Mali (Kyriacou et al., 
2006).  
Despite the tremendous diversity, the majority of var genes can be 
categorized based on their upstream sequence (Ups), chromosomal 
location, and direction of transcription into three major groups ups A, B 
and C and two intermediate groups (B/A and B/C). UpsA and ups B 
genes are subtelomeric genes that are oriented tail to tail, whereas ups C 
genes are found in the centre of the chromosomes and are oriented head 
to tail in a tandem repeat manner (Kraemer and Smith, 2003, Lavstsen et 
al., 2003) (Figure 1.6).  
  
Figure 1.6 Var genes classifications. Var genes can be classified by their 
chromosomal location and upstream promoter (Ups) type into subtelomeric ups 
A and B and the central ups C. 
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Rask et al (2010) redefined the homology blocks (HBs) concept that 
was initially described by Smith el al (2000) to establish other 
classifications of PfEMP1 based on domain cassettes (DC). The 
analysis was performed using data from seven genomes of P. falciparum 
including 3D7, IT4 and HB3. They defined DCs as the presence of at least 
two consecutive domains belonging to specific subclasses and found in 
at least three examined genomes. Subsequently, very encouraging 
studies have related some of the DCs to SM including DC8 and DC13 
(Avril et al., 2012, Claessens et al., 2012, Lavstsen et al., 2012), DC4 
(Bengtsson et al., 2013) and DC5 (Berger et al., 2013). 
Another proposed classification of PfEMP1 repertoires divided them into 
long and conserved (mainly Ups group A) and short and diverse (mainly 
Ups group B and C) (Buckee and Recker, 2012). This latter 
classification was suggested after a significant, non-random link 
between the domains composing var genes and the extent of their 
sequence conservation. Most of the PfEMP1s have a tandem DBL-CIDR 
domain at the N-terminus, known as the semi-conserved head structure. 
Short PfEMP1s have an extra DBL and CIDR to form four domain 
extracellular units. In contrast, long PfEMP1s have some other domains. 
Understanding the var gene diversity and classifications can be 
significant for designing vaccine and chemotherapies that target clinical 
malaria outcomes.  
Highly diverse PfEMP1s, mainly group C and some of group B, are 
more associated with mild disease or asymptomatic infection (AM). Field 
studies have attempted to find a proper association between var gene 
expression and disease manifestation in different parts of the world 
(Jensen et al., 2004, Kyriacou et al., 2006, Rottmann et al., 2006, Bertin 
et al., 2013). It was shown that the diversity was higher in isolates from 
AM patients. This finding was suggested due to the enormous var genes 
repertoire associated with asymptomatic infection as reported by 
occurrence of more singletons in isolates from AM. 
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On the other hand, isolates from severe malaria children mostly 
transcribe var group A that has DBL-1α domain with reduced number of 
cysteine residues (2-cys) in Brazil (Kirchgatter and Portillo Hdel, 2002), 
Kenya (Bull et al., 2005), Mali (Kyriacou et al., 2006) and Tanzania 
(Rottmann et al., 2006). Consequently, severe malaria is thought to be 
restricted to a subset of var genes (Jensen et al., 2004, Rottmann et al., 
2006, Avril et al., 2012, Claessens et al., 2012) not only that but limited 
subsets could be specifically accumulated in vital organs such as brain 
(Montgomery et al., 2007, Tembo et al., 2014). In vitro, 3D7 selected on 
pooled plasma from semi-immune children from Ghana and Tanzania 
(Jensen et al., 2004) showed up-regulated var genes were among the 
Group A var group that encode high molecular weight PfEMP1. Also, 
there was one Group B/A var was up-regulated as well, which also 
encodes a relatively large PfEMP1 with a complex domain structure. On 
the other hand, group C members were two-thirds of the down-regulated 
genes, and they encode relatively small PfEMP1 proteins. In Tanzania, 
for example, children with cerebral malaria had group A var genes up-
regulated (Mugasa et al., 2012). Recent studies have linked the 
expression of PfEMP1 encoded by ups A and ups B/A with children with 
CM.  
The diversity of the var gene family has challenged the identification of 
particular PfEMP1 variants involved in the sequestration during CM. 
However, the expression of a restricted subset of PfEMP1 has been 
proposed for causing severe malaria based on DCs as previously 
mentioned. It has been shown that var genes encoding DC8 and DC13 
were highly transcribed in children who had CM in Tanzania (Lavstsen et 
al., 2012). two other joint studies found that P. falciparum isolates 
expressing DC8 PfEMP1 had significant binding to brain endothelial cells 
compared to other PfEMP1 (Avril et al., 2012, Claessens et al., 2012). 
Also, Bengtsson et al. (2013) found that antibodies to DC4 were cross-
reactive with group A PfEMP1 (Bengtsson et al., 2013). In addition, DC5 
containing var genes were implicated with severe malaria children in 
Tanzania (Berger et al., 2013).  
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1.6.1 Var gene evolution: 
Although the var gene repertoire is highly diverse, in the sequenced 
genomes to date, they share three conserved variants (var1, var2csa, 
and type3 var). The occurrence of frequent recombination has 
contributed to the fact that it is difficult to examine var gene evolution. 
However, it was thought that mosaic recombination could have had a 
vital (negative) role in the evolution of the var2csa gene, a special 
member which has been associated with pregnancy-associated 
malaria (PAM) (Trimnell et al., 2006, Bockhorst et al., 2007). Var2csa 
led to this finding because its uniqueness in the genome and it 
recombines homologously only, although, its basic composition is still 
relatively similar to other var gene family members (Ferreira et al., 
2007, Zilversmit et al., 2013). 
The origin of P. falciparum itself is still an area of doubt (Prugnolle et al., 
2011). Recent findings go against earlier thoughts proposed in 1991 that 
P. falciparum acquired its virulence due to recent adaption in humans 
from avian malaria species (Waters et al., 1991). The former thought was 
challenged by the finding that P. falciparum diverged about 6-10 million 
years ago from the chimpanzee malaria P. reichenowi (Escalante and 
Ayala, 1995).  
P. reichenowi, which also encodes var genes (Rask et al., 2010), was 
included in genomic analysis together with P. falciparum isolates by 
Trimnell et al. (2006). They found that despite the conserved var2csa 
ortholog in all P. falciparum isolates, var2csa is highly polymorphic in 
comparison with other non-var genes. However, the unpredicted finding 
was the sequence similarity of the var2csa ortholog in the chimpanzee 
malaria P. reichenowi. Thus, it was suggested that var genes have co-
evolved for a long time with primates from an ancient origin about 6-10 
million years ago. In contrast, the same study analysed Type 3 var 
genes, the most highly conserved gene among upsA var genes, and 
confirmed Type 3 var orthologs in all P. falciparum isolates with one 
exception, which were not found in P. reichenowi (Trimnell et al., 2006). 
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Up to date, there are at least six divergent falciparum-like species that 
infect African Great Apes (chimpanzees and gorillas) (Prugnolle et al., 
2011) but the knowledge about PfEMP1 protein functions in non-human 
primate is very limited. However, Smith et al. (2013) have highlighted 
the importance of the co-evolution of var genes with primates so that it 
could improve our understanding of malaria pathogenesis in terms of 
the adaption of cytoadhesion traits. Experts believe that the 
investigation of ancestral PfEMP1 binding properties might be based on 
advantages for parasite growth and transmission (Smith et al., 2013).  
1.6.2 The structure and the shape: 
Currently, there are only two available PfEMP1-ligand structures. Recent 
studies have shown that full-length PfEMP1 ectodomains have different 
shapes. For example, ITvar13, an ICAM-1 binder, has a rigid extended 
structure and using a single domain to bind to ICAM-1 (Brown et al., 2013). In 
contrast, VAR2CSA forms a compact structure by folding back on itself 
using a single domain to bind with high affinity to its ligand CSA (Srivastava et 
al., 2010). VAR2CSA is composed of six DBL domains and a single 
CIDRpam domain, whereas IT4VAR13 follows a more typical structure of 
PfEMP1. It was suggested that PfEMP1s have at least two different 
shapes. Indeed, the development of therapeutic interventions targeting 
appropriate antigens needs more details about the molecular 
mechanisms of PfEMP1 recognition of host receptors to mediate 
sequestration, immune responses and possibly to limit the variation that 
needs to be incorporated.  
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1.7 Antigenic variation:  
The parasitic microorganism faces several challenges before it reaches a 
‘secure’ position in the host. It starts by avoiding mechanical clearance, 
immune recognition and destruction after immune responses. Thus, 
some pathogens have had to evolve sophisticated strategies to ensure 
possible lifelong existence in hosts and high infectivity for species 
continuity. Among the mechanisms that contribute to this is antigenic 
variation, which is defined as “the changes of the molecules of the 
parasites exposed to the immune system over the course of an infection”.  
(Deitsch et al., 2009). Therefore, it challenges the host to target such 
populations and importantly the host might not even be able to eliminate 
the organism, as seen in most of the P. falciparum infections (Pasternak 
and Dzikowski, 2009). As mentioned above, perhaps unusually for an 
intracellular parasite, many proteins are transported to the surface of IE 
during the development inside erythrocytes. However, only a small 
subset of their encoding genes is expressed at a given time. In the case 
of var genes, only a single gene among the whole repertoire is 
transcribed whereas all the others are silenced. This is known as 
mutually exclusive expression (Roberts et al., 1992, Smith et al., 1995), 
also called monoallelic expression, and it the most extreme form of clonal 
variation (Scherf et al., 1998). Single var gene transcription begins at the 
ring stage soon after merozoite invasion of the erythrocytes (Figure 1.7). 
Then, after about 16 hrs, it becomes in the poised state during 
trophozoite and schizont stages ready for activation in the following 
cycle. Then, var gene expression can switch to another variant over time 
which causes alterations in immune responses and adhesion 
phenotypes. Mutually exclusive expression is controlled by genetic and 
epigenetic control factors. In a recent review by Guizetti and Scherf 
(2013), they outlined var gene expression in P. falciparum in four stages; 
default silencing, activation, poised state and switching (Guizetti and 
Scherf, 2013). 
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Figure 1.7: Var gene activation and silencing throughout asexual blood stage 
development of P. falciparum. A. single var gene transcription begins at the ring 
stage soon post merozoites invasion of the erythrocytes reaching the peak at 
12-16 hrs post inasion. Then, it becomes in the poised state during trophozoite 
and schizont stages ready for activation in the following cycle. The figure is 
cited from (Guizetti and Scherf, 2013). 
 
Var gene silencing involves three factors; epigenetic elements, nuclear 
arrangement and intron role. First, studies have indicated that plasmodial 
Sir2 genes have an effect on the chromatin of clonally variant gene 
families (Duraisingh et al., 2005, Tonkin et al., 2009). Histone 
deacetylation by Sir2 might allow the formation of Histone 3 lysine 9 
trimethylation (H3K9me3), the silencing heterochromatin mark which is 
heavily found in promoter regions of repressed var genes (Chookajorn et 
al., 2007b). H3K9me3 histone modification stimulates heterochromatin 
formation through P. falciparum Heterochromatin Protein 1 (PfHP1) to 
silent but not active var genes (Perez-Toledo et al., 2009). Second, a 
striking feature of P. falciparum virulence is the nuclear arrangement 
(Scherf et al., 2008). Var genes tether at the nuclear periphery by an 
unknown mechanism (Lopez-Rubio et al., 2009, Ralph et al., 2005). The 
attachment of var genes at the periphery is suggested to be fundamental 
for default silencing (Guizetti and Scherf, 2013). This was explained by 
impairing perinuclear localization of intron-carrying var genes, which led 
to partial de-repression. Third, the intron and the var promoter mediate a 
significant role in control of silencing. The intron silences expression by 
one-to-one pairing with var promoter while unpaired intron activates the 
respective promoter (Deitsch et al., 2001, Frank et al., 2006). 
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The activation of a var gene, likewise, involves different factors. The 
activation starts by replacing H3K9me3, the suppression marker, by 
Histone 3 lysine 4 bi- and tri-methylation (H3K4me2/3) and Histone 3 
lysine 9 acetylation (H3K9ac) (Lopez-Rubio et al., 2007). Dependently, 
PfHP1 loses the association with the 5′ ups in the active gene (Perez-
Toledo et al., 2009). Another modification includes Histone 4 lysine 
acetylation which has a role in transcriptional activation, and it is 
regulated by a histone acetyltransferase MYST member called 
Plasmodium falciparum MYST (PfMYST) (Miao et al., 2010). In addition, 
there is an association between the enhanced transcriptional activities 
with the histone variant H2A.Z around the transcription start site during 
ring stages, while it is reduced in later stages and frequent removal might 
lead to different var gene activation in the subsequent cycle (Guizetti and 
Scherf, 2013). Moreover, in a recent study, it has been found that most of 
the var genes contain an important motif for mutual exclusive expression. 
It is an eight-base pair sequence motif found in the 5′ UTR known as 
mutually exclusive element (MEE). This was suggested to be the limited 
activating factor binding site (Guizetti and Scherf, 2013).  
It was suggested that a single var is transcribed early at ring stage and 
stops at about 12-16 hrs but remains in a state called poised state to be 
activated on the following erythrocytic cycle (Figure 1.7). The mechanism 
of the movement from active to the poised state is not yet understood. It 
has been described that a putative methyltransferase, PfSet10, has been 
specifically linked with the poised var gene (Guizetti and Scherf, 2013). 
Our understanding of the molecular mechanisms of var gene switching is 
still limited. There is no specific point known for the control of switching 
events in cell cycle. Variable var gene switching rates of isolates in vitro 
(Roberts et al., 1992)  differ from those seen in human volunteers (Peters 
et al., 2002). Horrocks et al. (2004) showed that each var gene owns its 
own rate of switching (Horrocks et al., 2004). 
Recently, mathematical modelling alongside experimental data 
concluded that var switching is non-random and involved highly 
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structured switching patterns, and this might adjust the length of infection 
(Recker et al., 2011). Interestingly, the pattern of ups A var gene 
expression in P. falciparum-infected patients changed in in vitro cultured 
parasites to low activation rates and being random in ups B and C 
parasites. It was suggested that the intrinsic switch rate might be affected 
by host factors (Guizetti and Scherf, 2013).  
There was no preferential expression observed in the Horrocks et al. 
(2004) study. However, later reports proposed that central var genes 
switch off slower than sub-telomeric var genes, and this could explain the 
quick drop in the sub-telomeric gene transcription during culture 
adaptation (Frank et al., 2007, Peters et al., 2007, Zhang et al., 2011). 
Recent analysis to characterise the antigenic switching network in HB3 
P. falciparum has shown that var gene activation followed a global 
hierarchy favouring towards highly diverse genes located in the central 
chromosomes (Noble et al., 2013).  
1.8 Immunity: 
Although, it has been more than 50 years since Cohen et al. (1960) 
showed the significant role of antibodies to mediate immunity to intra-
erythrocytic stage malaria (Cohen et al., 1961), the immunity to this stage 
is not yet fully understood. However, among the variant surface antigens 
(VSA) of P. falciparum, PfEMP1 is a prime target of protective antibodies, 
reviewed with other VSA in (Chan et al., 2014). The transmission 
intensity has been shown to play a major role in acquiring immunity 
(Nielsen et al., 2004). On the one hand, individuals in endemic areas 
acquired resistance to severe malaria manifestations by about the age of 
five years. However, they keep suffering from mild malaria due to 
exposure to repeated infections before achieving almost protective 
immunity to the clinical disease by adulthood. On the other hand, in low-
transmission areas all individuals at different ages are susceptible to 
malaria manifestations (Doolan et al., 2009). However, no clear 
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understanding of the mechanism of antibody-mediated protection is 
available (Crompton et al., 2014).  
The gradual acquisition of protective antibodies could be due to the high 
diversity of VSA as it is been shown above for PfEMP1 and antigenic 
variation. Thus, the role of PfEMP1 in immunity will be briefly highlighted 
here, while considering that other VSA are involved in the intra-
erythrocytic stage immunity, which can be seen in a recent review (Chan 
et al., 2014). Recent evidence showed that PfEMP1 is a major target of 
malaria humoral immunity in endemic regions (Chan et al., 2012). This 
supports an earlier observation by Bull et al. (1998) that frequent P. 
falciparum infections might provoke the production of specific antibodies 
to PfEMP1 (Bull et al., 1998). But, the issue is that P. falciparum–specific 
antibodies, in general, disappear or almost become undetectable for the 
recorded infections by about 3–9 months in young children (Akpogheneta 
et al., 2008, Portugal et al., 2013).  
Plasmodium plays a role in dysregulation of CD4+ T cell and B cell 
functions to evade humoral immunity. It was suggested that the response 
in children is mediated by short-lived plasma cells rather than long-lived 
plasma cells (LLPCs). The repeated infections that build gradual 
protection could be due to the role of LLPCs. The role of memory B cells 
(MBCs) is doubtful but recent studies support the ability of P. falciparum 
to produce long-lived MBCs, though they are relatively inefficient 
compared with other pathogen responses (Crompton et al., 2014).  
It is possible that Pattern Recognition Receptors on B cells and DCs 
enhance B cell responses due to the chronic exposure to PAMPs of P. 
falciparum. For example, TLR9 agonist CpG enhances the IgG and MBC 
response in naïve adults (Alcais et al., 2010), but not frequently exposed 
adults (Jallow et al., 2009). Also, TLR2 through GPI mediates signals to 
activate NF-KB and the production of inflammatory cytokines, including 
TNF, and adhesion molecules such as ICAM-1 which contribute to 
malaria pathogenesis through a vital process known as sequestration  
(Krishnegowda et al., 2005, Gowda, 2007). 
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1.9 Sequestration: 
Sequestration is another virulence mechanism besides antigenic 
variation that protects P. falciparum from immune detection and 
destruction and ensures prolonged survival for the species. It occurs at 
the mature stages of the asexual intra-erythrocytic cycle of P. falciparum 
and this explains their disappearance from the circulation due to their 
ability to localise to different organs such as brain. Craig et al (2012) 
highlighted several hypotheses that have associated the sequestration 
with the disease manifestations (Craig et al., 2012b). One reason may be 
that abnormal physiological changes occur to IEs, such as their rigidity 
(Dondorp et al., 1999, Dondorp et al., 2002), the other is the expression 
of adhesion-receptors in response to the pro-inflammatory mediators 
(Armah et al., 2005, Clark et al., 2008), also, toxin production (Schofield 
et al., 1996), and endothelial activation (Chakravorty et al., 2008, 
Hollestelle et al., 2006, Moxon et al., 2014). In addition, the impact of 
coagulation pathway in mediating IEs binding to ECs (Francischetti, 
2008, Moxon et al., 2013, Turner et al., 2013) and binding of IEs to 
specific adhesion receptors on endothelial cells (Ochola et al., 2011, 
Newbold et al., 1997).   
Sequestration was initially described when the Italian malariologists 
Marchiafava and Bignami saw high parasites density in malignant 
malaria patients compared with benign malaria patients. They described 
that in post-mortem there were high accumulations of parasites with 
predominant parasite pigment occupying the tissue microvascular in 
comparison with circulating parasites in the peripheral circulation. They 
also reported cerebral endothelium dysfunction (Craig et al., 2012b). 
Since then, there has been some advance in our understanding of some 
of the key events that facilitate sequestration and importantly could 
provide possible targets to develop either inhibitors or vaccines (Rowe et 
al., 2009). PfEMP1 is generally accepted as the key parasite surface 
molecule that mediates sequestration with multiple human receptors. 
Figure 1.8 illustrates the binding of IEs that occurs with several receptors 
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of endothelial cells, uninfected erythrocytes or platelets, which are 
variably associated with the severe malaria in phenomena known as 
cytoadhesion, rosetting and clumping respectively (Rowe et al., 2009). 
The binding of IE also occurs on receptors on other cells including dendritic 
cells, monocytes and macrophages to modulate host immune functions 
(Chua et al., 2013). The most common receptors that mediate the 
binding are CD36 (Barnwell et al., 1989, Oquendo et al., 1989), ICAM-1 
(Berendt et al., 1989), and EPCR (Turner et al., 2013). In addition, more 
than ten other receptors have been identified as being involved in the 
cytoadhesion.  
 
Figure 1.8: Adhesion of Plasmodium falciparum-infected erythrocytes to human 
cells. The diagram demonstrates the adhesion properties of P. falciparum-
infected erythrocytes to different host cells. IEs with trophozoites and schizonts 
of P. falciparum parasites have the ability to bind to a range of host cells, such 
as endothelium (cytoadherence), uninfected erythrocytes (rosetting) and 
platelets (platelet-mediated clumping). The figure has been cited from (Rowe et 
al., 2009). 
1.9.1 CD36:  
CD36 is an integral membrane protein expressed on a variety of host 
cells including endothelium and platelets (Rowe et al., 2009). CD36 is 
involved in immune responses in humans (Febbraio et al., 2001, 
Greenwalt et al., 1992), platelet adhesion (McGilvray et al., 2000) and the 
regulation of membrane transport systems. CD36, as stated before, is a 
common receptor for almost all P. falciparum isolates in field studies, 
though there are important exceptions such as var2csa expressing 
isolates do not bind to CD36 (Fried and Duffy, 1996, Beeson et al., 
2000). 
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In terms of clinical association, there is no certain role for CD36 in 
malaria pathogenesis (Rowe et al., 2009). CD36 adhesion phenotype is 
seen for IE from severe or uncomplicated malaria patients (Newbold et 
al., 1997, Rogerson et al., 1999). Other evidence showed it is more 
linked to uncomplicated malaria isolates (Ochola et al., 2011). In 
contrast, a very recent study conducted on patients from Benin found that 
isolates from CM patients bind to CD36 more than isolates from UM 
(Almelli et al., 2014). In another study, CD36 adhesion enabled 
protection from CM in South East Asia (Cortes et al., 2005). Also, it has 
been proposed that CD36 might provide protection against anaemia 
caused by malaria (Chilongola et al., 2009). Group B and C PfEMP1 
variants are more associated with binding to CD36 (Robinson et al., 
2003, Kraemer and Smith, 2006, Cabrera et al., 2014), which might 
support a link to UM. The binding site for P. falciparum was mapped to 
amino acids 139-184 of CD36 using blocking studies by monoclonal 
antibodies and peptides (Rowe et al., 2009). The binding to CD36 is 
reduced in CD36-deficient malaria patients, nevertheless, CD36 
deficiency does not protect against severe malaria (Fry et al., 2009). 
In addition, the role of CD36 as a receptor for rosetting has been 
restricted to laboratory isolates of P. falciparum, and this role is probably 
not clinically important based on field isolates because the group A 
PfEMP1 variants that are more associated with rosetting do not bind to 
CD36. In addition, a CD36 dependent clumping mediated phenotype was 
proven by inhibition with anti-CD36 antibodies, and by the absence of 
clumping by CD36-deficient platelets. However, not all CD36 binders can 
form clumps, which might be explained by either more receptors required 
for clumping or CD36 having distinct epitopes that can differentiate 
CD36-mediated clumping (Rowe et al., 2009).   
Some CIDR1 domains in the PfEMP1 head structure have been shown 
to bind CD36 (Baruch et al., 1997, Smith et al., 1998), and the majority of 
PfEMP1 variants encodes CIDR1 domains (Robinson et al., 2003). 
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1.9.2 ICAM-1: 
 Another commonly used receptor is ICAM-1. It has a cytoplasmic tail, a 
transmembrane domain and five extracellular Ig-like domains (van de 
Stolpe and van der Saag, 1996, Chakravorty and Craig, 2005). The 
central role of ICAM-1 on endothelial cells is allowing leukocyte 
transmigration from the circulation to the tissues in inflammatory sites 
induced by cytokine stimulation. This is mediated by the binding to 
leukocyte receptors such as leukocyte function-associated antigen 
(LFA-1) or macrophage-1 antigen (Mac-1). ICAM-1 also mediates 
binding to pathogenic organisms, such as human rhinoviruses (HRVs) 
(Greve et al., 1989, Staunton et al., 1989) and P. falciparum infected 
erythrocytes (Berendt et al., 1989). Early studies found that ICAM-1 
binding sites for IE, rhinoviruses, LFA-1 and fibrinogen are 
overlapping, but also have distinct regions (Berendt et al., 1992, 
Ockenhouse et al., 1992).  
Similar to CD36, the involvement of ICAM-1 in malaria pathogenesis is 
not clear. However, there are various evidences supporting the 
involvement of ICAM-1 in SM, including CM. Initially, in 1994, i t  w a s  
f o u n d  t h a t  post-mortem samples taken from people diagnosed with 
CM showed accumulation of IE co-localised with ICAM-1 in brain 
vessels (Turner et al., 1994). Additional lines of evidence of the 
involvement of ICAM-1 in CM can be found in chapter (3.1) (Madkhali et 
al., 2014). The interaction between IE and ICAM-1 involves the BED face 
of ICAM-1, including the DE loop (Tse et al., 2004) and DBLβ domains of 
PfEMP1 (Smith et al., 2000a, Howell et al., 2008). The results were 
observed from ICAM-1 binders Group A PfEMP1s; including PFD1235w, 
Dd2var32 (Jensen et al., 2004) and PF11_0521 (Oleinikov et al., 2009, 
Gullingsrud et al., 2013). 
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1.9.3 Endothelial protein C receptor (EPCR): 
EPCR is expressed at relatively low levels in microvascular endothelium 
of many organs including brain (Moxon et al., 2013). It is encoded by the 
endothelial protein C receptor gene (PROCR). It acts as a receptor for 
the zymogen, protein C in the process of protein C activation regulating 
coagulopathy protection. It is also involved in anti-inflammatory 
responses via the signalling receptor PAR1. It also binds to Mac-1 
(CD11b/CD18) leading to monocyte adhesion to ECs. As mentioned 
above ICAM-1 is able to bind to Mac-1, thus, both can bind to Mac-1 and 
PfEMP1. It was suggested that architectural similarities may exist 
between the two surface of Mac-1 and PfEMP1 (Aird et al., 2014). 
Recently, EPCR has been shown to be involved in CM by two different 
studies. First, Moxon et al (2013) have addressed the role of EPCR post-
mortem in children that had died of cerebral malaria. The study showed 
that IE at endothelial sites co-localized with loss of EPCR (Moxon et al., 
2013).  They also showed that children with CM had higher levels of 
soluble EPCR in CSF, however, the plasma level was not altered 
compared to other malaria syndromes, which suggests that EPCR local 
loss associated with sequestration mediates cerebral coagulation 
disruption and inflammation. Another study examined the binding of 
EPCR (Turner et al., 2013) to specific PfEMP1 variants that have been 
recently associated with SM (Avril et al., 2012, Claessens et al., 2012, 
Lavstsen et al., 2012). The study examined the binding of PfEMP1 
containing DC8 to EPCR on endothelial cells. It was found that DC8 
containing IE were adherent to the endothelial cells of many organs 
including the brain and that this was mediated by EPCR. This finding was 
confirmed by significantly higher binding to EPCR by parasites isolated 
from severe malaria patients when compared to the parasites isolated 
from mild or uncomplicated malaria patients. DC8 is a tandem of four 
domains DBLα2- CIDRα1.1- DBLβ12- and DBLγ4/6- domains, and DC13 
(also associated with SM) have the tandem of DBLα1.7-CIDRα1.4. 
Analysis using surface plasmon resonance showed that EPCR pre-
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incubation with either DC8 or DC13 CIDR domains blocks EPCR-APC 
interaction, showing that DC8 and DC13 domains use the APC binding 
site. The EPCR binding site has been mapped to CIDR1. A mutation of 
PROCR called rs867186-G allele has been linked to the elevated sEPCR 
in plasma. In this study, the association of PROCR rs867186 genotype 
was shown to protect from severe malaria examined in a Thai population 
(Naka et al., 2014). 
1.9.4 PECAM-1: 
Platelet endothelial cell adhesion molecule 1 (PECAM1 or CD31) is 
widely expressed on platelets, endothelial cells, monocytes and 
granulocytes. The PECAM1 binding site for IEs has been mapped 
to the first four immunoglobulin-like domains of PECAM1 (Rowe 
et al., 2009). Two PfEMP1 domains were previously shown to bind 
to PECAM-1; CIDR1α and DBL2δ (Chen et al., 2000). It was reported 
that about 50% of field isolates from Kenya bound to PECAM1 but 
there was no significant association between PECAM1 binding 
phenotype and severe malaria (Heddini et al., 2001). In addition, 
polymorphism studies showed no protection role for PECAM1 
against severe malaria in Africa. On the other hand it increased 
the risk of cerebral malaria in Thailand (Rowe et al., 2009). 
Recently, PECAM1 binding was assigned to PfEMP1 containing DC5, 
but other PfEMP1 variants were not excluded. DC5-PECAM1 binding 
was associated with severe malaria in Tanzanian children, although the 
numbers examined were limited. Thus, it was suggested that DC5-
PfEMP1 expressing parasites can mediate severe malaria. It was also 
shown that protection from malaria fever and anaemia was associated 
with anti-DC5 antibody levels (Berger et al., 2013). 
1.9.5 CSA: 
Pregnancy associated malaria (PAM) is characterised by considerable 
accumulation of IEs and monocytes in the placenta (Walter et al., 1982). 
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Despite the fact that adults develop clinical immunity in endemic areas, 
women become at risk to SM again their primigravida.  The adhesion of 
IEs to the placenta is mediated by CSA and VAR2CSA PfEMP1 
members.  Then, antibodies are acquired against VAR2CSA and women 
acquire protection against PAM in the following pregnancies. In fact CSA 
is the best representative for specific usage by distinct PfEMP1 members 
leading to specific malaria outcome, PAM. This example has opened the 
opportunity to identify certain members for other malaria syndromes such 
as CM. 
1.9.6 Other characterised receptors: 
1.9.6.1 Thrombospondin: 
Thrombospondin (TSP) is an adhesive glycoprotein found in plasma 
once thrombin activates platelets. Although it was the first molecule 
identified as a receptor for P. falciparum cytoadherence, little is known 
about it in malaria pathogenesis. Three different ligands have been 
identified binding TSP; PfEMP1, altered Band 3 protein, and red-cell-
derived phosphatidylserine (a membrane phospholipid). TSP binding was 
not associated with severe malaria from Kenyan isolates (Rowe et al., 
2009). 
1.9.6.2 Heparan sulphate:  
Evidence has shown heparin binding is involved in SM in Kenya (Rowe 
et al., 2009). The glycosaminoglycan heparan sulphate was described as 
a dual receptor responsible for rosetting and subsequently the binding of 
rosetting forms on ECs (Vogt et al., 2003). It was recently shown that 
rosetting and cytoadherence are mediated by different receptors for one 
isolate. Heparin cytoadhesion was strongly mediated by NTS-DBLα and 
DBL2γ domains, whereas, rosetting was mainly mediated by NTS-DBL1α 
domains with complement receptor 1, a rosetting mediating receptor. 
This finding demonstrated that an individual isolate can use different 
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receptors to mediate IE binding to ECs and uninfected erythrocytes 
(Adams et al., 2014). 
1.9.6.3 VCAM-1, E-selectin and P-selectin: 
The binding of field isolates to E-selectin and VCAM1 was very low and 
no link with disease severity was found. The parasite ligand has not been 
identified and the binding site on E-selectin is unknown (Schofield et al., 
1996). P-selectin binding was found in field isolates. Little is known about 
the binding sites on both IE and P-selectin. It seems that the binding site 
is distinct from the site of interactions between P-selectin and leukocytes 
because antibodies that block this interaction did not show any effect on 
P. falciparum binding. Purified PfEMP1 binding to P-selectin in vitro 
suggests PfEMP1 may be a ligand on IE (Rowe et al., 2009). 
1.9.6.4 Other receptors: 
Very recently, a group of EC receptors were tested for their binding to a 
pooled sample of Ghanaian patients isolates (Esser et al., 2014). They 
used Chinese Hamster ovary (CHO-745) cells transfected with 
tetraspanins members (CD9 and CD151), multidrug-resistance protein 1 
(MDR1), multidrug resistance-associated protein 2 (MRP2), truncated 
forms of tumour necrosis factor receptors 1 (TNFR1) and 2 (TNFR2) and 
the erythropoietin receptor (EPOR). The pooled sample bound to all 
these receptors higher than the lab strain FCR3. Other endothelial 
receptors have also been identified including fibronectin, integrin αvβ3, 
NCAM and others, summarised in (Rowe et al., 2009). However, no 
ligands on IE have been linked to these ECs receptors. Their roles in 
malaria pathogenesis are also unknown. The involvement of the whole 
set of these unknown roles in sequestration make it a more challenging 
task to tackle to inhibit malaria syndromes via adhesion, and could open 
the question about how the sequestration phenomenon is linked to 
severe malaria.  
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1.10 Gametocyte sequestration: 
Gametocytogenesis occurs through 5 different stages (I–V) in about two 
weeks. It was reported early on that developing gametocyte stages (I- IV) 
are not found in the peripheral circulation whereas the mature stage (V) 
is circulating for transmission. This sequestration is mainly seen in the 
spleen and bone marrow unlike asexual stages that bind in the 
microvasculature (Baker, 2010). Early work suggested that 
developmental gametocytes (I-IIa) binding to ECs was inhibited by anti-
CD36 and anti-ICAM-1 (Rogers et al., 1996). Interestingly, PfEMP1 was 
proposed to be responsible for hiding the first stages of gametocytes. 
Thus, it might be a valuable vaccine target for blocking transmission. It 
has been reported that the transcriptional switching in gametocytes 
prefers particular type C var genes in vitro, independent of the expressed 
PfEMP1 in the asexual forms (Sharp et al., 2006). This could exclude the 
role of PfEMP1 in the sequestration of stage IIb–IV gametocytes. Other 
work showed that the binding of stage III–IV gametocytes might be 
mediated ICAM-1, CD49c, CD166 and CD164 (Rogers et al., 2000). 
However, the binding was described as lower avidity. This confusion has 
been addressed in very recent data that has concluded that the 
gametocytes binding process is different from the asexual binding to ECs 
(Silvestrini et al., 2012), with gametocyte sequestration not being 
dependent on adhesion but instead on variable rigidity induced in 
different gametocyte stages. This is interesting because it shows 
interaction between parasite ligands and human receptors is not always 
required to mediate sequestration, but this could be important 
mechanism for mature gametocytes to restore their deformability and 
circulate in the blood stream for transmission (Aingaran et al., 2012).     
1.11 RIFIN proteins: 
Repetitive interspersed family proteins (RIFIN) are encoded by the 
largest multigene family identified in P. falciparum called rif genes 
(Cheng et al., 1998). There about 150–200 genes per haploid genome 
occupying the subtelomeric regions close to the var genes. RIFINs differ 
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from PfEMP1s by the presence of multiple RIFIN variants on the IE 
surface on different stages such as sporozoites, merozoites and 
gametocytes (Chan et al., 2014). RIFINS were classified into two groups; 
A-type and B-type RIFINs. Little information about their biological 
functions is available. Early studies implicated RIFINs in mediating 
rosetting phenotypes, but later studies showed that PfEMP1 is the main 
ligand for rosetting (Rowe et al., 2009). In addition, it was shown that one 
B-type rif was highly upregulated in mature gametocytes, calling into 
doubt the role of RIFINs in gametocytes sequestration (Liu et al., 2011).  
1.12 STEVOR proteins: 
The third largest protein family identified in P. falciparum is subtelomeric 
variable open reading frame proteins (STEVOR). It is encoded by the 
stevor multigene family. There are about 30–40 copies of stevor genes 
found in the genome. Also, they are found near to the var and rif genes 
(Cheng et al., 1998). Unlike var, many stevor copies were expressed in a 
single parasite at the same time. They are transcribed in all 
developmental stages (Chan et al., 2014). Stevor variants expression 
profile in IEs showed the same variants expressed during asexual and 
sexual forms (Sharp et al., 2006), which in turn could possibly exclude its 
roles in gametocyte adhesion. However, recent data have suggested 
some of STEVOR’s biological roles. Increased IE rigidity was caused by 
the excessive expression of stevor which may improve PfEMP1 mediated 
sequestration (Sanyal et al., 2012). Also, STEVOR was proposed to have 
a role in parasite invasion (Garcia et al., 2005). Supportively, in a very 
recent study about STEVOR, Niang, et al (2014) have reported a dual 
role for STEVOR in mediating rosetting phenotypes and enhancing 
merozoite invasion. STEVOR recognises Glycophorin C (GPC) on the 
erythrocyte surface and the binding was related to the GPC levels on the 
erythrocytes. Interestingly, the binding was PfEMP1-independent (Niang 
et al., 2014). 
38 
 
1.13 SURFIN proteins: 
Surfin proteins are high-molecular-weight antigens encoded by 10 
surf genes (Winter et al., 2005). The pattern of surf genes expression is 
different based on the intraerythrocytic stage (Mphande et al., 2008). It is 
thought that one member expressed at the mature stage was found at 
knobs of IEs, this might indicate that it co-localises with PfEMP1 (Winter 
et al., 2005). However, another variant was shown localising to the PV in 
immature intraerythrocytic stage. No distinct role for these proteins has 
been identified (Mphande et al., 2008).   
1.14 PfMC-2TM:  
A novel gene family is found at many of P. falciparum’s subtelomeric 
regions of the chromosomes. This family encodes protein called 
Plasmodium falciparum Maurer’s clefts two-transmembrane protein 
(PfMC-2TM). Little is known about PfMC-2TM, but it was shown that 
domains of this protein localized in the PV and PVM (Tsarukyanova et 
al., 2009).  
1.15 Modified erythrocyte band 3: 
Modified erythrocyte band 3 has been proposed to mediate binding of IE 
to Thrombospondin (Lucas and Sherman, 1998, Eda et al., 1999) and 
CD36 (Winograd et al., 2004). CD36 adhesion was reduced upon the 
induction of chemical modifications of band 3 but this was not observed 
for Thrombospondin (Winograd et al., 2004). A recent report has shown 
that binding to CD36 was significant even if parasites had little or no 
detectable PfEMP1 expression, but this was not observed for ICAM-1 
(Chan et al., 2012).  
1.16 PfEMP1-based Vaccine development:  
It seems logical that the major antigen expressed on the IE surface 
should be a target for vaccine development. However this can be 
countered by the arguments that PfEMP1 variants are highly polymorphic 
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and can rapidly switch upon the effect of immune responses. Therefore, 
PfEMP1 may not be the appropriate choice for vaccine inventors. 
Nevertheless, as explained above, accumulating evidence suggest that 
the PfEMP1-IE interactions could possibly be targets for therapeutic 
interventions to control malaria. The acquisition of natural antibodies that 
reduce the effects of the disease is obvious evidence. The recent 
classification of PfEMP1 based on the conserved DCs and their 
associations with SM is also a significant advancement in malaria 
pathogenesis and should lead to better understanding for targeting 
malaria. The good example is VAR2CSA which is an exceptional 
member of the PfEMP1 family that mediates binding to CSA in PAM, 
affecting especially a primagravidae and her child.  However, 
multigravidae are at less risk due to antibodies developed against 
VAR2CSA, which are cross-reactive due to the unusual conserved DBL 
binding domains composition.  This PfEMP1 has attracted researchers’ 
hope to develop a vaccine to PAM targeting VAR2CSA and as a tool in 
disease control (Hviid, 2010, Badaut et al., 2010). Also, Buckee and 
Recker (2012) in their recent evolutionary study of PfEMP1 domains 
have thought that the domains that mediate other adhesion phenotypes 
may have conserved features because of the functional constraints that 
mediate high affinity binding. Consequently, it was suggested that a large 
proportion of the var gene reservoir worldwide share the proposed 
conserved domains. This could lead to novel vaccine opportunities based 
on PfEMP1 even if it only aims to protect from severe disease outcomes 
(Buckee and Recker, 2012). 
The intensive focus on studying IE adhesion phenotypes and their 
contribution to malaria pathogenesis may well be explained by the 
significant outcomes of these studies in the past two decades which in 
turn might lead to the development of treatments targeting 
sequestration. The huge variation between the adhesion phenotypes 
and clinical outcomes usually bring doubt about the mechanisms that 
lead to the severe malaria. However, recent findings about the role of 
EPCR in CM are good evidence for the need of studying IE adhesion.  
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1.17 Aims: 
 Characterisation of the binding of a set of new ICAM-1 binding 
isolates to provide further information about the interaction 
between ICAM-1 and PfEMP-1 (Chapters; 3.1 and 3.2). 
 Comparison between the adhesion of ICAM-1 binding isolates to 
HUVEC and HBMEC (Chapter 3.3).    
 Characterisation of the adhesion phenotypes of upsC PfEMP1 
variants to CD36, ICAM-1 and primary endothelial cells (Chapter 
4.1).  
 An analysis of the adhesion phenotypes of PfEMP1 variants 
based on their length (Chapter 4.2). 
This was mainly achieved by static protein adhesion assay and flow 
endothelial cells adhesion assay. 
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2. Methods:  
2.1 Parasite culture:  
Information about parasite isolates is provided in the method section of 
each chapter. Parasites were cultured under standard culturing 
conditions. It was cultured in 1% haematocrit in  O+ human  erythrocytes, 
using complete medium (RPMI  1640  medium  supplemented  with  37.5 
mM HEPES,  7 mM  D-glucose,  6 mM  NaOH,  25 mg/ml  of  gentamicin 
sulphate, 2 mM L-glutamine, and 10% human serum) at a pH of 7.2, in a 
gas mixture of 96% nitrogen, 3% carbon dioxide, and 1% oxygen. The 
quantities of medium components to achieve required concentrations are 
given in the section below.  
2.1.1 Growth and washing media preparation: 
The materials below were mixed with the indicated quantities and filtered 
for parasite washing and growth medium under aseptic conditions in a 
laminar flow hood.  
2.1.1.1 Washing medium:  
 500 ml RPMI 1640 (R0883, Sigma, USA) stored at 4°C.  
 5 ml L- Glutamine solution (200 mM, G7513, Sigma) stored at -20°C. 
 18.75 ml of HEPES Buffer (1 M, H0887, Sigma) kept at -20°C and 
stored at 4°C once thawed. 
 5 ml 20% Glucose solution (7 mM, Sigma). 
 3 ml 1 M Sodium Hydroxide solution. 
 1.25 ml Gentamicin Sulphate solution to give 25 ng/μl (10 mg, G1272, 
Sigma) stored at 4°C. 
2.1.1.2 Growth medium:  
100 ml of the mixture was taken and used as washing medium; it was 
stored at 4°C. Then, 45 ml pooled human serum was added to the 
remaining mixture and then filtered and stored at 4°C. All solutions used 
in parasite culture were warmed in 37°C water bath or incubator prior to 
use. 
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2.1.1.3 Human pooled serum: 
Blood was collected from the Royal Hospital (Liverpool, UK) in non-
anticoagulant blood collection bags and stored overnight at 4°C. Then, it 
was centrifuged at 3000 rpm for 20 minutes. After this, the serum was 
carefully removed, mixed and stored in 45 ml aliquot in -20°C.  
2.1.2 Red Blood Cells separation:  
Non-erythrocyte components were removed from the whole blood before 
using it in parasite culture. First, 12.5 ml of Histopaque (10771, Sigma) 
was put in 50 ml Falcon tubes. 25 ml of washing medium was added and 
mixed with 25 ml of blood cells in a 50 ml Falcon tube. Then, 12.5 ml of 
the blood mixture was added to Histopaque dropwise. The solution was 
then centrifuged at 3000 rpm for 15 minutes after which the supernatant 
was removed before adding approximately triple the volume of washing 
medium. The mixture was mixed and centrifuged at 3000 rpm for 5 
minutes. The supernatant was aspirated and the RBC pellet was 
resuspended in an equal volume of washing media and stored at 4°C. 
The RBCs are known as washed RBC (wRBC) and have a haematocrit 
of approximately 50%.  
2.1.3 Parasites thawing: 
Appropriate volumes of 12% NaCl, 1.8% NaCl, 0.9% NaCl with 0.2% 
glucose, washing media and growth media were warmed at 37°C before 
used. The stabilate was carefully removed from liquid nitrogen following 
the code of practice according to LSTM policy.  The parasites were 
warmed rapidly at 37°C before transferring them into a 50 ml falcon tube. 
Depending on the volume of the pellet, one-fifth of its volume of 12% 
NaCl was added dropwise and mixed with the pellet. In other words, if 
the pellet was 1000 µl, then, 200 µl of 12% NaCl was added.  It was 
incubated at room temperature for five minutes. After that, five volumes 
of 1.8% NaCl to the original pellet volume was added dropwise and 
incubated for five minutes. This is followed by the addition of five 
volumes of 0.9% NaCl containing 0.2 % glucose and incubated for five 
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minutes at room temperature. The mixture was centrifuged at 1800 rpm 
in a bench top centrifuge for five minutes. The pellet was washed with 
washing medium and centrifuged at 1800 rpm for five minutes. Then it 
was resuspended in an appropriate volume of complete medium, 
transferred to a small culture flask and gassed for 30 seconds. The flask 
was incubated in a 37°C incubator.   
2.1.4 Evaluating parasite growth and continuous culture 
maintenance: 
The parasitemia was assessed using Giemsa thin smear and accordingly 
appropriate volume of wRBC was added. Parasitemia was assessed by 
making a Giemsa thin smear and examination under a light microscope. 
Five hundred (500) RBCs were counted, the number of IEs and their 
stages were recorded. The smears of cultures were acquired by taking a 
drop from culture and smoothly spread on a labelled glass slide and air-
dried at room temperature. The smear was fixed with absolute methanol 
for few seconds before staining with 10X diluted Giemsa for about 
20 minutes at room temperature. Giemsa stain stock solution was diluted 
with 10 % phosphate-buffered water (20 mM Na2HPO4 and 4 mM 
KH2PO4 at pH 7.2). Then, the stain was washed using tap water and air-
dried, before examining the smear under a binocular light microscope 
using an oil immersion (100×) objective lens.  
Parasites culture was mostly adjusted at 1% parasitemia and 1% 
haematocrit. The calculations for adjusting the parasitemia for continuous 
culturing were carried using the formula: P1 V1 = P2 V2, where P1 is the 
counted parasitemia for the assessed culture, V1 is the volume of the 
assessed culture, P2 is the required parasitemia to continue culturing the 
parasites, which is usually 1- 1.5 %, and V2 is the required volume of 
required to maintain the growth at given the parasitemia. To adjust the 
haematocrit at 1%, 10 µl of 100% packed RBCs was required for 1 ml of 
culture. But, because the stock of wRBC diluted to 50%, the volume must 
be doubled. Haematocrits of parasite culture and wRBC were assessed 
using a Coulter counter. 
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2.1.5 Parasite synchronisation:  
2.1.5.1 Plasmion flotation: 
The culture was transferred to a 50 ml Falcon tube and centrifuged at 
1800 rpm for five minutes and the supernatant was discarded. The pellet 
was resuspended in incomplete medium in 1.5X of pellet volume. Then, 
the mixture was transferred into a 15 ml Falcon tube.  After this, the 
suspension was mixed with an equal volume of Plasmion and allowed to 
settle for 20 - 30 mins at 37ᵒC. Trophozoite stage knobby IEs could be 
seen in the top layer of the suspension. This was carefully transferred to 
another 15 ml Falcon tube. The tube was centrifuged at 1500 rpm for 5 
minutes and the supernatant discarded. Then, the pellet was gently 
resuspended in 10 ml incomplete media and centrifuged at 1500 rpm for 
5 minutes. The supernatant was aspirated and a thin smear of it was 
prepared before adding the appropriate volume of complete medium and 
fresh wRBC, and gassed as described earlier. Smears taken after this 
procedure usually showed more than 50% IEs at mature stages. This 
selection was routinely performed to ensure that knobby populations are 
kept for adhesion assays as described earlier by (Jensen, 1978).  
2.1.5.2 Sorbitol: 
In some occasions, culture was synchronised using 5% of sorbitol 
(S3889 ,Sigma), which is a selective lysis for the IEs with trophozoites 
(Lambros and Vanderberg, 1979). It is used if the culture is at high rings 
parasitemia. The culture was pelleted and treated by 10X of 5% of 
sorbitol for 20 minutes 37ᵒC. Then, it was centrifuged at 1800 rpm for five 
minutes.  The supernatant was discarded and the pellet washed with 10X 
of washing medium. Then, the pellet was resuspended in an appropriate 
volume of growth medium, transferred to a new flask, gassed and 
incubated at 37ᵒC. To prepare 5% of sorbitol, 25 g of sorbitol (Sigma Co, 
UK) was dissolved in 500 ml of distilled water, filtered and kept at 4ᵒC.  
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2.1.6 ICAM-1 Selection:  
50 µl Protein A Dynabeads (10001D, Invitrogen) were washed 3 times 
with 200 µl 1% BSA/PBS using a magnet to retain the beads each time, 
and then resuspended in 200 µl 1% BSA/PBS (A8327, 30% Bovine 
serum albumin and D8537, Dulbecco’s phosphate buffer saline, Sigma). 
2.5 µg/ml ICAM-1Ref protein was added to the bead suspension. The 
mixture was rotated at 15 rpm at room temperature for 60 minutes. 
ICAM-1 labelled Dynabeads were purified on the magnet, washed three 
times in 1% BSA/PBS, and resuspended in 200 µl 1% BSA/PBS. 
Parasite culture was enriched for mature stages using Plasmion as 
described above. The enriched IE were incubated with ICAM-1 labelled 
Dynabeads and rotated for 45 minutes at room temperature. Unbound 
parasites were removed by three gentle washes with 1% BSA/PBS. IE-
bound beads were resuspended in complete media with fresh washed 
red blood cells and cultured as standard. 
2.1.7 Selection of IT4var14 on BC6 antibody:    
The selection for IT4var14 was carried out using BC6 mAb (Oxford 
University) that recognises IT4var14 specifically (Smith et al., 1995). It 
followed the same protocol for ICAM-1 selection, except protein G 
Dynabeads (10003D, Invitrogen) was used instead of Protein A 
Dynabeads. 
Batches of parasite stabilates were selected on recombinant ICAM-1 and 
BC6 were cryopreserved for providing enough materials for adhesion 
assays at relatively similar populations. This was made to minimize the 
effect of mixed populations and antigenic switching. The parasites were 
used in binding assays for only three weeks post-selection. 
2.1.8 Cryopreservation of parasites:  
The cultures of about 5-8% at ring stage parasitemia were pelleted and 
cryopreserved by re-suspending in a glycerolyte freezing medium. 
Cryopreservation was carried out after the following calculations:  
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Three volumes of the pellet resuspended in five volumes of the 
cryopreservation media. The addition of cryopreservation media was 
carried in two steps. First, the pellet resuspended with one-fifth volume of 
the required cryopreservation solution. Then, it was ensured that the 
pellet was completely resuspended in the media and allowed to stand for 
five minutes at room temperature. Second, the remaining volume was 
added gently but completely mixed before transferring to properly 
labelled cryovials. The cryovials were kept in a rack, covered with tissue 
to allow slow freezing at -80ᵒC for overnight. On the following day, vials 
were transferred to cryostore. Example for the calculations of 
cryopreservation is given below: If the pellet was 1000 µl, then the 
cryosolution required was 1666 µl. (1666 µl / 5) = 333 µl, this volume was 
first suspended with the pellet. Then, (1666-333) = 1333 µl, this 
remaining volume for second resuspension.  
2.2 ECs culturing:  
HDMEC (C-12210) and HUVEC (C-12200) were obtained from 
Promocell. The original vials contain 1 ml of cryopreserved cells at 
passage 1 (P1). HBMEC (ACBRI 376) (P3) were obtained from Cell 
system.  
2.2.1 Thawing ECs:  
Cryopreserved cells were warmed briefly at 37°C and properly sprayed 
with disinfectant prior to transferring the cells into T25 flask contains 5 ml 
of warmed medium.  The cells were allowed to attach for 2-3 hours at 
37°C in a CO2 incubator. Then, the medium was replaced by the same 
volume of warm medium and incubated for 48 hours. Cells were checked 
for confluence and culture media replaced. Once cells were confluent, 
sub-culturing was carried out following the standard protocol and 
manufacturer’s instructions.  
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2.2.2 ECs sub-culturing:  
All the used media were recommended by the manufacturers. HDMEC 
and HBMEC medium were cultured in Endothelial Cell Growth Medium 
MV (Ready-to-use) (C-22020) which was supplemented with Endothelial 
Cell Growth Medium MV SupplementMix (C-39225). HUVEC media 
Endothelial Cell Growth Medium (Ready-to-use) (C-22010) was 
supplemented with Endothelial Cell Growth Medium SupplementMix (C-
39215). Media were kept at 4°C and aliquots were warmed before use.    
Sub-culturing was done using Promocell detach kit (C-41220). The kit 
contains HEPES-buffered Balanced Salt Solution (HEPES-BSS), 
Trypsin/EDTA Solution and Trypsin Neutralization Solution (TNS). All 
solutions were aliquoted and warmed at 37 °C prior to use. Culture 
medium in the flask was aspirated; then, 1.5 ml of HEPES-BSS was 
added to wash the remaining medium and it was aspirated before adding 
1.5 ml of trypsin to detach the cells. Cell detachment was observed under 
an inverted microscope. Then, similar volume of TNS was added 
immediately as soon as the cells have detached in order to reduce 
possible effect of trypsin. The mixture was transferred into 15 ml Falcon 
tube and pelleted at 1200 rpm for 3 minutes. Then, the cells were 
resuspended gently into warm fresh media and distributed into gelatine 
coated T-75 flask. Cells at this stage considered at P2, cells were 
expanded until P3 and then cryopreserved for adhesion assays at P4, P5 
and P6.  
2.2.3 ECs cryopreservation: 
Cells were detached for cryopreservation as described for sub-culturing. 
But, instead of suspension in media, they were resuspended in 
Promocell Cryo-SFM (C-29910) at 5-7.5 X105 cells/ml. The vials were 
frozen gradually (-20°C/few minutes) to -70°C overnight before storing 
them in liquid nitrogen.  
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Recombinant proteins: 
Many thanks for Mr Tadge Szestak, laboratory manager, for providing 
proteins stocks of ICAM-1-Fc  reference  (ICAM-1Ref (Gray and Craig, 
2002)). Mutant ICAM-1 variants (ICAM-1  Kilifi  (ICAM-1Kilifi), ICAM-1 
S22/A (ICAM-1 S22/A)  , ICAM-1 L42/A (ICAM-1 L42/A) and ICAM-1 L44/A 
(ICAM-1 L44/A)) were prepared as described previously (Tse et al., 2004).  
2.3 Static adhesion assays: 
Purified  recombinant  proteins  were  spotted  in  triplicate  in  a radial  
pattern  using  2 µl  spots  on  60mm plastic petri dishes (Falcon 1007; 
Becton Dickinson, Oxford, UK) at concentrations of 50 µg/ml for ICAM-1, 
two plates were prepared for each parasite isolate. The dishes were 
incubated in a humidified chamber for 2hrs at 37ᵒC to allow the proteins 
to adsorb to the surface, after that the spots were aspirated off and the 
plastic petri-dishes were filled with 1% BSA/PBS, blocking buffer, and 
incubated overnight at 4ᵒC. The plates were warmed at 37ᵒC for one 
hour prior the assay. IE were suspended in binding buffer (RPMI 1640 
R4130 (Sigma, Dorset, UK) in 2% glucose at pH 7.2) at 3% parasitemia 
and 1% haematocrit. The blocking buffer was removed from the dish 
prior to adding 1.25 ml of the IE suspension. The plates were incubated 
at 37ᵒC for one hour with gentle resuspension every 10 minutes. Then, 
the IE suspension was removed by gentle manual washing (4–6 washes) 
with binding buffer medium. The bound IE were fixed with 1% 
glutaraldehyde in PBS for 1 hour and stained with 10% Giemsa for 20 
minutes. Six pictures were captured for each spot under x20 
magnification using software HC Image (Sewickley, USA). The pictures 
were analysed by Image-Pro version 7 (Rockville MD, USA). The results 
were expressed as the mean number of IE bound per mm2 of surface 
area. 
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2.4 Static inhibition assays: 
The same static binding technique described above was applied with the 
addition of mAbs at 5µg/ml to the IE suspension prior adding it to the 
plates. All the anti-ICAM-1 mAbs were commercially available; 15.2 (AbD 
serotec), My13 (Invitrogen), 8.4A6 (Sigma), BBIG-I1 (R&D systems). 
Anti-CD36 IVC7 was kindly provided from Dr van der Schoot. 
2.5 Flow cell adhesion assay:  
Sub-culturing followed the standard protocol following manufacturer’s 
instructions. Cells were washed with HEPES-buffered Balanced Salt 
Solution), trypsinised and neutralised. However, for the flow assay 
Accutase (Sigma) was used as an alternative detaching reagent instead 
of trypsin. 
Details about the system can be found on the Cellix website via: 
http://www.cellixltd.com/. TheVenaFlux is a semi-automated microfluidic 
system able to perform cell adhesion studies under shear flow mimicking 
in vivo flow rates. It is designed to facilitate the study of cell adhesion, 
and to be more physiologically relevant than static assays. Its 
construction makes it easier to use than previous systems used to mimic 
physiological rates of flow in vessels for P. falciparum adhesion studies. 
The system includes VenaEC 8-channels designed for growth of human 
endothelial cells with continuous feeding during the experiment and 
parameters that can be adjusted and monitored during the experiment 
through the VenaFlux software. 
VenaEC 8-channels (Cellix - Dublin, Ireland) were coated with 12 µl of 
100 µg/ml fibronectin and incubated in a humidified petri-dish at 4°C 
overnight. Cells were activated with 10 ng/ml TNF 16–24 hours before 
the day of the assay. On the following day, VenaEC 8-channels were 
warmed at 37°C for 30 minutes. The endothelial cells (EC) were treated 
with Accutase, detached and then neutralised with medium. The EC were 
pelleted at 1200 rpm for 3 minutes and resuspended in an appropriate 
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volume EC medium to achieve 1.5×106 cells/ml. Then, 5 µl of this 
suspension were seeded onto each channel and incubated at 37°C. 
Once the cells attached to the channels, they were fed every 30 minutes 
until the EC become confluent, usually within 2–3 hours. The IE 
suspension for both binding and inhibition assays was prepared as 
described in static assays except the haematocrit was adjusted to 2%. 
The assay was run following the Cellix protocol using the VenaFlux 
software. VenaEC 8-channels were connected to Cellix system in a 
microscope stage enclosed within a plastic chamber to keep the 
temperature at 37°C. The flow through the channels was adjusted to run 
0.04 Pa and the IE suspension was drawn through the channel for five 
minutes. After that, binding buffer was passed through the cell at the 
same rate to wash for two minutes. The bound IE were counted in six 
fields and converted to the number of IE/mm2. For binding inhibition, all 
mAbs were used at 5 µg/ml. The IVC7 anti-CD36 mAb was kindly 
provided by Prof. Ellen van der Schoot (Sanquin, Amsterdam). 
2.6 Flow protein adhesion assay:  
Flow protein adhesion assay was carried out using the same system that 
was mentioned above with the following changes; The proteins chip was 
called Vena8 Fluoro+™ biochip (Cellix) and it was coated with 5 µl of 50 
µg/ml ICAM-1 or CD36, and incubated in a humidified petri-dish at 37°C 
for two hours before blocking with 1% BSA/PBS and kept at 4°C 
overnight. On the following day, the channels were warmed at 37°C for 
30 minutes while the IE suspension was prepared as described in static 
assay protocol except that the haematocrit was adjusted to 2%. 
2.7 Detection of IT4-ICAM-1 gene expression:   
2.7.1 RNA extraction:  
Synchronized ring stage parasites 16–18 h pelleted infected erythrocytes 
were completely dissolved in 10× volumes of TRIZOL reagent 
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(Invitrogen) and stored at −80 °C until RNA puriﬁcation. RNA extraction 
was performed as previously described (Kyes et al., 2000). Appropriate 
precautions were taken to avoid RNase contamination when preparing 
and handling RNA. 
Frozen samples were allowed to warm at room temperature for 10-15 
minutes. All the following volumes were added based on 1 ml of 
dissolved parasites in Trizol. 200 µl of chloroform which was added until 
the sample homogenized. The sample was vigorously shaken by hand 
for 15 seconds and incubated for 2–3 minutes at the room temperature. 
The sample was centrifuged at 12,000 × g for 30 minutes at 4°C. The 
sample was very carefully removed from the centrifuge, because RNA 
remains in an upper colourless aqueous phase which should be nearly 
half of the whole mixture. The tube was then angled at 45° and the 
aqueous phase was carefully transferred into a new tube. Thereafter, 
RNA was precipitated by adding 500 µl of 100% isopropanol and mixed 
gently by inverting the tube for a few times and incubated on ice for 120 
minutes or alternatively at 4°C overnight. The sample was quickly 
vortexed before centrifugation at 12,000 × g for 30 minutes at 4°C. After 
precipitation, RNA pellets as a gel-like form and the pellet is usually 
unseen at this step, thus, extra care is required while pipetting the 
supernatant out.  RNA was washed with of 500 µl 75% ethanol (75 
ethanol: 25 DEPC-H2O) and then centrifuged at 7500 × g for 5 minutes 
at 4°C. The supernatant was discarded and the RNA pellet was allowed 
for air-drying at room temperature for no more than 5 minutes. Then, the 
pellet resuspended by DEPC-H2O by just dropping the solvent onto it and 
incubated at 55–65°C for 10 minutes. It was then placed on ice and 
mixed by pipetting before measuring the concentration using Nanodrop. 
The sample was immediately treated with DNase I or alternatively stored 
at –80°C if not proceeding to cDNA synthesis.  
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2.7.2 cDNA synthesis: 
DNase I treatment was carried out according to the manufacturer’s 
instructions. Following the DNase I treatment, cDNA synthesis was 
performed using SuperScript™ III RT (Invitrogen).  It was carried out in 
20-µl reaction volume which is suitable for 10 pg–5 µg of total RNA. The 
reaction included 1 µl of 250 ng of random primers, 250 ng of the RNA, 1 
µl 10 mM dNTPs, 4 µl 5X First-Strand Buffer, 1 µl 0.1 M DTT, 1 µl 
RNaseOUT™ (Recombinant RNase Inhibitor) (Invitrogen), 1 µl of 
SuperScript™ III RT, 1 µl of E. coli RNase H (Invitrogen) and distilled 
water. 
The reaction was initiated by adding random primers, RNA, dNTPs, 
water and then, heat incubated at 65°C for 5 minutes, followed by at least 
1 minute incubation on ice. The tube was briefly centrifuged before adding 
5X First-Strand Buffer, DTT, RNaseOUT and SuperScript™ III RT and 
gently mixed by pipetting up and down. Then, it was incubated at 25°C for 
5 minutes, 50°C for 45 minutes and 70°C for 15 minutes in PCR machine. 
There was need to do another reaction that was not treated by 
SuperScript RT to give RT negative control for the q-RT-PCR.  
2.7.3 Quantitative PCR: 
The q-RT-PCR was run using Stratagene mx3005p (Agilent). PCR 
cycling conditions were 95°C for 3 mins followed by 40 cycles of 95°C for 
10 s, 60°C for 10 s with a final cycle at 95°C for 1 min, 55°C for 30 s, 
95°C for 30 s. The reaction contained nuclease-free PCR-grade H2O, 
10 µl 2× SYBR green QPCR master mix, 1 µM of primers, and 50 ng 
cDNA. The internal controls were genes encoding adenylosuccinate 
lyase and seryl-tRNA synthetase. Data were acquired using the formula:  
     2
-∆CT= 2 - (the mean of three readings CT of IT4varX – the mean of CT of housekeeping genes).  
Ct values were obtained by exporting data sheets from the MxPro QPCR 
Software (version 4.10). 
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The primers of IT4-ICAM-1 isolates were published by (Wang et al., 
2012). The sequences are given in the following table: 
Target  
IT-ICAM1 
 gene 
Forward primer Reverse primer 
IT4var01 TGCAATGTAACACACTCACG CACTATACCACAGGCATCTTC  
IT4var13 TCGGGCAACAACACTATCAA CCCCATTCAATAAACCATCG 
IT4var14 AAACCGACACAACAACCGACGACGAC ACTATTTCGCACGCATCTGGTGGC 
IT4var16 ACCGGAAGCACCACAAGAAC GCACCACTTATGCATTTCCATCC 
IT4var31 CAAGATGGCAGCATTGAAAA CGCCTCCTTCTGCATCTTAC 
IT4var41 GGACATGTCAGGTCATCACG ACCATTCTGCCCATTCAGTC 
Table 2.1.1: The primers of IT4-ICAM-1 isolates were published by (Wang et al. 
2012). 
2.8 Adult Hyperimmune sera (HIS) reactivity: 
Fluorescence-activated cell sorting (FACS) was used to assess the 
ability of adult HIS to recognise the surface of IEs with upsC HB3 P. 
falciparum isolates that were not able to bind to recombinant proteins 
such as CD36 and also did not bind to ECs. More than 50% of mature 
stages were enriched using Plasmion as previously described. Then, 3 µl 
of the washed pellet was resuspended in 1 ml of PBS with 1% bovine 
serum albumin (1%BSA/PBS) to prepare the IE suspension. 100 µl which 
contains about 8-10 × 106 cells were transferred to 1.5 ml Eppendorf 
tubes. The cells were washed and the pellet of all isolates including A4 
was resuspended with 1:10 of 30 mg adult HIS sera (unknown reactivity) 
and 1:10 human sera (negative control, serum was collected from the 
Royal Hospital (Liverpool)). The positive control for PfEMP1 labelling was 
IT4var14 (A4) incubated with 20 µg/ml BC6 for an hour at 37°C followed 
by the appropriate secondary antibody.  
After incubation, cells were pelleted and washed twice with 1% 
BSA/PBS. After that, bound IEs were resuspended in 1:100 dilution of 
APC-conjugated mouse anti-human IgG secondary antibody (Molecular 
probes) mixed with 10 µg/ml ethidium bromide for staining the IE nuclei. 
For A4-BC6 labelling, APC conjugated goat anti-mouse IgG (Thermo 
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Scientific) was used. Cells were incubated covered from light for 60 
minutes at 37°C. Then, cells were washed twice with 1% BSA/PBS and 
resuspended with 400 µl of Cell Wash (FACS solution). The analysis was 
performed using Becton-Dickinson FACSCalibur flow cytometer (BD 
LSR11). Data were acquired using FACSCalibur flow cytometer, and 
50,000 events were collected and analyzed with FlowJo software (Tri 
Star, San Carlos, CA, USA).  
2.9 FACS for Endothelial Cells receptors detection:  
Cells were grown in 12 well-plates until they become confluent at 37°C in 
a 5% CO2 incubator. The cells in some wells were stimulated with 10 
ng/ml TNF overnight. The cells were washed with HEPES, trypsinized 
and neutralised as described above. Cells were centrifuged at 5000 rpm 
for 5 minutes and the pellets were washed with 1% BSA/PBS prior to 
adding conjugated monoclonal antibody APC- mouse anti human ICAM-
1, APC- mouse anti human-EPCR and FITC mouse anti human CD31 for 
both stimulated and non-stimulated cells (BD Biosciences Ltd). It was 
incubated at 37°C for 60 minutes in dark conditions. In parallel, isotype 
matched antibody were used to ensure the absence of non-specific 
labelling (BD Biosciences Ltd). The cells were then washed with 1% 
BSA/PBS before transferring to FACS solution to measure the receptor 
expression by FACS.  
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3.1 An Analysis of the Binding Characteristics of a 
Panel of Recently Selected ICAM-1 Binding P. 
falciparum Patient Isolates.   
3.1.1 Introduction: 
The later stages of the asexual intraerythrocytic cycle of P. falciparum 
are not seen in the circulation because of their ability to localise to 
different organs in a phenomenon called sequestration. Understanding 
some of the key events that facilitate sequestration is important to identify 
possible targets to develop either inhibitors or vaccines (Rowe et al., 
2009). Plasmodium falciparum erythrocyte membrane protein-1 (PfEMP-
1) (Baruch et al., 1995, Smith et al., 1995, Su et al., 1995) mediates 
sequestration with various human receptors (Rowe et al., 2009)  
including ICAM-1 (Berendt et al., 1989), CD36 (Barnwell et al., 
1989, Oquendo et al., 1989) and EPCR (Turner et al., 2013).  
ICAM-1 binds to LFA-1 or Mac-1 and also mediates binding to 
pathogens, such as human rhinoviruses (HRVs) (Greve et al., 1989, 
Staunton et al., 1989), and P. falciparum infected erythrocytes (Berendt 
et al., 1989). The ICAM-1 binding sites for IEs, rhinoviruses, LFA-1 
and fibrinogen are overlapping, but also have distinct regions (Berendt 
et al., 1992, Ockenhouse et al., 1992).  
Several lines of evidences support the involvement of ICAM-1 in malaria 
pathology. First, a  study conducted on post-mortem samples obtained 
from people diagnosed with CM showed accumulation of IEs in  brain 
vessels that co-localised with ICAM-1 (Turner et al., 1994). In addition, 
ICAM-1 was found up-regulated in brain accompanied with P. 
falciparum infection (Turner et al., 1998). Isolates from SM patients and 
particularly from CM revealed higher binding to ICAM-1 than isolates 
from AM (Newbold et al., 1997, Ochola et al., 2011, Turner et al., 2013), 
although this is not observed in all studies. Additional line of evidence is 
the association between CM and a homozygous mutation in ICAM-1 
in Kilifi, Kenya, named ICAM-1
Kilifi 
(Fernandez-Reyes et al., 1997), 
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although it should be noted that other observations such as those in the 
Gambia and Thailand did not show an association between ICAM-1Kilifi 
and severe malaria (Bellamy et al., 1998, Ohashi et al., 2001). In 
contrast, ICAM-1Kilifi was suggested to have a protective role in Gabon 
(Kun et al., 1999).  
The binding site of ICAM-1 to PfEMP1 has been studied using alanine 
replacement mutagenesis and ICAM-1-specific mAbs. The binding region 
on ICAM-1 for P. falciparum IEs was revealed to involve the BED face of 
ICAM-1 which is three β-strands of ICAM-1 named B, D, and E, including 
the DE loop (Figure 3.1.1) (Tse et al., 2004). Earlier studies have 
investigated ICAM-1 binding phenotypes under both flow and static 
conditions on endothelial cells and purified proteins. These studies have 
shown that IE have subtle differences in binding to ICAM-1 with variable 
affinities and avidities ranging from 2.8 nM to 144 nM for a number of 
PfEMP1 variants from the IT4 lineage (Brown et al., 2013).  
  
Figure 3.1.1: The crystal structure of the N-terminal domain of human ICAM-1, 
showing the binding sites for IEs with P. falciparum, LFA-1, fibrinogen. The 
strands of the β-barrel are labelled A to G. The figure shows the BED side. It is 
cited from (Tse et al., 2004)  
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PfEMP-1 proteins are encoded by 50-60 extremely variable var genes 
per parasite genome (Gardner et al., 2002). Inspite of the variation of the 
var genes, they can be categorised into three major groups; A, B, and C 
based on their chromosomal locations and promoter sequence (Kraemer 
and Smith, 2003, Lavstsen et al., 2003). Group A var genes are more 
conserved than the others and have been associated with severe malaria 
(Jensen et al., 2004). A typical PfEMP-1 structure contains two to seven 
Duffy-binding–like (DBL) domains and one to two cysteine-rich 
interdomain region (CIDR) domains (Gardner et al., 2002). Specific 
domains have been implicated in binding to certain host receptors (Smith 
et al., 2000a). A very recent sub-classification for DBL and CIDR 
domains from seven parasites genomes has identified number of shared 
combinations of short tandem domain cassettes (DCs) in several 
different parasite strains (Rask et al., 2010). Among the Group A PfEMP-
1s, there are  several  ICAM-1– binding DBL domains isolates identified 
so far, including PFD1235w, Dd2var32 (Jensen et al., 2004) and 
PF11_0521 (Oleinikov et al., 2009, Gullingsrud et al., 2013). Additionally, 
from these isolates, it was possible to classify a novel tandem three-
domain of PfEMP1 region named DC4, and antibodies to this region 
have been described to be cross-reactive with group A PfEMP1 proteins 
that bind to ICAM-1 (Bengtsson et al., 2013). However, although DC8 
and DC13 cassettes found in Group A PfEMP1 proteins were associated 
with SM (Avril et al., 2012, Claessens et al., 2012, Lavstsen et al., 2012), 
IEs expressing DC8 and DC13 did not to bind to ICAM-1 (Avril et al., 
2012, Lavstsen et al., 2012). 
In the current chapter, the binding phenotypes for ICAM-1-selected, 
recently lab-adapted patient isolates was investigated under static and 
flow adhesion assays. The analysis included four mutant ICAM-1 variants 
that have previously shown different effects on laboratory isolates (Tse et 
al., 2004) and the effect of four anti-ICAM-1 mAb using static assays, 
increasing the number of the isolates in comparison with earlier studies. 
Understanding crucial events in cytoadherence is important in identifying 
possible targets in order to develop either effective inhibitors or vaccines. 
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3.1.2 Methods:  
3.1.2.1 Parasites isolates:  
Laboratory isolates, A4 (Ockenhouse et al., 1992) and ItG (Roberts et al., 
1992) and lab-adapted patient isolates 8146, 8206, 8131, 6392, PO-69, 
(from Kenya) J1, PCM-7, BC-12  and GL-6 (from Thailand (Poyomtip et 
al., 2012)) were cultured as described in general methods using  
standard  culturing  techniques at 1% haematocrit in  O+ human  
erythrocytes  (Trager and Jensen, 1976).  A batch of parasite stabilates 
selected on recombinant ICAM-1 was made to reduce the effect of 
antigenic switching and mixed populations. The parasites were used in 
binding assays for only about 10 cycles after ICAM-1 selection.  
All patient isolates were collected with consent as part of clinical studies 
in Thailand and Kenya, and all patient material have been removed 
during culture, replaced with blood sourced commercially from the UK 
Blood Transfusion Service. 
3.1.2.2 ICAM-1 selection:  
Described in the general methods.   
3.1.2.3 Adhesion assays:  
Static and flow protein adhesion assays were used to assess the binding 
of parasites to ICAM-1. Also, flow endothelial cells were performed on 
HDMEC. The binding to CD36 and ICAM-1 on ECs was inhibited by 5 
µg/ml anti-CD36 IV-C7 and anti-ICAM-1 15.2 mAbs. All these procedures 
were explained in the general methods including culturing ECs.   
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3.1.3 Results:  
3.1.3.1 Static adhesion of new ICAM-1 binding isolates on ICAM-1Ref: 
Based on the level of binding to ICAM-1Ref, all the isolates were 
categorised into high and low-avidity parasites. ItG was defined as a 
high-avidity ICAM-1 binder whereas, A4 was characterised as low-avidity 
ICAM-1 binder from previous studies (Gray et al., 2003). Only two of the 
lab-adapted isolates were high-avidity ICAM-1 binders; 8146 and 8206. 
The rest of the isolates were assigned as low-avidity binders (Figure 
3.1.2). 
 
Parasites 
Mean IE 
binding/mm2 
N SE 
ItG 4746 24 470 
A4 1939 9 477 
8146 5147 9 1150 
P069 1515 11 250 
PCM7 689 6 269 
6392 1584 8 655 
8131 424 10 93 
BC12 1362 10 188 
8206 5901 11 942 
J1 2391 8 622 
GL6 1968 9 531 
Table 3.1.1: Static adhesion of IEs with selected ICAM-1 binding isolates to 
ICAM-1Ref. The table presents the means of IE binding/mm2, the number of 
experiments and the SE. 
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Figure 3.1.2: Static adhesion of IEs with selected ICAM-1 binding isolates to 
ICAM-1Ref, 2 μl spots of 50 μg/ml ICAM-1Ref were placed onto 6 cm dishes and 
standard protein static binding assays conducted with IE suspended in binding 
buffer at a parasitaemia of 3% and a haematocrit of 1%. The results show the 
mean of binding and the bars represents SE (n can be found in table 3.1.1). 
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3.1.3.2 Static adhesion of new ICAM-1 binding isolates to mutant 
ICAM-1 variants: 
The current study showed that there were considerable differences in IE 
binding to mutant ICAM-1 proteins (Figures 3.1.3 - 3.1.6). The binding of 
isolates was variably disturbed by the ICAM-1Kilifi mutation. ICAM-
1Kilifi affected the binding of four isolates by approximately 50%. 
Furthermore, there were three isolates whose binding was decrased by 
more than 75%, 6392, PCM7 and 8131. Whereas the ItG and PO69 
parasites was only reduced by 20% (Figure 3.1.3 and Table 3.1.2). The 
S22/A mutation considerably reduced the binding of the high-avidity 
isolates and some of the low-avidity isolates; GL6 and 6392, by around 
80%. In addition, there was a moderate effect on PO69, BC12 and J1 
(Figure 3.1.4 and Table 3.1.3). On the other hand, the effect of L42/A 
mutation revealed critical effect on all of the isolates, decreasing the 
binding by at least 50% incomparison with ICAM-1Ref, with the binding 
almost entirely inhibited for most isolates, including the high-avidity 
isolates (Figure 3.1.5 and Table 3.1.4). By contrast, L44/A mutation 
increased the binding for some isolates, and reduced the binding of GL6 
only (Figure 3.1.6 and Table 3.1.5).  
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A) Static adhesion of new ICAM-1 binding isolates on ICAM-1Kilifi: 
Parasites 
Mean IE 
binding/mm2 
N SE 
ItG 3807 20 489 
A4 897 9 236 
8146 3315 6 1461 
P069 1219 8 408 
PCM7 103 5 40 
6392 126 5 42 
8131 103 7 22 
BC12 609 8 86 
8206 3984 7 1116 
J1 1386 5 557 
GL6 1031 8 378 
Table 3.1.2: Static adhesion of IEs with selected ICAM-1 binding isolates to 
ICAM-1Kilifi.  The table presents the means of IE binding/mm2, the number of 
experiments and the SE. 
 
 
 
Figure 3.1.3: Static adhesion of IEs with selected ICAM-1 binding isolates to 
ICAM-1Kilifi. The results show the %ICAM-1Ref binding and the bars represent SE 
(n can be found in table 3.1.2). 
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B) Static adhesion of new ICAM-1 binding isolates on ICAM-1S22/A: 
Parasites 
Mean IE 
binding/mm2 
N SE 
ItG 336 20 67 
A4 1221 9 285 
8146 663 6 315 
P069 1084 8 347 
PCM7 819 5 306 
6392 359 5 120 
8131 693 7 228 
BC12 895 8 121 
8206 111 7 26 
J1 1020 5 542 
GL6 109 8 37 
Table 3.1.3: Static adhesion of IEs with selected ICAM-1 binding isolates to 
ICAM-1S22/A. The table presents the means of IE binding/mm2, the number of 
experiments and the SE. 
 
 
 
Figure 3.1.4: Static adhesion of IEs with selected ICAM-1 binding isolates to 
ICAM-1S22/A. The results show the %ICAM-1Ref binding and the bars represent 
SE (n can be found in table 3.1.3). 
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C) Static adhesion of new ICAM binding isolates on ICAM-1L42/A: 
Parasites Mean IE 
binding/mm2 
N SE 
ItG 103 4 13 
A4 281 3 187 
8146 67 3 20 
P069 163 3 38 
PCM7 35 3 6 
6392 471 3 119 
8131 204 3 27 
BC12 583 3 29 
8206 90 4 23 
J1 107 3 73 
GL6 45 3 8 
Table 3.1.4: Static adhesion of IEs with selected ICAM-1 binding isolates to 
ICAM-1L42/A. The table presents the means of IE binding/mm2, the number of 
experiments and the SE. 
 
 
 
Figure 3.1.5: Static adhesion of IEs with selected ICAM-1 binding isolates to 
ICAM-1L42/A. The results show the %ICAM-1Ref binding and the bars represent 
SE (n can be found in table 3.1.4). 
 
0
20
40
60
80
100
%
 o
f 
R
e
f 
b
in
d
in
g
 
Parasite isolates  
65 
 
D) Static adhesion of new ICAM binding isolates on ICAM-1L44/A: 
Parasites Mean IE 
binding/mm2 
N SE 
ItG 4920 4 648 
A4 2767 3 850 
8146 8458 3 1123 
P069 1724 3 284 
PCM7 761 3 47 
6392 4257 3 681 
8131 1069 3 347 
BC12 2000 2 293 
8206 10385 4 248 
J1 2058 3 579 
GL6 821 4 18 
Table 3.1.5: Static adhesion of IEs with selected ICAM-1 binding isolates to 
ICAM-1L44/A.  The table presents the means of IE binding/mm2, the number of 
experiments and the SE. 
 
 
Figure 3.1.6: Static adhesion of IEs with selected ICAM-1 binding isolates to 
ICAM-1L44/A. The results show the %ICAM-1Ref binding and the bars represent 
SE (n can be found in table 3.1.5). 
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3.1.3.3 Static inhibition of new ICAM binding isolates using anti-
ICAM-1 mAbs:  
The effect of anti-ICAM-1 mAbs on the binding of IE to purified ICAM-1 
under static conditions has been investigated using specific mAbs 
reacting with epitopes on Ig-like domains one and two. MAbs 15.2, BBIG-
I1 and My13 mapping to domain one, and 8.4A6 mAb mapping to domain 
two were used in a study that differentiated between the binding sites on 
ICAM-1 for IE and LFA-1 (Berendt et al., 1992).  Different mAbs have 
shown different inhibitory effects on the isolates (Figures 3.1.7 - 3.1.10). 
The results are shown as the percentage of the binding of each isolate 
against the binding to ICAM-1Ref. The binding to ICAM-1 of most of the 
isolates was reduced by about 75% by two mAbs My13 and 15.2. 
Nevertheless, there was only 40% inhibition caused by 15.2 and My13 to 
PO69 (Figure 3.1.7 and 3.1.8 and Tables 3.1.6 and 3.1.7). The range of 
inhibition of BBIG-I1 was between 25%–75% for nearly all isolates except 
there was almost no effect on 8206 (Figure 3.1.9 and Table 3.1.8). There 
was different inhibition caused by 8.4A6; the effect varied between 25–
50% for most of the isolates, although there was no effect by 8.4A6 on 
the ItG and 8206 isolates (Figure 3.1.10 and Table 3.1.9) These 
variations again suggest the use of variable contact residues between 
ICAM-1 and variant PfEMP-1 proteins. 
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A) Static inhibition of new ICAM binding isolates using 15.2 mAb:  
Parasites Mean IE 
binding/mm2 
N SE 
ItG 158 4 46 
A4 649 4 249 
8146 355 4 93 
P069 1021 4 135 
PCM7 55 4 9 
6392 105 4 17 
8131 15 4 7 
BC12 248 4 60 
8206 1434 4 395 
J1 233 4 70 
GL6 428 4 329 
Table 3.1.6: 15.2 mAb static inhibition of IEs with selected ICAM-1 binding 
isolates to ICAM-1Ref.  The table presents the means of IE binding/mm2, the 
number of experiments and the SE. 
 
 
  
Figure 3.1.7: 15.2 mAb static inhibition of IEs with selected ICAM-1 binding 
isolates to ICAM-1Ref.  The results show the %ICAM-1Ref binding and the bars 
represent SE (n can be found in table 3.1.6). 
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B) Static inhibition of new ICAM binding isolates using My13 mAb:   
Parasites Mean IE 
binding/mm2 
N SE 
ItG 685 4 184 
A4 300 4 80 
8146 795 4 233 
P069 1106 4 245 
PCM7 54 4 10 
6392 270 4 72 
8131 45 4 9 
BC12 1075 4 327 
8206 1818 4 527 
J1 432 4 70 
GL6 269 4 134 
Table 3.1.7: My13 mAb static inhibition of IEs with selected ICAM-1 binding 
isolates to ICAM-1Ref.  The table presents the means of IE binding/mm2, the 
number of experiments and the SE. 
 
 
Figure 3.1.8: My13 mAb static inhibition of IEs with selected ICAM-1 binding 
isolates to ICAM-1Ref.  The results show the %ICAM-1Ref binding and the bars 
represent SE (n can be found in table 3.1.7). 
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C) Static inhibition of new ICAM binding isolates using BBIG-I1mAb:   
Parasites Mean IE 
binding/mm2 
N SE 
ItG 984 4 182 
A4 503 4 129 
8146 2372 4 1088 
P069 1106 4 342 
PCM7 69 4 10 
6392 353 4 114 
8131 105 4 36 
BC12 979 4 401 
8206 4407 4 788 
J1 1573 4 678 
GL6 747 4 610 
Table 3.1.8: BBIG-I1 mAb static inhibition of IEs with selected ICAM-1 binding 
isolates to ICAM-1Ref.  The table presents the means of IE binding/mm2, the 
number of experiments and the SE. 
 
 
Figure 3.1.9: BBIG-I1 mAb static inhibition of IEs with selected ICAM-1 binding 
isolates to ICAM-1Ref.  The results show the %ICAM-1Ref binding and the bars 
represent SE (n can be found in table 3.1.8). 
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D) Static inhibition of new ICAM binding isolates using 8.4A6 mAb: 
Parasites Mean IE 
binding/mm2 
N SE 
ItG 5494 4 1597 
A4 885 4 366 
8146 2173 4 280 
P069 740 4 174 
PCM7 183 4 39 
6392 578 4 182 
8131 101 4 28 
BC12 659 4 145 
8206 6769 4 1820 
J1 760 4 97 
GL6 144 4 32 
Table 3.1.9: 8.4A6 mAb static inhibition of IEs with selected ICAM-1 binding 
isolates to ICAM-1Ref.  The table presents the means of IE binding/mm2, the 
number of experiments and the SE. 
 
 
Figure 3.1.10: 8.4A6 mAb static inhibition of IEs with selected ICAM-1 binding 
isolates to ICAM-1Ref.  The results show the %ICAM-1Ref binding and the bars 
represent SE (n can be found in table 3.1.9). 
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3.1.3.4 Characterisation of new ICAM-1 binding isolates to HDMEC 
under flow conditions:  
A) Flow adhesion of new ICAM-1 binding isolates to HDMEC 
The binding level on HDMEC under flow conditions was similar for seven 
out of eleven isolates examined within the range 200–300 
IE/mm2 (Figure 3.1.11). In contrast, two isolates, J1 and 8146, bound 
within the range 600–700 IE/mm2 to HDMEC although J1 being assigned 
as low-avidity ICAM-1 binder on purified ICAM-1. Another two isolates, 
8131 and 8206, revealed relatively less binding to HDMEC although 
8206 was considered as a high-avidity ICAM-1 binder on ICAM-1 protein. 
Additional analysis using an anti-ICAM-1 mAb revealed similar activity for 
15.2 mAb on almost all isolates, reducing binding by approximately 50% 
(Figure 3.1.12 and Table 3.1.10). However, the binding was reduced by 
approximately 80% for eight isolates in the presence of the IV-C7, anti-
CD36, mAb and for the other three was reduced by about 60% (Figure 
3.1.13 and Table 3.1.11). 
 
 
Figure 3.1.11: HDMEC flow endothelial cell adhesion assay of IEs with selected 
ICAM-1 binding isolates: HDMEC seeded on channels pre-coated with 
fibronectin; IE were passed on confluent cells for five minutes followed by 
washing by binding buffer for two minutes before counting 6 fields. The 
parasitaemia was 3% and a haematocrit of 2%. The results show the mean of 
binding and the bars represents SE (n >3).  
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B) ICAM-1 inhibition of new ICAM binding isolates using 15.2 mAb 
under flow condition: 
Parasites Mean IE 
binding/mm2 
N SE 
ItG 115 15 18 
A4 91 3 10 
8146 279 3 39 
P069 68 3 13 
PCM7 118 3 1 
6392 123 3 27 
8131 29 3 5 
BC12 228 3 4 
8206 42 3 4 
J1 336 3 31 
GL6 171 3 40 
Table 3.1.10: Flow ICAM-1 inhibition on HDMEC of IEs with selected ICAM-1 
binding isolates, anti-ICAM-1 (15.2) was used at 5 μg/ml. The table shows the 
mean of the IEs binding in the presence of 15.2 mAb, N: number of experiments 
and the SE.  
 
 
Figure 3.1.12: Flow ICAM-1 inhibition on HDMEC of IEs with selected ICAM-1 
binding isolates using anti-ICAM-1 (15.2) mAb at 5 μg/ml. The figure shows the 
% binding against no inhibitory effect and the bars represents SE (n can be 
found in table 3.1.10). 
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C) CD36 inhibition of new ICAM binding isolates using IVC7 mAb 
under flow condition: 
Parasites Mean IE 
binding/mm2 
N SE 
ItG 26 8 5 
A4 22 3 3 
8146 42 3 11 
P069 64 3 2 
PCM7 15 3 2 
6392 37 3 4 
8131 18 3 2 
BC12 114 3 13 
8206 13 3 2 
J1 42 3 17 
GL6 27 3 8 
Table 3.1.11: Flow CD36 inhibition on HDMEC of IEs with selected ICAM-1 
binding isolates, anti-CD36 (IVC7) mAb was used at 5 μg/ml. The table shows 
the mean of the IEs binding in the presence of IVC7 mAb, N: number of 
experiments and the SE.  
 
 
Figure 3.1.13: Flow CD36 inhibition on HDMEC of IEs with selected ICAM-1 
binding isolates using anti-CD36 (IVC7) mAb at 5 μg/ml. The figure shows the 
% binding against no inhibitory effect and the bars represents SE (n can be 
found in table 3.1.11). 
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3.1.4 Discussion:  
The aim of this part was to establish the binding characteristics of a set of 
new ICAM-1 binding isolates to provide additional information about the 
interaction between ICAM-1 and the parasites. The purpose of using field 
isolates is usually to examine the association between clinical outcomes 
and binding phenotypes. The selection of ICAM-1 binding PfEMP-1 
populations in this study introduces bias by potentially increasing small 
sub-populations from the original sample and so cannot be used to 
derive associations between the binding phenotypes and clinical 
outcomes. Our original study used three genetically distinctive ICAM-1-
binding laboratory isolates (two of which (A4 and ItG) are included in this 
study for comparison), screened against 25 mutant ICAM-1 proteins 
using static and flow adhesion systems (Tse et al., 2004).  
Based on this earlier work, binding and inhibition assays were carried on 
a larger number of recently lab-adapted isolates using the ICAM-1 
mutations previously revealed to disrupt the binding and discriminating 
between laboratory isolates, using static assays only. Binding to 
endothelial cells was examined using a flow adhesion system.  
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Figure 3.1.14: Summary of the effects of mutant ICAM-1 variants and mAb 
inhibition on recently ICAM-1 selected isolates. 
Alanine replacement mutagenesis and ICAM-1-specific mAbs have 
provided more details about the binding region on ICAM-1 for P. 
falciparum-IEs (summarised in Figure 3.1.14). The binding between IEs 
and ICAM-1 was shown to involve the BED face of ICAM-1, containing 
the DE loop (Tse et al., 2004). The binding phenotypes from earlier 
studies were categorised based on the isolate’s avidity to ICAM-1. 
Overall, the new binding and inhibition data support the original 
outcomes that different ICAM-1-binding isolates can use variable contact 
residues in the DE loop of ICAM-1 to bind. Furthermore, current data 
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support earlier findings by indicating an important role for L42 for all 
ICAM-1-binding isolates.  
Two ICAM-1-specific mAbs 15.2 and My13, which have been mapped to 
epitopes including the L42 residue, decreased the binding of all the 
isolates. The binding of low-avidity-ICAM-1 isolates was more affected by 
these mAbs than high-avidity-ICAM-1 parasites. 8.4A6 mAb, which 
targets an epitope on domain two, can also prevent the binding of all 
isolates. This may be explained by the epitope in domain two being in a 
position close to domain one or disturbing the structure of this domain, as 
they have been shown to interact to produce the native ICAM-1 structure 
(Berendt et al., 1992). Interestingly, most of the isolates were low-avidity 
ICAM-1 binders similar to A4, which was previously associated with a 
signature that reveals isolates from SM cases (Ochola et al., 2011).  
Flow adhesion on endothelial cell assays more accurately resembles the 
situation seen in the human circulation than static assays (Chakravorty 
and Craig, 2005). In the current study, we used TNF-activated HDMEC, 
which expresses both CD36 and ICAM-1 receptors as well as other 
endothelial receptors, by using the Cellix system to measure IEs 
adhesion. The Cellix system has shown comparable results with former 
flow-based systems on different endothelial cells (data not shown). The 
binding to TNF- activated HDMEC was nearly the same level for seven 
out of elevenisolates, comparable to ItG and A4, which bind in the range 
200-300 IEs/mm2. The binding was reduced with both anti-ICAM-1 and 
anti-CD36 mAbs with the latter showing greater inhibition than anti-ICAM-
1. This could be explained by ‘receptor co-operation’ between ICAM-1 
and other receptors (Chakravorty and Craig, 2005, Davis et al., 2013). It 
is possible that ICAM-1 is not the only receptor involved in CM pathogy 
and, for example, a recent study has shown the ability of IEs to bind to 
EPCR and associated with SM, including CM (Turner et al., 2013, Esser 
et al., 2014).  
ICAM-1 has been suggested to play a capturing role from the circulation 
thereby contributing to the pathogenesis of CM (Gray et al., 2003). 
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However, the role of CD36 in sequestration is not clearly understood. 
CD36 binding is a typical phenotype for the majority of paediatric isolates 
and in some studies has been shown to be more linked with binding to 
isolates from UM cases. It has been suggested that the host uses CD36 
to control the parasitemia prior to host immune responses or to reduce 
pro-inflammatory responses (Ochola et al., 2011).  
 
The molecular basis of the variable binding to ICAM-1 is believed to be 
due to differences in the contact residues between ICAM-1 and the 
variant PfEMP1s. PfEMP1 binds to ICAM-1 through a different set of 
DBLβ domains mostly from groups B or C and it would be challenging to 
target DBLβ domains in these two groups due to their high sequence 
diversity. This is observd particularly in approaches to distinguish ICAM-1 
binding DBLβ domains from non-binding ones, which has only been fairly 
successful (Howell et al., 2008). There are ICAM-1 binders among the 
group A PfEMP-1 that contain a definable DC4 cassette (Bengtsson et 
al., 2013), but this is still at a very preliminary stage and requires more 
investigation to see if it could offer a starting point for the development of 
a vaccine targeting CM by preventing IEs sequestration via ICAM-1 in the 
brain. The variability in the binding characteristics between IEs and 
ICAM-1 suggests that it may well be a difficult problem to find a cross-
blocking theraputic intervention, although the vital role of the L42 residue 
and anti-DC4 blocking antibodies gives some support for this approach.  
The divergent binding pattern to variants of ICAM-1 of different IEs is 
similar to that revealed by the causative agent of the common cold, 
Human Rhinovirus (HRV). The main serotypes of HRV use ICAM-1 to 
invade the epithelium and two different HRV serotypes have revealed 
varying adhesion phenotypes to ICAM-1Ref and ICAM-1Kilifi, and their 
association with variable clinical outcome (Xiao et al., 2004). Very 
recently, an anti-human ICAM-1 antibody that specifically binds domain 
one of human ICAM-1, prevented entrance of two major groups of 
rhinoviruses, decreased virus burden, cellular, inflammation and pro-
inflammatory cytokine induction in vivo. Notably, this antibody did not 
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affect ICAM-1 binding to LFA-1, leaving this critical host pathway intact 
(Traub et al., 2013). Similar approaches might be used to lead to the 
development of novel treatment candidates to cut malaria morbidity and 
mortality rates but require a good understanding of the variety of IEs 
adhesion to ICAM-1. 
The essential outcome of this part of the study is the identification of vital 
targets on the sites of the interactions between parasite ligands and host 
receptors, which may result in the development of inhibitors which target 
IEs sequestration. In spite of the presence of rapid and effective parasite-
killing drugs, mortality still recorded among children with SM 
complications, in particular at the immediate period after admission to 
hospital. Several strategies to improve survival in malaria have been 
highlighted in a recent review (Miller et al., 2013). Among these is 
targeting parasite adhesion to the vascular endothelium. Anti-adhesion 
therapeutics is a promising project in the discovery of novel 
treatments, including compounds based on the structure of 
endothelial receptors (Dormeyer et al., 2006). High-throughput 
screening could identify adhesion blocking molecules that inhibit IE from 
binding or activating microvascular endothelium (Miller et al., 2013). The 
good example of this kind of rational-inhibitor design is (+)-EGCG, a 
polyphenol compound demonstrating significant inhibition ranging 
from 37 - 80% by the new ICAM-1-binding parasites used in the 
current study (Patil et al., 2011). The variaiable inhibition by (+)-
EGCG might be because of the variable contact residues on 
PfEMP1 of different patient isolates. The action mode of (+)-
EGCG is assumed to be its structural simulation of part of the ICAM-
1 binding site for IE based around the L42 loop.  
To conclude, the isolates tested in this chapter use variable contact 
residues on ICAM-1 for their binding. Nevertheless, L42/A inhibits the 
binding of all isolates, which support the concept of a conserved region 
used by PfEMP1 to bind on ICAM-1 and that could be used to target 
interventions.  
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3.2 A binding analysis of IT4 P. falciparum isolates 
that express ICAM-1-binding DBLβ domains.  
3.2.1 Introduction: 
The adhesion of IE to the endothelium of vital human organs is crucial to 
mediate malaria pathology. IE-ICAM-1 adhesion phenotype has been 
associated with CM (evidence of the involvement of ICAM-1 in CM has 
been mentioned in the previous chapter). Variable domains of PfEMP1 
have been shown to mediate several interactions with human receptors 
such as some CIDRα domains binding to CD36 (Baruch et al., 1997), 
and some DBLβ domains binding to ICAM-1 (Smith et al., 2000a, Howell 
et al., 2008). 
DBL domains are members of a parasite adhesion-domain superfamily 
that are expressed on erythrocyte invasion ligands and named 
erythrocyte binding ligands (EBLs).  DBL domains were originally 
described as “cysteine-rich domains containing functional binding regions 
that determine invasion specificity” (Su et al., 1995). The authors coined 
the term ‘DBL’ based on the homology described with the cysteine-rich 
domain of P. vivax Duffy binding domains. Therefore, the occurrence of 
DBL domains was reported in two distinct stages in the P. falciparum 
asexual cycle. First, it is implicated in the complex system in P. 
falciparum of merozoite invasion of erythrocytes, unlike P. vivax and P. 
knowlesi that are restricted to the use of single receptors to invade 
erythrocytes (Higgins and Carrington, 2014). Secondly, DBLs are found 
in PfEMP1 proteins on the surface of IEs mediating interaction with 
human receptors such as ICAM-1(Smith et al., 2000a).  
The first sequence comparison of PfEMP1 in 1995 showed that DBL 
domains have diverse degrees of sequence similarities. There were four 
DBL types defined and called DBL1, DBL2, DBL3, and DBL4. The DBL1 
type is what is called DBLα nowadays and is always present at the amino 
terminal end of PfEMP1. It is followed by a CIDR domain forming what is 
called the conserved head structure (Su et al., 1995). Then, Rowe et al. 
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(1997) showed that DBLα binds to CR1 and mediates rosetting. In 1998, 
CIDR1 domains were shown to mediate CD36 binding followed by the 
identification of DBL-β domain (before known as DBLβ-C2) as ICAM-1 
binding domains in early 2000. Later in 2000, the adhesive domains of 
PfEMP1 were classified based on the available PfEMP1 sequences and 
some functional binding data into different subclasses α, β, γ, δ, ζ, and ε. 
(Smith et al., 2000b, Rask et al., 2010).  
Crystal structures are available for several DBL domains including some 
belonging to PfEMP1. The first structure of one of the DBL domains from 
the PfEMP1 family was completed in 2008 (Higgins, 2008).  Although low 
sequence identity has been observed among DBL domains, they have a 
conserved skeleton. It was revealed that there is a notable low level of 
sequence identity, with only 4% of residues identical and around 15% of 
residues similar in 10 different DBLs studied from both EBA and PfEMP1 
variants. Nevertheless, DBL domain structures are built on a conserved 
skeleton, with a fundamental helical architecture found in all domains. 
The conserved residues are inside the skeleton of the folds, maintaining 
the structure of the domain (Higgins and Carrington, 2014).  
 
Figure 3.2.1: The structure of a 
DBL domain. Conservation of 
the DBL fold. Conserved 
residues are plotted onto the 
structure of the DBL3X domain 
of VAR2CSA, with absolutely 
conserved residues in red and 
similar residues in yellow. The 
conserved residues include 
three main patches: one 
stabilizing subdomain 2 
(W1404, W1405, and W1414), 
one stabilizing subdomain 3 
(W1457 and Y1508) and one 
stabilizing the interface 
between subdomains 2 and 3 
(R1268, D1353, Q1445, 
W1453, and E1456). The figure 
has been cited from (Higgins 
and Carrington, 2014). 
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The DBL domain’s composition was described as it contains three 
subdomains SD1, SD2, and SD3 (Singh et al., 2006).  SD1 and SD2 fold 
together, with SD2 having four helical bundles present in all DBLs and 
SD1, which does not show conserved secondary structure, wrapped 
around SD2 (Higgins and Carrington, 2014).  
In SD2 of DBL3X of VAR2CSA, there are three conserved tryptophan 
residues, (W1404, W1405, and W1413) located on the forth helix of SD2. 
The supposed role of these tryptophans is maintaining the fold through 
stabilizing contacts with other helices. SD3 is made of a long, two α-
helical hairpin joined by two conserved residues with an extra partial 
helical strand that lies back along the bundle. In addition, there is a third 
residue (G1360) that mediates a tight turn between the second and third 
helices.  Three disulphide bonds stabilise the distal end of SD3 in almost 
all cases. A series of salt bridges form a rigid interface that link SD2 and 
SD3 together by the remaining conserved residues on SD2 and SD3. In 
addition, there are different loops and helices in domains from both EBA 
and PfEMP1 proteins. DBL domains from PfEMP1 are often longer and 
more complex than domains from EBA members (Higgins and 
Carrington, 2014). 
DBL domains were classified into six classes α, β, γ, δ, ζ, and ε based on 
shared homology blocks. For example, all DBLβ domains share three 
homology blocks, in addition, DBLβ domains that share one or more HB 
are sub-classified with a numerical digit (e.g. DBLβ3 and DBLβ5) (Rask 
et al., 2010). Also, the domain position can be shown by a prefix 
containing the letter D (for domain) and the number of the domain 
position from the side of the N-terminal segment e.g. DBLβ3_D4 
(Bengtsson et al., 2013). Domain classifications have been associated 
with particular IE adhesion phenotypes. For instance, DBLβ3 and DBLβ5 
subclasses of the DBL domains were shown to bind to ICAM-1. 
DBLβ3_D4 was in DC4 that has recently been shown mediate the ICAM-
1 binding of some of the group A PfEMP1 (Bengtsson et al., 2013). 
DBL:ICAM-1 interactions still need more investigations for more 
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understanding of the platform of therapeutic interventions based on this 
interaction.  
Howell et al. (2008) expanded the image of the PfEMP1::ICAM-1 
complex. They used the sequences of IT4 strains and performed site-
directed mutagenesis to DBLβ domains and assessed the binding 
capacities to identify critical binding residues. Howell and colleagues 
examined the binding of 21 DBLβ (known before as DBLβ-C2) domain 
recombinant proteins from all var genes in groups A, B and C of the IT4 
parasite isolates using magnetic beads. They found that only some of IT4 
expressed DBLβ can bind to ICAM-1. The IT4 PfEMP-1 expressing DBL-
β ICAM-1 binding isolates will be called IT4-ICAM-1 isolates in this 
thesis. Biophysical study has characterized the interaction of ICAM-1 with 
the full extracellular domains from IT4VAR13, a member of IT4-ICAM-1 
isolates.  Brown et al. (2013) showed that the binding occured on the 
ICAM-1 N terminus forming a 1:1 complex and is exclusively mediated by 
DBLβ. It was also shown that PfEMP1 extracellular domains experience 
minimal structural changes as they bind to ICAM-1 due to their rigid, 
elongated architecture (Brown et al., 2013).  
On the other hand, VAR2CSA shape is compact, that formed by folding 
itself back towards itself using multiple domains  (Srivastava et al., 2010). 
However, the binding to its ligand was recently found to be mediated mainly 
by the DBL2 domain which is located at the tip of the folded multi-
domains protein (Clausen et al., 2012, Higgins and Carrington, 2014). 
VAR2CSA is composed of six DBL domains and a single CIDRpam 
domain, whereas IT4VAR13 follows the structure of a more typical 
PfEMP1. It was suggested that PfEMP1s have at least two different 
shapes. Indeed, the development of therapeutic interventions targeting 
appropriate antigens needs more details about the molecular 
mechanisms of PfEMP1 recognition of host receptors to mediate 
sequestration, immune responses and possibly to limit the antigenic 
variation. 
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The aim of this section is to examine the binding phenotypes of isogenic 
IT4-ICAM1 isolates on different sets of mutant ICAM-1s and inhibition of 
ICAM-1 binding under static conditions. Also, it aimed to investigate the 
binding to HDMEC under flow conditions. 
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3.2.2 Methods:  
3.2.2.1 IT4-ICAM-1 isolates:  
Table 3.1 provides some information about IT4-ICAM-1 isolates used in 
this study. It includes the alias name given from their original sources 
with ID and ups category given in vardom database. It can be accessed 
through the following link ((http://www.cbs.dtu.dk/services/VarDom/)). 
Also, it shows the available affinities values obtained from Brown et al. 
(2013) study, in nanomolar range. The table also includes the percentage 
of  transfected COS cells bound to five or more ICAM-1/Fc-coated beads 
cited from (Howell et al., 2008). All isolates were cultured as described in 
the general methods section. The synchronisations were carried using 
sorbitol and Plasmion.   
ID Alias Ups 
IT4VARXXDBLβ-ICAM-
1D1D5-Fc KD m × 10
−9 
rDBL 
reactivity on 
bead* 
IT4var01 3G8 C NA 98±4 
IT4var13 GC503 B 2.6 100 
IT4var14 A4 B NA 100 
IT4var16 ItG B 51.1 100 
ITvar31 P5B6 B 144 100 
Table 3.2.1: IT4-ICAM-1 isolates information. The table shows the alias for their 
originals, ID and ups classification from vardom database. The affinities 
between rDBLβ and ICAM-1D1D5- Fc cited from (Brown et al., 2013) (NA: not 
available in the original study). * Last column shows % of transfected cells 
associated with five or more ICAM-1/Fc-coated beads (Howell et al., 2008).  
3.2.2.2 ICAM-1 selection:  
Isolates were selected on ICAM-1 and stabilates were made and 
cryopreserved to minimise the switching that occurs in long-term culture; 
each stabilate was cultured for up to three weeks. RNA was collected in 
Trizol on the same day of cryopreservation. The dominant var type was 
confirmed by qRT-PCR after selection. The protocol has been given in 
general methods.  
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3.2.2.3 q-RT-PCR:  
Described in the general methods.   
3.2.2.4 Adhesion assays:  
Static and flow protein adhesion assays were used to assess the binding 
of parasites to CD36 and ICAM-1. Also, flow assays were performed on 
HDMEC. The binding to CD36 and ICAM-1 on ECs was inhibited by 5 
µg/ml anti-CD36 IV-C7 and anti-ICAM-1 15.2 mAbs respectively. All 
procedures are described in the general methods section, including 
culturing ECs.   
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3.2.3 Results: 
3.2.3.1 Confirmation of dominant IT4 DBL-β ICAM-1 binding var 
gene transcript levels after selection on ICAM-1:  
In order to maximise the expression of a dominant ICAM-1 binding 
variant and to improve the adhesion phenotypes related to specific 
PfEMP1 members, several ICAM-1 selections were carried out and 
stabilites were frozen to maintain access to the same population during 
the study.  
The analysis of var gene transcription in parasite isolates was performed 
on samples taken at the time of freezing. RNA was harvested from ring-
stage parasites, and var gene expression profiling was identified by RT- 
qPCR. Figure 3.2.2 shows that four of the isolates have expressed a 
single primary IT4-ICAM-1 var transcript more than five fold changes. It 
should be noted that ITvar16 had a secondary var transcript of ITvar41.  
Figure 3.2.2 var gene transcription profile after ICAM-1 selection.  
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3.2.3.2 Static adhesion of IT4-ICAM-1 binding isolates on ICAM-1Ref: 
All five isolates were predominantly expressing single ICAM-1 binding 
PfEMP-1. Based on the level of binding to ICAM-1Ref, IT4var01 and 
IT4var14 had a similar level of binding of about 2000 IE/mm2. Each of the 
other three had different avidities for ICAM-1Ref: IT4var16 had been 
previously categorised as high ICAM-1 binder, and about 5000 IE/mm2 
were counted. The binding of IT4var13 was just under 900 IE/mm2. 
Interestingly, IT4var31 bound far less than other isolates at 134 IE/mm2, 
about 35 fold less than the strongest binder in the set of IT4-ICAM 
isolates (Figure 3.2.3). 
 
 
 
Figure 3.2.3: Static adhesion assay of IEs with IT4-ICAM-1 binding isolates, 2 μl 
spots at 50 μg/ml ICAM-1Ref were placed onto 6 cm dishes and standard 
protein static binding assays carried out with IE suspended in binding buffer at a 
parasitaemia of 3% and a haematocrit of 1%. The results show the mean of 
binding and the bars represents SE (n >3). 
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3.2.3.3 Static adhesion of IT4-ICAM-1 isolates binding to mutant 
ICAM-1 variants: 
Despite the variation between the avidities of IT4-ICAM isolates binding 
to ICAM-1Ref, all isolates except ITvar01 were significantly affected by the 
S22/A mutation. In fact, it increased the binding of ITvar01. The natural 
mutant ICAM-1Kilifi reduced the binding of three isolates to nearly no 
binding. However, for IT4var16 there was no significant effect and this is 
in agreement with previous data (Tse et al., 2004). Importantly, as it was 
shown in the previous chapter, ICAM-1L42/A significantly affected the 
binding of all isolates compared to their binding to ICAM-1Ref, 
emphasising the importance of this conserved residue for binding. ICAM-
1L44/A reduced the binding for three of IT4-ICAM isolates. It did not affect 
the binding of IT4var16 at all. On the other hand, it increased the binding 
of IT4var14 to about 143% compared to the ICAM-1Ref binding. Results 
are summarised in (Tables 3.2.2- 3.2.5 and Figures 3.2.4-3.2.7)  
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A) The binding of IT4-isolates to ICAM-1S22/A:  
Parasites 
mean IE 
binding/mm2 
N SE 
IT4var01 2779 3 307 
IT4var13 83 3 20 
IT4var14 1221 9 285 
IT4var16 336 20 67 
IT4var31 38 3 8 
Table 3.2.2: Static adhesion assay of IEs with IT4-ICAM-1 binding isolates, 
ICAM-1S22/A was used at 50 μg/ml. The table shows the mean of the IEs 
binding, N: number of experiments and the SE.  
 
 
 
Figure 3.2.4: Static adhesion assay of IEs with IT4-ICAM-1 binding isolates, 
ICAM-1S22/A was used at 50 μg/ml, the results show the %ICAM-1Ref binding and 
the bars represent SE (n can be found in table 3.2.2). 
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B) The binding of IT4-isolates to ICAM-1Kilifi:  
Parasites 
mean IE 
binding/mm2 
N SE 
IT4var01 29 3 5 
IT4var13 31 3 7 
IT4var14 897 9 235 
IT4var16 3807 20 489 
IT4var31 17 3 2 
Table 3.2.3: Static adhesion assay of IEs with IT4-ICAM-1 binding isolates, 
ICAM-1Kilifi was used at 50 μg/ml, the table shows the mean of the IEs binding, 
N: number of experiments and the SE.  
 
 
Figure 3.2.5: Static adhesion assay of IEs with IT4-ICAM-1 binding isolates, 
ICAM-1Kilifi was used at 50 μg/ml, the figure shows the %ICAM-1Ref binding and 
the bars represent SE (n can be found in table 3.2.3). 
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C) The binding of IT4-isolates to ICAM-1L42/A:  
Parasites 
mean IE 
binding/mm2 
N SE 
IT4var01 14 3 10 
IT4var13 28 3 11 
IT4var14 281 3 187 
IT4var16 103 4 13 
IT4var31 14 3 3 
Table 3.2.4: Static adhesion assay of IEs with IT4-ICAM-1 binding isolates, 
ICAM-1L42/A was used at 50 μg/ml, the table shows the mean of the IEs binding, 
N: number of experiments and the SE. 
 
 
Figure 3.2.6: Static adhesion assay of IEs with IT4-ICAM-1 binding isolates, 
ICAM-1L42/A was used at 50 μg/ml. The figure shows the %ICAM-1Ref binding 
and the bars represent SE (n can be found in table 3.2.4). 
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D) The binding of IT4-isolates to ICAM-1L44/A:  
Parasites 
mean IE 
binding/mm2 
N SE 
IT4var01 481 3 222 
IT4var13 276 3 84 
IT4var14 2767 3 851 
IT4var16 4920 4 648 
IT4var31 58 3 23 
Table 3.2.5: Static adhesion assay of IEs with IT4-ICAM-1 binding isolates, 
ICAM-1L44/A was used at 50 μg/ml, the table shows the mean of the IEs binding, 
N: number of experiments and the SE .  
 
 
Figure 3.2.7: Static adhesion assay of IEs with IT4-ICAM-1 binding isolates, 
ICAM-1L44/A was used at 50 μg/ml, the figure shows the %ICAM-1Ref binding and 
the bars represent SE (n can be found in table 3.2.5). 
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3.2.3.4 Inhibition of IT4-ICAM-1 isolates using different anti-ICAM-1 
mAbs: 
As mentioned in the previous chapter, the effect of anti-ICAM-1 mAbs on 
the binding of IE to purified ICAM-1 under static conditions has been 
studied using specific mAbs reacting with epitopes on Ig-like domains 1 
and 2. MAbs 15.2, BBIG-I1 and My13 mapping to domain 1, and 8.4A6 
mAb mapping to domain 2 were used in a study that differentiated 
between the binding sites on ICAM-1 for IE and LFA-1 (Berendt et al., 
1992). The previous chapter showed that different mAbs have different 
inhibitory effects on the isolates. Table (3.2.6) and figure (3.2.8) show the 
binding of all isolates was nearly completely reduced by mAb 15.2, 
except for ITvar14 which was inhibited by about 70%, though it should be 
noted the SE is relatively wide. Two anti-ICAM-1 mAbs, My13 and BBIG-
I1, showed essentially a similar inhibitory effect to 15.2. The binding for 
IT4var01, IT4var13 and IT4var31 was almost totally inhibited. Moreover, 
IT4var14 and IT4var16 were reduced by about 80% compared to the 
binding to ICAM-1Ref (Tables 3.2.7 and 3.2.8 and Figures 3.2.9 and 
3.2.10). The effect for 8.4A6 anti-ICAM-1 mAb was only significant on 
one isolate. The inhibition caused by 8.4A6 did not affect the binding of 
IT4var16 and IT4var31isolates at all. However, IT4var01 was completely 
inhibited by 8.4A6 and the effect was varied, giving 25% and 50% for 
IT4var13 and IT4var14 respectively (Table 3.2.9 and Figure 3.2.11). 
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A) The inhibition of IT4-isolates using 15.2 mAb:  
Parasites 
mean IE 
binding/mm2 
N SE 
IT4var01 60 3 12 
IT4var13 21 3 8 
IT4var14 649 4 249 
IT4var16 158 4 48 
IT4var31 4 3 1 
Table 3.2.6: Static inhibition assay of IEs with IT4-ICAM-1 binding isolates, 15.2 
was used at 5 μg/ml, the table shows the mean of the IEs binding, N: number of 
experiments and the SE.  
 
 
Figure 3.2.8: Static inhibition assay of IEs with IT4-ICAM-1 binding isolates, 
15.2 was used at 5 μg/ml, the figure shows the %ICAM-1Ref binding and the 
bars represent SE (n can be found in table 3.2.6). 
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B) The inhibition of IT4-isolates using My13 mAb:  
Parasites 
mean IE 
binding/mm2 
N SE 
IT4var01 48 3 10 
IT4var13 22 3 8 
IT4var14 300 4 80 
IT4var16 685 4 184 
IT4var31 3 3 1 
Table 3.2.7: Static inhibition assay of IEs with IT4-ICAM-1 binding isolates, 
My13 mAb was used at 5 μg/ml, the table shows the mean of the IEs binding, 
N: number of experiments and the SE.  
 
 
Figure 3.2.9: Static inhibition assay of IEs with IT4-ICAM-1 binding isolates, 
My13 mAb was used at 5 μg/ml, the figure shows the %ICAM-1Ref binding and 
the bars represent SE (n can be found in table 3.2.7). 
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C) The inhibition of IT4-isolates using BBIG-I1 mAb:  
Parasites 
mean IE 
binding/mm2 
N SE 
IT4var01 63 3 15 
IT4var13 26 3 5 
IT4var14 503 4 129 
IT4var16 984 4 182 
IT4var31 5 3 1 
Table 3.2.8: Static inhibition assay of IEs with IT4-ICAM-1 binding isolates, 
BBIG-I1 mAb was used at 5 μg/ml, the table shows the mean of the IEs binding, 
N: number of experiments and the SE.  
 
 
Figure 3.2.10: Static inhibition assay of IEs with IT4-ICAM-1 binding isolates, 
BBIG-I1 mAb was used at 5 μg/ml, the figure shows the %ICAM-1Ref binding 
and the bars represent SE (n can be found in table 3.2.8).  
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D) The inhibition of IT4-isolates using 8.4A6 mAb:  
Parasites 
mean IE 
binding/mm2 
N SE 
IT4var01 53 3 11 
IT4var13 652 3 183 
IT4var14 885 4 366 
IT4var16 5494 4 1597 
IT4var31 140 3 51 
Table 3.2.9: Static inhibition assay of IEs with IT4-ICAM-1 binding isolates, 
8.4A6 mAb was used at 5 μg/ml, the table shows the mean of the IEs binding, 
N: number of experiments and the SE.  
 
 
Figure 3.2.11: Static inhibition assay of IEs with IT4-ICAM-1 binding isolates, 
8.4A6 mAb was used at 5 μg/ml, the figure shows the %ICAM-1Ref binding and 
the bars represent SE (n can be found in table 3.2.9). 
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3.2.3.5 The binding of IT4-ICAM-1 isolates on HDMEC under flow 
conditions: 
The binding to ICAM-1Ref was variable from protein based static adhesion 
assays. Despite this variation, all isolates bound to HDMEC in a relatively 
similar pattern in the range of 200-300 IE/mm2, with a slight increase to 
464 IE/mm2 for ITvar01 (Figure 3.2.12). Further investigation using an 
anti-ICAM-1, 15.2 mAb, revealed more than 85% of binding was inhibited 
for IT4var13. However, the inhibition was less for IT4var01 and IT4var31 
inhibiting the binding by 40% and 30% respectively (Table 3.2.10 and 
Figure 3.2.13).  Furthermore, because HDMEC expresses CD36, when 
the binding was blocked by anti-CD36 mAb, it was reduced by about 
90% in all of the isolates. In fact, the binding of IT4var31 was inhibited by 
more than 95% (Table 3.2.11 and Figure 3.2.14).  
 
 
Figure 3.2.12: HDMEC flow endothelial cell adhesion assay of IT4-ICAM-1 
isolates. HDMEC seeded on channels pre-coated with fibronectin; IE were 
passed on confluent cells for five minutes followed by washing by binding buffer 
for two minutes before counting 6 fields in two different channels. The 
parasitaemia was 3% and a haematocrit of 2%. The results show the mean of 
and the bars represents SE. 
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ICAM-1 inhibition on HDMEC for IT4-isolates using 15.2 mAb:  
Parasites 
mean IE 
binding/mm2 
N SE 
IT4var01 276 3 37 
IT4var13 46 3 11 
IT4var14 91 3 10 
IT4var16 115 15 18 
IT4var31 165 2 18 
Table 3.2.10: Flow ICAM-1 inhibition of IEs with IT4-ICAM-1 binding isolates on 
HDMEC, 15.2 mAb was used at 5 μg/ml. The table shows the mean of the IEs 
binding in the presence of 15.2 mAb, N: number of experiments and the SE.  
 
 
Figure 3.2.13: Flow ICAM-1 inhibition of IEs with IT4-ICAM-1 binding isolates on 
HDMEC using 15.2 mAb at 5 μg/ml. The figure shows the % binding against no 
inhibitory effect and the bars represents SE (n can be found in table 3.2.10). 
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CD36 inhibition on HDMEC for IT4-isolates using IVC7 mAb: 
Parasites mean IE 
binding/mm2 
N SE 
IT4var01 57 3 8 
IT4var13 51 3 18 
IT4var14 22 8 3 
IT4var16 26 3 3 
IT4var31 6 2 3 
Table 3.2.11: Flow CD36 inhibition of IEs with IT4-ICAM-1 binding isolates on 
HDMEC, IVC7 was used at 5 μg/ml. The table shows the mean of the IEs 
binding in the presence of IV-C7 mAb, N: number of experiments and the SE.  
 
 
Figure 3.2.14: Flow CD36 inhibition of IEs with IT4-ICAM-1 binding isolates on 
HDMEC using IV-C7 mAb at 5 μg/ml. The figure shows the % binding against 
no inhibitory effect and the bars represents SE (n can be found in table 3.2.11). 
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3.2.4 Discussion:  
 
 Figure 3.2.15: Summary of the effects of mutant ICAM-1 variants and mAb 
inhibition on IT4-ICAM-1 isolates. 
 
Studying PfEMP1 interactions with host receptors is significant to 
understand the mechanism of malaria pathogenesis. It is hoped it will 
lead to vaccine development once appropriate targets have been 
identified, for example, the PfEMP1::ICAM-1 interaction is thought to be 
involved in CM although not exclusively. Previous studies have 
demonstrated that PfEMP1-ICAM-1 interaction is entirely mediated by a 
single DBLβ domain and have also shown that there is an overlap 
between the binding site of IE on ICAM-1 and other receptors such as 
LFA-1, Mac-1 and Rhinoviruses but has distinct elements. Moreover, the 
binding site of different parasites is disrupted by different mutations 
leading to subtle differences between the various parasite variants.  
In the current chapter, the binding of isogenic IT4-ICAM-1 isolates was 
characterised on purified ICAM-1 variants under static conditions. The 
difference between this part and the previous one is mainly using 
laboratory clones that express known ICAM-1- binding PfEMP1 variants 
confirmed by qRT-PCR from one genotype, IT4. Also, ICAM-1 blocking 
by different mAbs was investigated. It was not surprising to see aspects 
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of distinct adhesion for all PfEMP1 variants based on the use of ICAM-1 
variants binding and inhibition using mAbs against ICAM-1.  
Mutant ICAM-1s and anti-ICAM-1 mAbs approaches have illustrated that 
isogenic IE expressing variant PfEMP1 members bind to different 
residues in the DE loop of ICAM-1 (Summarised in Figure 3.2.15). 
However, incorporating current data with data from the previous chapter 
supports the use of the conserved region as a basis for designing cross-
variant inhibitors of adhesion, with a significant role for L42 for all ICAM-
1-binding isolates examined so far. Using SPR Brown et al. (2013) 
observed that the binding of PfEMP1 occurs to an overlapping binding 
site on ICAM-1. This was shown by the competition of two different DBLβ 
domains to bind to ICAM-1. The dissociation of the first bound domain 
decreased upon the exposure of the second domain. The degree of 
ICAM-1 binding variation observed in the previous chapter is also 
observed for the IT4-ICAM-1 isolates even though they are genetically 
identical.  
Howell et al. (2008) determined that rDBLβ of some IT4 isolates bound to 
ICAM-1 and suggested that variant single rDBLβ domains were capable 
of binding ICAM-1 almost equally based on their method. In contrast, this 
is not the case when the whole PfEMP1 is expressed on the surface of 
IEs, as seen in IE binding studies. It was shown that PfEMP1 architecture 
experiences slight changes upon binding to ICAM-1 (Brown et al., 2013). 
However these changes were not in vivo, where it might introduce 
significant structural effects. 
Interestingly IT4VAR31 was the lowest ICAM-1 binder among the 
isolates tested here. This is consistent with previous adhesion 
characterisation and predicted to be due to secondary structure folding of 
the binding domain (Smith et al., 2000a). It was also reported that 
ITVAR31 DBLβ bound ICAM-1 with the lowest affinity among IT4-ICAM-1 
isolates investigated before (Brown et al., 2013). Binding to HDMEC is 
exactly following the pattern observed for lab-adapted ICAM-1 isolates as 
described in the previous chapter (Madkhali et al., 2014). However, 
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IT4var31, the lowest binder on purified ICAM-1 bound to HDMEC 
similarly to other isolates. ICAM-1 mAb treatment showed about 30% 
inhibition suggesting a role of CD36 in mediating the binding.  
The affinities of DBLβ of IT4-ICAM-1 reported by the Brown et al. study 
(Brown et al., 2013) correlated with IE adhesion level on ECs but did not 
correlate with the IE adhesion level on purified proteins in the current 
study. The affinity of DBLβ of IT4var13 and IT4var16 was 2.6 and 51.1 
nM respectively, but the binding of IT4var13 was lower than the of  
IT4var16 as shown by static protein assay. On the other hand, the level 
of the binding of IT4var13 was higher than all IT4-ICAM-1 isolates on 
HDMEC except for IT4var01 that was not included in Brown et al. study. 
The high affinity of IT4var13 was supported by the fact that it showed the 
most reduced binding when ICAM-1 was blocked on HDMEC and the 
least affected by anti-CD36 mAb. CD36 binding varied between IT4 
isolates expressing different PfEMP1 variants under flow conditions 
((Figure 4.2.2) shown in the chapter4.2). This is consistent with a recent 
study examined rolling velocities to CD36 under dynamic flow conditions 
(Herricks et al., 2013). The authors thought that PfEMP1 sequence 
variability or surface expression levels play an essential role in mediating 
the whole binding avidity of IEs. The modelling of the interactions 
between PfEMP1 and human receptors were based on recombinant 
proteins. It should be considered that binding properties may be changed 
by other domains on whole PfEMP1 and more possible changes can take 
place on the surface of IEs when surrounded by many structural 
molecules (Janes et al., 2011).  
It is also interesting to know that all IT4-ICAM-1 isolates are DBLβ5 
except IT4var31, which is DBLβ3 (and the smallest in terms of domain 
composition, more details are found in chapter 4.2). Janes and 
colleagues investigated if DBLβ subclasses can predict ICAM-1 binding 
based on the recombinant DBLβ-ICAM-1 binding data. It was shown that 
all DBLβ5 domains from IT4 genotype bound to ICAM-1. Moreover, an 
extra DBLβ3 domain bound ICAM-1, IT4var31. It was suggested DBLβ5 
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could be a marker for ICAM-1 adhesion phenotype. This was not only 
seen in IT4 isolates but also from an Indian isolate that bound strongly to 
ICAM-1 called JDP8-ICAM-1, although only one isolate of JDP8 has 
been examined so far. Based on both adhesion data in this study and 
kinetic parameters from Brown et al. study, it can be suggested that IE 
with isolates expressing DBLβ5 PfEMP1 bind at higher levels and more 
avidity than IE with isolates expressing DBLβ3 PfEMP1 (at least among 
IT4 isolates) on purified ICAM-1. However, this is not to argue that 
DBLβ5 PfEMP1s are associated with disease severity, which has not 
been tested. Another criticism against overplaying the role of DBL β5 is 
due to the existence of only one isolate that expresses DBLβ3 among 
IT4-ICAM-1 isolates.  
In fact, from other genotype, 3D7, there was a DBLβ3 PfEMP1 that 
bound to ICAM-1. However, adhesion data of the 3D7-ICAM-1 binder 
that express DBLβ3 was shown based on different adhesion method and 
so probably no valid comparison can be argued from this data. The 
current study should have included DBLβ3 3D7-ICAM-1 binder isolate to 
widen the adhesion phenotype of DBLβ3 isolates. Particularly, when it is 
known that this is a Group A isolate and based on the shared 
combinations of short tandem domains, known as DCs, it is DC4 which 
has been associated with SM (Bengtsson et al., 2013). Group A var 
genes are more conserved than the others and have been linked with 
severe malaria (Jensen et al., 2004). There is, therefore, a deficiency 
about the prediction of the ICAM-1 binding based on a single domain 
subclass. Moreover, the transcription of DBLβ3 was more associated 
with SM patients and associated with group A PfEMP1 (Bengtsson et al., 
2013). Indeed, this is different from predicting the association of DBLβ 
subclasses with disease outcome, which is still not established. More 
information about the binding of DC4 isolates to ECs and the expression 
of these isolates from clinical samples may provide a useful link for 
therapeutic interventions.  
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3.3. The endothelium and cytoadhesion assays 
perspective: a comparison between the binding of 
IT4-ICAM-1 isolates on activated HUVEC and 
HBMEC.  
3.3.1. Introduction:  
It has been more than a century since Marchiafava and Bignami found 
the pivotal observation that IEs are sequestered in the brain 
microvasculature, affecting the blood flow by causing a mechanical 
obstruction. Cytoadhesion is a form of sequestration that has a major role 
in malaria pathogenesis either directly by blockages of blood vessels or 
indirectly by inflammation mediation, coagulation defects and 
endothelium dysfunction (Storm and Craig, 2014). The endothelium plays 
distinctive roles in several physiological processes including the blood 
flow regulation, coagulation, permeability, inflammation, and innate and 
adaptive immunity (Aird, 2012). ECs have, also, significant heterogeneity 
in their structure which is detected by the expression of certain receptors 
on their surfaces which are so called vascular “ZIP codes or molecular 
signatures”. The variation of the surface receptor phenotypes plays a 
critical role in the pathogenesis of several diseases, including malaria 
(Aird et al., 2014). These variations, beside the variations of molecules 
exported to surface of IEs, result in variable binding properties of the IEs 
to host endothelia and consequently variable malaria outcomes (Moxon 
et al., 2011, Aird et al., 2014).  
One of the major advancements in malaria research was the ability to 
culture P. falciparum in vitro in 1976. This came in parallel with the 
successful isolation and culturing of ECs in vitro. Together, this allowed 
the study of P. falciparum adhesion phenotypes to explore therapeutic 
interventions to control malaria morbidities and mortalities (Udeinya et 
al., 1981). From this, the role of the interactions between parasite 
proteins on the surface of IEs with host endothelium has been studied. 
Studying adhesion of IEs to ECs in vitro has been performed using 
different methods. It was first described using confluent HUVEC on 
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coverslips under static conditions (Udeinya et al., 1981). Then, to simplify 
the culturing conditions and expand the number of adhesion studies, an 
alternative model based on transfected melanoma cells was described 
(Schmidt et al., 1982). Indeed, these methods have contributed to 
revealing significant information about the adhesion of IE, despite some 
concerns raised about receptor expression levels in transfected 
melanoma cells (C32). Then, in order to investigate more about the 
interactions between IEs and individual receptors, purified receptors were 
placed in petri dishes, and incubated with parasites to facilitate the study 
of IEs binding (Ockenhouse et al., 1991). This, for example, has allowed 
the in-depth study of interactions such as the use of mutant proteins for 
determining the binding sites that mediate specific interactions.  
Until now, static protein and cell adhesion assays are still commonly 
used and produce useful results. Nonetheless, they do not resemble an 
accurate model of the cytoadherence mechanisms that occur in hosts 
(Nash et al., 1992; Rogerson et al., 1997). The fact that static assays 
exclude the roles of variable forces affecting the binding of IEs inside the 
vasculature raised the need for a model that included the shear stress 
controlling the blood flow. Thus, the flow adhesion assay was developed 
to enable adhesion studies in the relevant environment that mimic, albeit 
approximately, physiological conditions (Nash et al., 1992, Cooke et al., 
1994). This enables investigators to describe the dynamics and kinetics 
of the interaction of the IEs with their ligands, i.e. the concepts that 
describe the behaviours of IEs on different receptors such as tethering, 
rolling and firm adhesion linked to the function of human receptors on 
ECs (Cooke et al., 1994). For example, ICAM-1 is thought to play 
tethering role and rolling on ECs, whereas IEs do not require rolling on 
CD36. Although most phenotypes observed using static assays show 
similar behaviour under flow, an exception was found that IT4var16 (ItG), 
a high ICAM-1 binder on static assay, was a relatively very weak binder 
on flow systems using HUVEC (Gray et al., 2003).  
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To improve the flow model, the use of microfluidics has been adopted to 
study parasite adhesion, which allows for further refinement about the 
behaviours of IEs on different receptors considering the size of the 
channels used in microfluidics. For example, the use of the commercial 
Cellix system in our lab has given an advantage of using very small 
quantities of materials to run the experiments (Madkhali et al., 2014).  
This could be particularly useful in field studies where enough materials 
usually hamper the studies. The Cellix system is currently being used in 
Malawi, although some challenging issues are being encountered in 
using complex equipment in this setting(personal communication).  
A very recent study has shown ECs in brain microvasculature might have 
a different response to curvature than ECs from non-brain cells, 
regardless of their size, such as HUVEC and HDMEC. The curvature in 
this context means the reciprocal of the monolayers of endothelial cells 
radius (Ye et al., 2014). Analysis of the influence of curvature and shear 
stress on cell morphology has shown no significant change in HBMECs. 
In contrast, HUVECs showed a significantly increased elongation under 
shear stress in comparison to static conditions. Nonetheless, these 
changes were smaller than induced by curvature, emphasising the vital 
role for curvature in controlling cell morphology (Ye et al., 2014).  
The aim of this part of the thesis was comparing the pattern of binding of 
IT4-ICAM-1 isolates on HUVEC and HBMEC. This was carried out using 
flow adhesion assays.  
3.3.2 Methods:  
Parasite and endothelial cell cultures, and the flow adhesion assay were 
described in the general methods. The parasite isolates details have 
been given in Table 3.2.2.1 (Previous chapter). ICAM-1 expression on 
ECs was confirmed using FACS as described in the general methods.  
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3.3.3 Results:  
3.3.3.1 Receptor expression:  
Preliminary sets of FACS experiments confirmed the expression of the 
positive endothelial cell marker CD31 with and without TNF stimulation. 
EPCR expression was higher if not stimulated and slightly reduced upon 
TNF stimulation. This is consistent with previous reports that confirmed 
this expression of ECs receptors.  
 
Figure 3.3.1: Preliminary FACS analysis of ICAM-1 and EPCR expression on 
HUVEC without (left panel) and with (right panel) TNF stimulation. TNF 
stimulation was for 24 hrs using 10 ng/ml. Endothelial positive marker (CD31), 
ICAM-1 and EPCR are shown at the upper, the middle and the bottom panels 
respectively.  
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Figure 3.3.2: Preliminary FACS analysis of ICAM-1 and EPCR expression on 
HBMEC without (left panel) and with (right panel) TNF stimulation. TNF 
stimulation was for 24 hrs using 10 ng/ml. Endothelial positive marker (CD31), 
ICAM-1 and EPCR are shown at the upper, the middle and the bottom panels 
respectively.  
 
Figure 3.3.3: Preliminary FACS analysis of HUVEC and HBMECs confirming 
ICAM-1 expression without TNF stimulation  and with TNF stimulation. The 
graph shows the corrected mean fluorescence intensity. 
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3.3.3.2 The binding of IT4-ICAM-1 isolates on HUVEC and HBMEC 
under flow conditions:  
All the isolates tested were known ICAM-1 binders from data derived 
using static and flow adhesion assays as shown in previous chapters. 
The pattern of binding on HBMEC was the same as that on HUVEC. The 
quantities of IEs bound on HBMEC were comparable to the binding to 
HUVEC (Figure 3.3.4, Tables 3.3.1 and 3.3.2). However, anti- ICAM-1 
(15.2) affected the binding on HBMEC more than HUVEC for all isolates 
except one (Figure 3.3.5, Tables 3.3.3 and 3.3.4). Previous 
characterisation has shown that IT4var16 bound relatively low to HUVEC 
under flow condition despite it being recognised as a higher avidity binder 
to purified ICAM-1 and cells under static condition. The binding was 
nearly similar to IT4var31, which has lower avidity to ICAM-1 as shown in 
the previous section. Importantly, this phenotype has also been noticed 
to HBMEC as well. 
Parasites 
mean IE 
binding/mm2 
N SE 
IT4var01 377 3 79 
IT4var13 166 3 24 
IT4var14 240 3 28 
IT4var16 56 2 11 
IT4var31 30 2 1 
Table 3.3.1: the binding of IT4-ICAM-1 isolates to HUVEC. The table presents 
the means of IE binding/mm2 and the number of experiments and the SE. 
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Parasites 
mean IE 
binding/mm2 
N SE 
IT4var01 296 3 64 
IT4var13 184 3 36 
IT4var14 248 3 49 
IT4var16 74 2 22 
IT4var31 29 2 20 
Table 3.3.2: the binding of IT4-ICAM-1 isolates to HBMEC. The table presents 
the means of IE binding/mm2 and the number of experiments and the SE. 
 
Parasites 
mean IE 
binding/mm2 
N SE 
IT4var01 15 3 6 
IT4var13 32 3 14 
IT4var14 76 3 7 
IT4var16 7 3 5 
IT4var31 10 2 4 
Table 3.3.3: ICAM-1 inhibition of IEs with IT4-ICAM-1 binding isolates on 
HUVEC when 15.2 mAb was used at 5 μg/ml. The table shows the mean of the 
IEs binding in the presence of 15.2 mAb, N: number of experiments and the SE.  
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Parasites 
mean IE 
binding/mm2 
N SE 
IT4var01 18 3 4 
IT4var13 2 3 1 
IT4var14 27 3 2 
IT4var16 3 3 2 
IT4var31 6 2 2 
Table 3.3.4: ICAM-1 inhibition of IEs with IT4-ICAM-1 binding isolates on 
HBMEC when 15.2 mAb was used at 5 μg/ml. The table shows the mean of the 
IEs binding in the presence of 15.2 mAb, N: number of experiments and the SE.  
 
 
Figure 3.3.4: The binding of IT4-ICAM-1 isolates to HUVEC and HBMEC. The 
results show the mean and the bars represents SE (n can be found in tables 
3.3.1 and 3.3.2).  
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Figure 3.3.5: ICAM-1 inhibition of IEs with IT4-ICAM-1 binding isolates on 
HUVEC and HBMEC using anti-ICAM-1 (15.2) mAb at 5 μg/ml. The figure 
shows the % binding against no inhibitory effect and the bars represents SE (n 
can be found in tables 3.3.3 and 3.3.4). 
3.3.4 Discussion:  
Diverse endothelial receptors have been associated with binding to 
different variants of PfEMP1 (Rowe et al., 2009, Turner et al., 2013, 
Esser et al., 2014). Among these receptors is ICAM-1, which is 
expressed on diverse ECs including HUVEC and HBMEC. Previous 
adhesion studies investigating the role of ICAM-1 in cytoadhesion were 
carried out using HUVEC due to the difficulty of HBMEC isolation and 
routine culturing in vitro in the early studies (Udeinya et al., 1981). 
HUVEC is similar to HBMEC in their abilities to express ICAM-1 and not 
expressing CD36. In contrast, HDMEC expresses both ICAM-1 and 
CD36. However, HUVEC is different from HBMEC, because HUVEC is 
isolated from large cells, whereas HBMEC is isolated from microvascular 
ECs. This chapter aimed to characterise the binding of IT4-ICAM-1 
isolates on HBMEC and HUVEC to examine their binding patterns under 
flow conditions.   
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The adhesion that occurred on HBMEC was almost similar to the 
adhesion on HUVEC (Fig 3.3.3). In the previous chapters, it has been 
shown that the binding on HDMEC was in the range of 200-300 IE/mm2 
for most of the isolates including IT4var16 and IT4var 31.  However, the 
binding of these two isolates was low on both HUVEC and HBMEC under 
flow conditions. The low binding of IT4var31 was consistent with the 
binding data from protein adhesion results in 3.2 chapter and biophysical 
analysis (Brown et al., 2013). The binding of IT4-ICAM-1 isolates on 
HDMEC was discussed before and thought to be CD36 mediated as 
shown by mAb inhibition data. Although the IT4-ICAM-1 isolates were 
proven as ICAM-1 binders having subtle differences in affinities ranging 
from 2.8 nM to 144 nM. The low binding of the IT4var16 to HUVEC is 
observed for HBMEC as well. This emphasises the complexity of binding 
that occurs in the cellular context, because in protein assay the IT4var16 
was shown to have highest avidity to ICAM-1, whereas the binding to 
ECs that express ICAM-1 was relatively low binding. Indeed, PfEMP1 
architecture including its structure, length, domain compositions plays 
such role for optimising the binding (chapter 4.2 will analyse binding data 
based on the domain compositions). 
The dynamics inside the human body must be considered to understand 
the pathological events of malaria. In this context, the adhesion cascade 
of leukocytes is the most studied example and has given insights into the 
rheological events that take place at the molecular and cellular levels. 
This cascade was long recognised to have three major steps; rolling, 
activation and arrest. However, recent updates have considered other 
additional steps; slow rolling, adhesion strengthening, spreading, 
intravascular crawling before cellular transmigration (Ley et al., 2007, 
Robert et al., 2013). Indeed, ICAM-1 plays a significant role in this 
cascade by mediating binding to the LFA-1, which is recognised as a 
mobile molecule.  
Mobile LFA-1 is explained by the ability to switch the molecular 
conformational state transiently to mediate its biological role, though the 
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mechanism is not fully understood.  It has been highlighted that LFA-1 
can mediate lateral mobility across the membrane in order to regulate 
integrin activation and adhesion to ICAM-1. The mobility is altered upon 
chemokine stimulation. Similarly, it might be considered that the mobile 
PfEMP1 can be affected by several variables including stimulation 
effects, the architecture of the PfEMP1 variant, and other possible 
effects. For example, the knobs form an average of 135 nm protrusions 
on the IEs, and the DBLβ of IT4var13 was found at about 15 nm above 
the IE membrane enabling ready access to the ligand. The position of 
this domain at the tip of the extracellular domain could facilitate efficient 
recognition and increase the possibility of binding to other ligands 
explaining the co-operation seen in endothelial binding (Brown et al., 
2013).  
A parasite sub-line of 3D7 expressing two distinct var genes on a single 
IE adhered to both ICAM1 and PECAM1 and bound efficiently to ECs, 
however more investigations are required to support these findings to re-
evaluate the extent of any breakdown in the mutually exclusive var gene 
expression model (Joergensen et al., 2010)  Not only that but, also, it is 
started to recognise that one adhesion form can influence another 
adhesion form contributing to the parasites sequestration. This was 
demonstrated by a single IE that mediated cytoadhesion and rosetting 
simultaneously via two different receptors (Adams et al., 2014). These 
several interactions inside the host must be put into consideration to 
widen the view of the multi-cellular events that take place to understand 
the malaria pathophysiology.  
It is known that ICAM-1 is induced upon inflammatory stimulation, and it 
binds to diverse ligands including LFA-1, Mac-1 and even to monocytes 
which express ICAM-1. The interactions between proteins inside the 
hosts are exposed to many influences including competitive interactions 
with several cellular factors and post-translational modifications (Herce et 
al., 2013). In a recent study on experimental CM in mice, glycocalyx was 
lost in brain vessels more than in UM (Hempel et al., 2014). This effect 
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enhances the interactions of leukocytes and platelets with the endothelial 
cells which have been shown to play a potential role in malaria 
pathophysiology (Wassmer et al., 2011, Hempel et al., 2014). Loss of 
endothelial glycocalyx may be caused by several mechanisms including 
inflammation and hypoxia which are crucial in CM pathology (Hempel et 
al., 2014).  
In addition, it was suggested that HBMEC were different from other small 
and large vasculatures in their interactions with some agents including α- 
thrombin which is involved in the coagulation cascade. In Moxon et al. 
(2013) study, thrombomodulin was found to play a role in CM. The recent 
finding of EPCR involvement in SM has enhanced the understanding that 
multiple processes take place inside the host to cause disease, such as 
coagulation as well as more standard inflammatory responses. 
In fact, many events besides the cytoadhesion must be considered 
during the infection including inflammatory responses, platelet 
coagluopathology and endothelial dysfunction. Thus, the host might 
contribute to the disease outcome by induced endothelial damage that 
can take place by different process independent of cytoadherence 
including metabolic acidosis and plasma uric acid (N'Dilimabaka et al., 
2014). Also, persistent endothelial activation and inflammation were 
observed up to one month after the infection. This was recognised by the 
elevated plasma levels of soluble ICAM-1, angiopoetin 2, and C-reactive 
protein (Moxon et al., 2014).  It is possible that damaged ECs increase 
the disease severity by increasing the risk of developing co-infection 
contributing to the high mortality in Sub-Saharan Africa. Mallewa et al. 
(2013) found that the interaction between P. falciparum and viral 
infections could increase the risk of developing severe outcomes 
(Mallewa et al., 2013).  
Unfortunately, adhesion studies in vivo are hampered due to the lack of 
appropriate animal models that represent human disease 
pathophysiological manifestations (Craig et al., 2012a). The considerable 
information about the host-parasites interactions has been provided 
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through in vitro cytoadhesion studies. There is an appreciable number of 
adhesion studies carried out in the field that used static proteins assays 
(Ockenhouse et al., 1991, Chaiyaroj et al., 1996, Newbold et al., 1997, 
Rogerson et al., 1999, Heddini et al., 2001, Chilongola et al., 2009, 
Ochola et al., 2011, Almelli et al., 2014). There are variations in the 
outcomes of these studies (Craig et al., 2012b). However, there is a need 
for multi-expert decision to standardise a model for adhesion assay (cells 
of choice and system) to ensure a comprehensive usage of the ongoing 
research to study adhesion phenotypes. It is thought that the need to 
implicate the flow adhesion system using endothelial cells may well 
bridge the gaps between the roles of different adhesion receptors. 
Particularly, a valid model is, now, available to investigate the rosetting 
phenotypes using flow assays. Recently, it has been shown that a dual 
binding phenotype occurred on ECs with rosetting for the same isolate 
(Adams et al., 2014). 
However, using ECs in field studies with fresh patient isolates is quite 
difficult (Janet Storm personal communication). However, it is important 
to use ECs at least to avoid the major disadvantage of protein adhesion 
study that focus on individual receptors. It is now apparent that different 
receptors mediate different functions such as static and rolling adhesions 
by CD36 and ICAM-1 respectively, which may work synergistically 
(Chakravorty and Craig, 2005, Rowe et al., 2009). Recently seven 
extracellular domains from IT4var19, a HBMEC selected isolate, bound 
to multiple ECs and most domains bound almost equally to all endothelial 
cell types. However, individual domains have shown differences in the 
level of binding to specific cell types (Avril et al., 2013).  
In conclusion, despite the differences observed between HUVEC and 
HBMEC in a recent report (Ye et al., 2014), HUVEC was shown to be a 
reliable model for ICAM-1 adhesion phenotypes that occur on HBMEC.  
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4.1: UpsC PfEMP-1 analysis: 
4.1.1 Introduction: 
Malaria successful transmission continues in the presence of human 
hosts as carriers, vectors and appropriate environment. WHO reported 
198 million total malaria cases in 2012 (uncertainty range: 124–
283 million) and the vast majority of cases were UM. Ineffective case 
management might lead to the development into SM, contributing to the 
morbidity and mortality of the disease. Some efforts targeting malaria 
transmission have been successful (WHO, 2013). However, 
asymptomatic carriers render malaria transmission control problematic by 
providing vital reservoirs of parasites for mosquitoes. The ongoing host 
reservoirs remain a major obstacle for control programs in endemic 
countries due to the sequestered parasites in humans avoiding immune 
responses and facilitating transmission. This sequestration is mediated 
by variable PfEMP1 members encoded by var genes. 
It has been mentioned before that in spite of their great diversity, most 
var genes can be classified based on the upstream sequence (ups), 
chromosomal location and direction of transcription into three major 
groups (ups A, B and C) and two intermediate groups (B/A and B/C). 
UpsA and upsB genes are subtelomeric genes that are oriented tail to 
tail, whereas ups C genes are found in the centre of the chromosomes 
and are oriented head to tail in a tandem repeat manner (Kraemer and 
Smith, 2003, Lavstsen et al., 2003). Recent data have suggested strong 
associations between upsA PfEMP1 and SM (Jensen et al., 2004, Avril et 
al., 2012, Bengtsson et al., 2013, Lavstsen et al., 2012, Turner et al., 
2013). In contrast, upsC and some of upsB were associated with UM 
(Jensen et al., 2004, Kyriacou et al., 2006, Rottmann et al., 2006). 
Evidence about these associations comes mainly from var genes 
expression from infected individuals studied by qRT-PCR (Mugasa et al., 
2012, Kyriacou et al., 2006, Rottmann et al., 2006). Also, data acquired 
from the reactivity of immune sera with laboratory isolates in vitro, such 
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as selection of 3D7 parasites on pooled plasma from semi-immune 
children from Ghana and Tanzania (Jensen et al., 2004). The result 
showed that up-regulated var genes were among the group A and group 
B/A. In contrast, group C members were mostly down-regulated 
suggesting their association with mild malaria. However, the adhesion of 
IEs with identified PfEMP1 variants that are potentially linked with UM 
has been rarely addressed (Janes et al., 2011). The first part of the 
current chapter will be more on PfEMP1 variants that are favour the 
establishment of chronic malaria, a concept that is often ignored in the 
usual focus on SM.  
The establishment of chronic malaria is linked with a shift in PfEMP1 
expression and it is thought that this trait of PfEMP1 is towards variants 
that are less adapted for optimal adhesion (that cause serious effects 
upon the host) (Buckee and Recker, 2012). However, some studies have 
shown that UM is more associated with CD36-adhesion phenotype 
(Ochola et al., 2011, Newbold et al., 1997). The linkage between human 
receptor usage and PfEMP1 expression in mild disease has been 
controversial. For example, a very recent report found that binding to 
CD36 is associated with CM more than ICAM-1 (Almelli et al., 2014). 
However, there are some concerns about the adhesion method used in 
this study due to the concentrations of used proteins and time of 
incubation.  
The molecular mechanisms of the adhesion of isolates found associated 
with UM cases in the cellular context should be investigated. Studying 
the adhesion phenotypes of upsC PfEMP1 proteins will provide more 
information to understand their role in causing chronic infections. It was 
hoped to broaden the vision about these essential members particularly 
as being important within the malaria eradication/ elimination programs. 
The project has many challenges to find a reliable conclusion based on 
available data. Nevertheless, current data confirms the diversity of var 
genes that can be implicated with adhesion phenotypes. In other words, 
there is no distinct adhesion phenotype that can be found from the limited 
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number of isolates examined in this study. For example, all upsC isolates 
of IT4 examined here bound to CD36, and one isolate bound to ICAM-1. 
In contrast, HB3 isolates did not bind either CD36 or ICAM-1.  
The aim of the current chapter is characterisation of the binding 
phenotypes of IEs with different PfEMP1 variants from genetically distinct 
parasites to improve our understanding of their association with clinical 
data from field studies. 
Part I:  
i- Assess upsC isolates’ abilities to bind CD36 and ICAM-1 under 
static and flow conditions. 
ii- Characterise upsC isolates binding phenotypes on HDMEC, 
HUVEC and HBMEC under flow conditions.  
Part II: 
i- Collect the adhesion data from flow assays of IEs isolates with 
known PfEMP1 domain compositions and analyse their 
adhesion phenotypes based on the form of PfEMP1 
expressed.  
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4.1.2 Methods:  
4.1.2.1 Parasite culture:  
All isolates were grown as described in general methods. A table of upsC 
isolates describing their alias, their var gene ID and the literature they 
were used in, is provided below (Table 4.1.1). The synchronisation was 
performed using sorbitol and Plasmion.   
Alias ID The source and var 
expression 
confirmation 
3G8 IT4var01 (Janes et al., 2011) 
4E12 IT4var37 
P5C2 IT4var43/66 
BA06 HB3var35 (Noble et al., 2013) 
BH08 HB3var29 
CH05 HB3var31 
DF06 HB3var30 
Table 4.1.1: UpsC isolates from IT4 and HB3 parasites. The table presents the 
alias of the parasites from their original sources and their ID which is used in the 
text of the current thesis. 
 
4.1.2.2 Selection for knobby IE (Plasmion flotation):  
Described in the general methods.   
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4.1.2.3 Adhesion assays:  
Static and flow protein adhesion assays were used to assess the binding 
of IE to CD36 and ICAM-1. Also, flow assays on endothelial cells were 
performed using HDMEC and HUVEC. The binding to CD36 and ICAM-1 
on ECs was inhibited by 5 µg/ml of anti-CD36 IVC7 and 5 µg/ml anti-
ICAM-1 15.2 mAbs respectively. All these procedures are explained in 
the general methods section, including culturing ECs.   
4.1.2.4 Adult Hyperimmune sera (HIS) reactivity: 
Described in the general methods.   
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4.1.3 Results:  
4.1.3.1 Characterisation of upsC isolates binding to CD36: 
All IT4 isolates bound to CD36 with different avidities. The binding of 
IT4var37 was about 1500 IE/mm2, being the highest isolate bound to 
CD36. On the other hand, the binding of all of the HB3 isolates was 
nearly at the level of the negative background (PBS which usually gives 
few IEs after several washes (1-5 IE) (Table 4.1.2 and Figure 4.1.1). The 
same pattern was also observed under flow conditions. IT4var37 bound 
to CD36 with higher avidity than other IT4 isolates (Table 4.1.3 and 
Figure 4.1.2). 
 
A) Static adhesion of upsC isolates to CD36: 
Parasites 
mean IE 
binding/mm2 
N SE 
IT4var01 1257 3 42 
IT4var37 1497 3 303 
IT4var43/66 986 3 139 
HB3var29 17 2 1 
HB3va30 8 2 1 
HB3var31 13 2 1 
HB3var35 8 2 1 
Table 4.1.2: Static adhesion of IE with upsC isolates to CD36. The table 
presents the means of IE binding/mm2, the number of experiments and the SE. 
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B) Flow adhesion of upsC isolates to CD36: 
Parasite mean IE 
binding/mm2 
N SE 
IT4var01 370 3 59 
IT4var37 417 3 51 
IT4var43/66 330 3 54 
HB3var29 2 2 1 
HB3var30 1 2 1 
HB3var31 1 2 1 
HB3var35 1 2 1 
Table 4.1.3: Flow adhesion of IE with upsC isolates to CD36. The table 
presents the means of IE binding/mm2, the number of experiments and the SE. 
 
 
Figure 4.1.1: Static adhesion assay, the binding of upsC isolates to CD36. 
CD36 was used at 50 μg/ml. The figure shows the mean of binding (IE/mm2) 
and the bars represents SE (Numbers are given in table 4.1.2). 
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Figure 4.1.2: Flow adhesion assay, the binding of upsC isolates to CD36. 50 
μg/ml of CD36 was used. The figure shows the mean of binding (IE/mm2) and 
the bars represents SE (Numbers are given in table 4.1.3) 
4.1.3.2 Characterisation of upsC isolates binding to ICAM-1: 
Among all isolates, only IT4var01 bound with high avidity to ICAM-1, the 
binding was 1713 IE/mm2. The binding seen with IT4var43/66 to ICAM-1 
is thought due to the presence of IT4var31 expressing parasites from the 
origin of the isolate (Janes et al., 2011). Whereas IT4var37 was the 
highest CD36 binder, it and all the HB3 isolates did not bind to ICAM-1 at 
all under static and flow conditions (table 4.1.3 and figures 4.1.3 and 
4.1.4). 
A) Static adhesion of upsC isolates to ICAM-1: 
Parasites mean  IE 
binding/mm2 
N SE 
IT4var01 1713 3 331 
IT4var43/66 186 3 108 
Table 4.1.4: Static adhesion of IE with upsC isolates to ICAM-1. The table 
presents the means of IE binding/mm2, the number of experiments and the SE. 
Data of other isolates are not shown because they showed no detectable 
binding to ICAM-1.   
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B) Flow adhesion of upsC isolates on ICAM-1: 
Parasite mean IE 
binding/mm2 
N SE 
IT4var01 523 2 84 
IT4var43/66 16 2 3 
Table 4.1.5: Flow adhesion of IE with upsC isolates to ICAM-1. The table 
presents the means of IE binding/mm2, the number of experiments and the SE. 
Data of other isolates are not shown because they showed no detectable 
binding to ICAM-1.   
 
 
Figure 4.1.3: Static adhesion assay of upsC isolates to ICAM-1. ICAM-1 was 
used at 50 μg/ml. The figure shows the mean of binding (IE/mm2) and the bars 
represents SE (n can be found in Table 4.1.4). 
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Figure 4.1.4: Flow adhesion assay of upsC isolates to ICAM-1. ICAM-1 was 
used at 50 μg/ml. The figure shows the mean of binding (IE/mm2) and the bars 
represents SE (n can be found in Table 4.1.5). 
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4.1.3.3 Characterisation of upsC isolates on HDMEC under flow 
conditions: 
The binding of upsC isolates to HDMEC was similar to the pattern of the 
binding to purified CD36. IT4var37, which bound to CD36 but did not bind 
to ICAM-1, was the highest HDMEC binder, even higher than isolates 
that bound to both CD36 and ICAM-1 such as IT4var01 and other IT-
ICAM-1 isolates. In contrast, HB3 isolates were comparable to the 
binding of negative background (Table 4.1.4 and Figures 4.1.5). There 
was no difference for HB3 isolates when CD36 and ICAM-1 were blocked 
using anti-CD36 and anti-ICAM-1 mAbs. On the other hand, IT4var37 
was almost totally inhibited by anti-CD36 mAb and no effect was 
observed upon ICAM-1 blocking, supporting the adhesion data. The 
effect of CD36 blocking was about 90% for all IT4 isolates as found 
before (previous chapters).  
Table 4.1.6: the binding of IE with upsC isolates to HDMEC. The table presents 
the averages of IE/mm2 and the number of experiments and the SE. 
 
Parasites mean IE 
binding/mm2 
N SE 
IT4var01 464 3 98 
IT4var37 628 2 104 
IT4var43/66 152 2 34 
HB3var29 8 2 1 
HB3var30 11 2 1 
HB3var31 8 2 1 
HB3var35 6 2 1 
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A) Flow adhesion of upsC isolates to HDMEC: 
 
Figure 4.1.5: Flow adhesion assay, the binding of upsC isolates to HDMEC. The 
figure shows the mean of binding (IE/mm2) and the bars represents SE (n can 
be found in Table 4.1.6). 
 
B) Inhibition of upsC isolates on HDMEC using anti-CD36 and anti-
ICAM-1 mAbs under flow condition:  
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Parasite mean 
IE/mm2 
N SE 
 IT4var01 57 3 8 IT4var01 236 3 37 
IT4var37 41 2 15 IT4var37 647 2 136 
IT4var43/66 19 2 7 IT4var43/66 75 2 10 
Table 4.1.7: The binding of IE with upsC isolates to HDMEC in the presence of 
5 µg/ml IV-7   (anti-CD36 mAb) (A) and in the presence of 5 µg/ml 15.2 (anti-
ICAM-1 mAb) (B). The Table presents the means of bound IE/mm2 and the 
number of experiments and the SE.  
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Figure 4.1.6: HDMEC CD36 inhibition of IT4 upsC isolates in the presence of 5 
µg/ml IV-C7 (anti-CD36 mAb). The graph presents the % of binding compared 
to the binding on HDMEC with no mAb effect. (n can be found in Table 4.1.7)  
 
 
 
Figure 4.1.7: HDMEC ICAM-1 inhibition of IT4 upsC isolates in the presence of 
5 µg/ml 15.2 (anti-ICAM-1 mAb). The graph presents the % of binding 
compared to the binding on HDMEC with no mAb effect. (n can be found in 
Table 4.1.7)  
0
10
20
30
40
50
60
70
80
90
100
IT4var01 IT4var37 IT4var43/66
%
 o
f 
b
in
d
in
g
  
IT4 upsC  isolates  
0
20
40
60
80
100
120
IT4var01 IT4var37 IT4var43/66
%
 o
f 
b
in
d
in
g
  
IT4 upsC  isolates  
131 
 
4.1.3.4 Characterisation of upsC IT4 and HB3 PfEMP-1 isolates on 
HUVEC under flow conditions: 
The binding to HUVEC is similar to the ICAM-1 binding pattern. Only 
IT4var01 bound to HUVEC with high avidity confirming the results of 
adhesion protein static and flow assays. HB3 isolates did not bind to 
HUVEC and HBMEC, similar to what was observed on HDMEC. 
IT4var01 binding was reduced by anti-ICAM-1 mAb, as shown in chapter 
three (Table 4.1.8 and Figure 4.1.8).   
 
Table 4.1.8: the binding of IE with upsC isolates to HUVEC. The table presents 
the means of IE binding/mm2 and the number of experiments and the SE. 
 
 
 
 
 
 
 
Parasites mean IE 
binding/mm2 
N SE 
IT4var01 377 3 79 
IT4var37 8 3 3 
IT4var43/66 19 3 5 
HB3var29 1 2 1 
HB3var30 3 2 1 
HB3var31 1 2 1 
HB3var35 2 2 1 
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Figure 4.1.8: Flow adhesion assay, the binding of upsC isolates to HUVEC. The 
figure shows the mean of binding (IE/mm2) and the bars represents SE 
(Numbers are given in table 4.1.6). 
 
 
 
4.1.3.5: Cross reactivity of UpsC HB3 isolates with HIS:  
The IT4var14 control isolate showed clear labelling with BC6 mAb that 
recognises IT4var14 specifically (Smith et al., 1995). The optimal 
functional concentration of HIS was 30 mg/ml for IT4var14 (figure 4.1.9). 
Thus, this concentration was used to examine the reactivity of HB3 
isolates that were suspected to export functional PfEMP1 on their IE 
surfaces. Figure 4.1.10 demonstrates that about 40% of all HB3 upsC 
isolate populations were positive with HIS compared to human sera used 
for parasite culture obtained from individuals who have not previously 
been exposed to malaria. Also, the corrected MFI presented is at a very 
similar level after correction with the normal human sera (figure 4.1.11).   
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Figure 4.1.9: FACS analysis of IEs IT4var14. IEs were labelled with A) BC6 and 
B) 30 mg/ml HIS both highlighted in green. Also, human sera used for culture 
was used as a control (red lines) and anti-IgG isotype control (grey lines).    
 
 
Figure 4.1.10: FACS analysis of IEs with UpsC HB3 isolates; A) HB3var29 B) 
HB3var30, C) HB3var31 and D) HB3var35. IEs were labelled with human sera 
used for culture as a negative control (orange highlighted) and 30 mg/ml HIS 
(violet highlighted). The percentage of reactive IEs with HIS is shown by APC+ 
population of each isolate.  
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Figure 4.1.11: FACS analysis of IEs with UpsC HB3 isolates. The graph shows 
the corrected mean fluorescence (MFI) intensity for the four upsC HB3 isolates. 
4.1.4 Discussion:  
One of the fundamental questions about malaria pathogenesis is how 
chronic infections are maintained despite limited var gene repertoire in a 
single parasite genome (50-60 var genes). The associations between 
particular gene expression, malaria outcomes, ups-classifications, and 
host factors are not fully understood. However, the correlation of specific 
P. falciparum adhesion phenotypes with malaria outcomes has been 
partially improved in the last decade. Studies have found the expression 
of group C PfEMP1 variants as a characteristic of asymptomatic or 
chronic disease. This association is usually based on either the reactivity 
of semi-immune individuals or the relative var expression of isolated 
parasites from infected individuals (Jensen et al., 2004, Kyriacou et al., 
2006, Rottmann et al., 2006) but no adhesion data on primary ECs have 
been acquired from the field.  
One study has assessed the binding of some IT4 variants including three 
group C variants (Janes et al., 2011). However, Janes and colleagues 
used quite different type of cells based adhesion assays, using a number 
of transfected CHO cell lines each of which expressed different human 
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receptors including CD36, ICAM-1, E-selectin and VCAM-1. It should 
however be noted that they did use a similar protein-based adhesion 
assay to what was used in this study. We aimed in this study to assess 
the binding phenotypes of some of the upsC variants that were examined 
in the Janes et al. study using primary endothelial cells as well as 
investigating the binding to the commonly used human receptors CD36 
and ICAM-1. To be more representative, isolates from two distinct 
genotypes IT4 and HB3 were used in this study.  
The binding of all upsC isolates to ICAM-1 was not expected from both 
genotypes due to their lack of DBLβ-ICAM-1 binding domains, except 
IT4var01. The binding of IT4var01 to ICAM-1 was discussed in the 
previous chapter as it is among IT4-ICAM-1 isolates. The thought about 
ICAM-1 role in only mild malaria based on the finding that upsC isolates 
can bind to ICAM-1 can be argued. IT4var01 is the only one of the DBLβ 
domain-containing PfEMP1s (total 23) from the IT4 parasite isolates that 
are upsC and bind ICAM-1. It was previously reported that upsC variants 
can be found in all disease manifestations despite their relatively low 
expression (Rottmann et al., 2006). It was also shown that a solo domain 
sub-classification cannot be easily described as a predictor for ICAM-1 
binding. Likewise, the ups classification also cannot exclude the binding 
of ICAM-1 to one ups group. Having a single PfEMP1 in the whole 
genome which is upsC and binds to ICAM-1 may not be enough reason 
to simply conclude that ICAM-1 is more likely to be associated with mild 
malaria rather than SM. In fact, the evidence that supports the role of 
ICAM-1 in mediating SM is stronger than its association with UM, even 
though in some reports the SM link did not reach significance. The 
available data suggest that upsC PfEMP1s seem to be under less 
selection to bind ICAM-1, at least in IT4 and HB3 parasites. 
IT4 isolates from both upsB and upsC were CD36 binders. This is 
consistent with previous findings that ups B and C PfEMP1 variants are 
more associated with CD36 (Robinson et al., 2003, Kraemer and Smith, 
2006, Cabrera et al., 2014). The role of CD36 in malaria pathogenesis is 
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not clear. The association between CD36 and mild malaria was mainly 
drawn by the finding that the majority of PfEMP1 variants encode CIDR1 
domains which provide the binding motif for CD36 in the head structure 
of PfEMP1 (Robinson et al., 2003, Baruch et al., 1997, Smith et al., 
1998). Also, several reports showed that CD36 adhesion phenotypes in 
the field are associated with uncomplicated cases and not SM (Newbold 
et al., 1997, Ochola et al., 2011).  
However, binding to CD36 cannot be generalised to all upsC PfEMP1. 
This is demonstrated by HB3 isolates and their incapacity to bind to 
CD36 and HDMEC and other ECs. Consistently with this study Xiao et al. 
(1996) reported very low binding of HB3 parasites to a variety of ECs 
including HMEC-1, HBEC-5i, HUVEC and C32 despite selecting six 
times to obtain higher binding, and even though after repeated selections 
CD36 and ICAM-1 inhibition did not affect the binding, considering that 
CD36 and ICAM-1 were expressed by C32 and HUVEC respectively. 
Moreover, Rowe’s lab team published (2012) a selection protocol to 
enhance the binding of parasites to HBEC-5i (Claessens and Rowe, 
2012). They used HB3 parasite and the initial binding was very low on 
different ECs including HBEC-5i and HDMEC under a static conditions. 
This last point is important as static conditions generally show higher 
binding than in flow condition, which was used in this study. Note, the 
next part of this thesis compares binding data based on PfEMP1 length 
and will show results of upsA and upsB binding to ECs. 
The lack of ability of HB3 isolates to bind ECs raised the question of 
whether these isolates were knobby or not. Therefore, the selection of 
knobby populations was confirmed using Plasmion, which was routinely 
practiced during this study. The plasmion flotation used to enrich the 
knobby parasites was easy and straightforward. It was clear under the 
microscope that there were high levels of parasitaemia after plasmion 
enrichments. The results would have been more confirmed testing the 
transcription of kahrp+ by RT-PCR. However, there were some parasites 
transcribed kahrp but did not float in gelatin (Janes et al., 2011). 
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It is not easy to claim that PfEMP1 has been successfully exported and 
presented in structural confirmation in the absence of a universal marker. 
The alternative avenue was to test the HB3 isolates’ cross reactivity with 
adult hyper immune sera (HIS) on FACS, even though it is known that 
upsC are highly diverse. However, all the isolates were cross reactive 
with HIS which could suggest that PfEMP1 is expressed and reactive 
considering that it is the a significant immunodominant molecule on the 
surface of IEs. However, this is not enough as there are some molecules 
are immunogenic other than PfEMP1. Previous studies have used flow 
cytometry to show that PfEMP1 is the prime target of immune antibody 
reactivity (Chan et al., 2012). Evidence of the involvement of PfEMP1 
was mainly derived from the recognition of the IEs surface by HIS was 
abolished after trypsin treatment. However, there are other antigens on 
the surface of IEs including the RIFINS and BAND 3 are known to be 
sensitive to trypsin (Williams and Newbold, 2003).  
The lack of binding to ECs or at least minimal binding capacities does not 
exclude the adaption to bind elsewhere to ensure chronic infections. It is 
possible that upsC parasites are adapted to not induce high binding that 
might harm the host. However, the mechanism of this is still unknown. It 
might be seen through the tolerance of group C expressing parasites for 
several environmental stress conditions (Rosenberg et al., 2009). 
The achievement of chronic infection is acquired by immune evasion 
through antigenic variation that allows parasites to switch between 
PfEMP1 variants displayed on IEs by differential expression of around 60 
members per parasite genome. In the chronic infections, parasites must 
avoid intensive inflammatory response induction that can harm the hosts. 
However, they must be sequestered as mature asexual parasites are not 
found in the circulation and to avoid splenic destruction. The binding of 
HB3 isolates suggests that some parasite variants may not require 
attachment at higher quantities to the ECs, potentially increasing the risk 
of affecting the hosts. It is known that the parasitemia is higher in the 
acute malaria than the chronic. This is obvious particularly with the high 
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parasitemia that often occurs in SM, which is theoretically resulting from 
high sequestered parasites. The low sequestration level might best 
represented by following the typical parasitemia wave that was observed 
in a natural infected child. Dondorp et al. (2005) was able to identify a 
method to calculate the biomass of sequestered parasites. It was given 
that the plasma concentration of P. falciparum histidine-rich protein 2 
(PfHRP2) is correlated with sequestered-parasite biomass. The 
sequestered-parasite biomass in Thai patients suffering from SM was 10-
fold higher than those with UM. This supports the low adhesion levels of 
isolates representing chronic infections (Dondorp et al., 2005).  
HB3 and IT4 were isolated from Central America and Southeast Asia 
respectively. Their var gene repertoires have been compared with the 
reference P. falciparum genome sequence, 3D7, which represents 
African isolates.  The parasite genomes of IT4, HB3 and 3D7 have nearly 
the same proportions of var genes in each var group regardless of their 
distinct var repertoire origins (Kyes et al., 2007). IT4 isolates are 
commonly used for adhesion assays in vitro. They, overall, showed 
relatively comparable binding to CD36 and consequently to HDMEC. 
This is clearly demonstrated in this study and many other studies using 
different methods of adhesion assays. One reason for their extensive use 
is that they maintain the asexual life cycle in vitro and do not transform to 
gametocytes easily, unlike other isolates such as 3D7 and HB3.  
Probably, as mentioned above, one of the differences between HB3 and 
IT4 parasites is the ability of HB3 parasites to transform to gametocytes 
easily. Should HB3 upsC variants have a role in reducing the binding in 
the hosts or binding to other tissues, such as adipose tissue, to induce 
the generation of sexual stages to ensure the transmission of the 
parasites to vectors? If yes, how it can be achieved? It is suggested that 
parasites may have evolved to control their biomass inside hosts to 
switch to gametocytes  (Cunnington et al., 2013). This is supported by 
recent findings about exosome-like vesicles (EVs) which mediate 
communication between IEs to deliver genetic materials that are 
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proposed to affect behavioural changes such as the requirement of 
gametocytes production. However, the role of EVs in controlling parasites 
biomass is still unexplored. 
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4.2 An analysis of the binding phenotype of 
PfEMP1 variants based on their length.  
4.2.1 Introduction:  
PfEMP1 is a major pathogenic virulence factor on the surface of IEs, 
where it mediates the binding to human tissues including the 
endothelium. Researchers remain uncertain about predicting the ability of 
PfEMP1 binding to ECs based on sequence features alone. Many 
studies have attempted to categorise adhesion phenotypes based on 
variable PfEMP1 features. The most common is the ups classification, as 
found in the previous part of the current chapter. Also, sub-classifications 
of single binding domains have been used such for DBLβ and ICAM-1. 
However, it has been shown that sub-classifications of single domains 
are not exclusively proper predictors for IE binding on ECs. Similarly, not 
all upsC share a common adhesion phenotype to use for binding 
predictions.  
However, another recent theoretical classification of PfEMP1 repertoires 
has divided them into long and conserved (mainly Ups group A) and 
short and diverse (mainly Ups group B and C) (Buckee and Recker, 
2012). This classification was suggested after a significant, non-random 
link between the number of domains composing var genes and the 
extent of their sequence conservation. Most of the PfEMP1s have a 
tandem DBL-CIDR domain at the N-terminus, known as the semi-
conserved head structure. Short PfEMP1s have an extra DBL and CIDR 
to form 4 domain extracellular units. In contrast, long PfEMP1s have 
some more domains. Understanding the var gene diversity and 
classifications can be significant for designing vaccine and 
chemotherapies to target malaria outcomes. The aim of this part of the 
thesis is to collect the adhesion data from flow assays of parasite 
isolates with known PfEMP1 domain compositions and analyse their 
adhesion phenotypes based on this composition.  
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4.2.2 Methods:  
Flow adhesion assays have been carried out as described before. The 
isolates were grouped into long and short PfEMP1 variants based on 
their compositions found in the vardom database or their original 
references (Figure 4.2.1). Three extra isolates from HB3 were included; 
HB3var05, long and upsA, and HB3var13 and HB3var27, both short and 
upsB.  
 
 
 
Figure 4.2.1: Schematic representation of isolates from IT4 and HB3. It 
includes their locations, cen: central and sub: subtelomeric. It also shows 
the ups classification and more importantly the number of DBL and CIDR 
domains that compose the PfEMP1. The aqua (blue) colour is used for 
large (long) domains for all the figures in this chapter, and orange is used 
for short (small). 
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4.2.3 Results 
The adhesion data of all isolates to CD36 (Figure 4.2.2), ICAM-1 (Figure 
4.2.3) HDMEC (Figure 4.2.4), HUVEC (Figure 4.2.5) shows the pattern of 
binding of IEs with PfEMP1 variable structures. The aqua colour is used 
for large (long) domains for all the figures in this chapter, and orange is 
used for short.   
4.2.3.1 The binding of short PfEMP1: 
All HB3 isolates used in this study did not bind to either CD36 nor to 
ICAM-1 on both static and flow adhesion assays. A minor exception was 
HB3var13 (short and upsB) which bound transiently to CD36 under flow 
conditions, however almost all bound IE were removed during the 
washing step. The binding of this isolate on HDMEC was extremely low, 
and this was similar to HUVEC and HBMEC that do not express CD36. 
Also, blocking CD36 on HDMEC did not alter the binding. The binding of 
IE expressing other short HB3 proteins to ECs was negligible. There 
were two short PfEMP1s from the IT4 lineage; IT4var31 and IT4var37. 
Generally, all IT4 isolates used in this study bound to CD36. Interestingly, 
the strongest CD36 binder, IT4var37, as previously shown in the 
previous section, did not bind to ICAM-1 in both static and flow adhesion 
assays. It did bind to HDMEC but not CD36 negative ECs; this is 
basically because this PfEMP1 does not have a DBLβ domain. In 
contrast, the other short PfEMP1 from IT4 lineage was IT4var31, which 
has DBLβ3 that makes it able to bind to purified ICAM-1 as well as ICAM-
1 expressing ECs.   
4.2.3.2 The binding of long (large) PfEMP1: 
All long PfEMP1 from IT4 bound to different ECs with highly variable 
avidities. Among all the HB3 isolates used there was only HB3var05 that 
is long and upsA. HB3var05 did bind to all ECs used in this study under 
flow conditions, higher than other HB3 isolates. The binding was 
relatively similar on three ECs variants at about 100 IE/mm2. Moreover, 
the binding was not affected by anti-CD36 and anti-ICAM-1, supporting 
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the protein adhesion assays. In contrast, the binding of all IT4 IEs with 
long PfEMP1 on HDMEC was higher than IEs with HB3var05; IT4var14 
was lowest among them and it was nearly twice as high as HB3var05. 
 
Figure 4.2.2: Flow adhesion assay to CD36. The binding of IEs with long and 
short PfEMP1 isolates from IT4 and HB3 lineages.  
 
 
 
 
Figure 4.2.3: Flow adhesion assay to ICAM-1. The binding of IEs with long and 
short PfEMP1 isolates from IT4 and HB3 lineages.  
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Figure 4.2.4: Flow adhesion assay to HDMEC. The binding of IEs with long and 
short PfEMP1 isolates from IT4 and HB3 lineages.  
 
 
 
 
 
Figure 4.2.5: Flow adhesion assay to HUVEC. The binding of IEs with long and 
short PfEMP1 isolates from IT4 and HB3 lineages.  
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4.2.4 Discussion: 
The compositions of genomic repertoires of var genes are structurally 
organised. A major outcome of the analysis conducted by Buckee and 
Recker (2012) was that var genes can be divided into either ‘short and 
diverse’ or ‘long and conserved’. The adhesion data of isolates from 
these two different lineages were analysed to test the hypothesis that 
PfEMP1 length might be considered a major factor for IE adhesion. 
Isolates were grouped based on the number of DBL and CIDR domains 
composing PfEMP1. They were classified into either short PfEMP1 
containing only four domains or large PfEMP1 containing more than four 
domains.  
Overall, long PfEMP1 of both HB3 and IT4 can bind to all ECs examined 
in this study with variable avidities and different receptors usage. Also, 
IT4 isolates either short or long can bind ICAM-1 provided that they 
express ICAM-1-binding DBLβ domains. CD36 binding phenotype is 
associated with CIDRα2–6 sequence types and linked to ups B and C 
proteins. By contrast, CIDRα1, β, γ and δ are associated with upsA 
variants and do not show association with CD36 adhesion phenotype. 
The expression of CIDRα2–6 was in all IT4 isolates investigated in the 
current study. All IT4-ICAM-1 isolates either short or long bound to CD36, 
confirming earlier findings that CIDR-CD36 binding domains are found in 
both small and large PfEMP1 proteins and have nearly 40% sequence 
identity (Robinson et al., 2003, Janes et al., 2011). Also, the binding 
avidities were variable and, interestingly, the shortest had the higher 
avidity on both HDMEC and purified CD36. This goes in agreement with 
recent experiments tested the rolling velocities of a group of IT4 isolates 
to CD36 and to examine the effect of flow rate on adherent IEs cell 
shape. It was suggested that the binding of IT4 isolates to CD36 is 
selected for optimal binding regardless the size of PfEMP1 variants 
(Herricks et al., 2013).  
However, the situation is completely different regarding the HB3 isolates. 
All HB3 isolates seemed to lack, based on sequence, the components for 
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ICAM-1 binding and therefore their binding to ICAM-1 was not expected. 
Remarkably, the binding to CD36 was comparable with the negative 
background, except for one isolate that was able to bind transiently to 
CD36 but binding was quickly removed and could not be counted. This is 
perhaps due to the formation of bonds rate, Kon, and dissociation rate, 
Koff. It is thought that adhesion occurs based on the distance separation 
between the host receptors and IEs ligands. Usually, high binding results 
from high Kon and low Koff. Whereas, the transient binding could be due to 
that both parameters being high, allowing adhesion to occur but be 
quickly disassociated.  
In the previous chapter, it was concerned about the ability of HB3 to 
express PfEMP1 properly.  However, the major finding in this chapter is 
ups A HB3 isolate, HB3var05, bound to all ECs. These data at least 
provide some support that HB3 can express PfEMP1 to allow adhesion. 
Therefore, the lack of binding in the upsC isolates is unlikely to be due to 
non-expression of PfEMP1.  
HB3var05 bound to all ECs and was not blocked by anti-CD36 or by anti-
ICAM-1. The adhesion to ECs is mediated by numerous human 
receptors. It was very difficult to examine the particular receptor that was 
mediating the adhesion of this isolate using mAbs blocking assays, due 
to limited experimental time. Fortuitously, very recent data examined the 
association of DC5 type PfEMP1 with SM; it was shown that the 
adhesion by DC5 was mediated by PECAM-1 (CD31). Importantly, 
HB3var05 was categorised as a DC5 type PfEMP1 (Berger et al., 2013). 
This is in agreement with the current study that binding to ECs was not 
inhibited by anti-CD36 or by anti-ICAM-1.  
DC5 PfEMP1 expression was cross reactive with serum from SM 
patients. DC5 is composed of DBLγ12-DBLδ5-CIDRβ4-DBLβ9.  
However, it was shown that two recombinant proteins, DBLδ5-CIDRβ4, 
play a central role of DC5 for the cross reactivity. Nevertheless, the 
binding to PECAM-1 was not reduced by antibodies raised against these 
two domains, but rather it was inhibited by IgG against the whole DC5 
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domains (Berger et al., 2013). From these observations it was suggested 
that DC5 PfEMP1s seem to be compact. In other words, it means the 
domains of the molecules fold back on itself rather than being an 
extended molecule offering “beads on a string” structure where a single 
domain may behave independently of other domains. This is similar to 
VAR2CSA that mediate PAM. Although, the association of DC5 with SM 
is still at a very early stage, the suggestion of using compact structures 
may not support the hypothesis that the PfEMP1 length could facilitate an 
optimal adhesion; it could be the structure, the shape and the domains 
composition of the PfEMP1.   
The binding to ICAM-1 and HUVEC, that express ICAM-1 but not CD36, 
was relatively low for IT4var31, the only short PfEMP1 among IT4-ICAM-
1 isolates. Interestingly, it is also the only one that expresses DBLβ3 as 
described previously. It is difficult to conclude that the lower avidity is 
because of the architecture of the PfEMP1 on the IE or sub-classification 
of the DBL domain. It is more likely neither of the reasons because 
IT4var16, which is long and has DBLβ5, is a higher ICAM-1 binder on 
purified proteins but shows nearly to the same level of binding as 
IT4var31 on HUVEC and HBMEC. Thus, these controversial 
observations could be better interpreted if there was adhesion data for 
isolates that are long and express DBLβ3 from the same lineage. 
However, none of IT4-ICAM-1 isolates have DBLβ3 except IT4var31.  
Similar to CD36, different avidities were observed for binding to HDMEC 
regardless of the PfEMP1 length. Binding could be mainly due to CD36 
because CD36 inhibition reduced this by almost 90%. This could also be 
explained by co-operation occurring between CD36 and ICAM-1 on 
HDMEC, often referred to synergism but in this adhesion context 
probably better seen as cooperation until formal synergism can be 
demonstrated. 
The other notion is that IEs of IT4 isolates tend to bind with higher 
avidities to ECs, unlike IEs with HB3 isolates. It is unknown if their origin 
has an impact on this less adapted binding or not. The comparison 
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between isolates within and between different genotypes is rarely 
addressed. Ideally, this is should be carried by obtaining PfEMP1 
variants from different genotypes that are identical at least in their 
domains composition and compare their adhesion phenotypes to ECs. 
To the best of the knowledge, in vitro, there is no available comparison 
data that characterised the adhesion phenotypes of IEs with the PfEMP1 
expression profiles from distinct genotypes. It is difficult to identify the IEs 
expressing PfEMP1 that have the same domains composition. 
Especially, there are heterogeneous parasite populations in the clinical 
samples, but assuming that a single genetically distinct clone was 
isolated; IEs population usually express a single PfEMP1 variant. This is 
hampered by the difficulty to find a single genotype express different 
PfEMP1 variants in clinical samples and allows them to grow in vitro 
without altering their var gene expression to investigate their binding 
phenotypes. This lack of knowledge has precluded a conclusive link of 
the adhesion abilities based on the genotype of the parasites. 
Cytoadhesion in PAM is mediated by the interaction between VAR2CSA 
and CSA expressed on placental proteoglycans. Interestingly, CSA is 
expressed elsewhere in the microvasculature, but it does not mediate 
VAR2CSA binding of IEs. Very recent study has addressed the tropism 
of the placenta-VAR2CSA specific adhesion using synthetic membranes 
with variable CSA gaps intervals. It was found that VAR2CSA-CSA 
binding was highly dependent on the CSA distance at different 
hydrodynamic settings (Rieger et al., 2015). 
The ratio of short PfEMP1s in HB3 isolates is larger than IT4 isolates, 
albeit they both have a higher ratio of large PfEMP1 proteins compared 
to 3D7 (Kyes et al., 2007). The impact of expressing higher numbers of 
small PfEMP1 proteins in 3D7 and HB3 is not clear. One major difference 
between the three commonly used parasite lines, HB3, IT4 and 3D7 is 
the presence of conserved type 3 var gene in IT4 and 3D7 whereas it is 
absent in HB3. Type 3 var gene is also present in many other parasites 
that have been studied. This work did not attempt to correlate disease 
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outcomes with adhesion phenotypes and the length of PfEMP1. 
However, considering that most upsA are long and more linked to SM, 
whereas ups B and C contain the diverse and short PfEMP1s, VAR3 is 
an exceptional protein because it is highly conserved, very short and 
upsA. The expression of VAR3 has been associated with SM (Wang et 
al., 2012) but no adhesion data are available for this type of var gene. 
Also, no functional role has been identified for VAR3. Rask et al. (2010) 
showed VAR3 is not found in P. falciparum genome IGH, nor in P. 
reichenowi genome that infects chimpanzees. On the other hand, DC5 is 
dominantly present in P. falciparum genomes and even P. reichenowi, 
which could suggest a specialised evolutionary role of these var genes. It 
might be that P. falciparum first were not specialised to sequester like 
other older parasites. Then, the presence of DC5 which is found to bind 
to CD31 probably which I call “used to be the first target” on human 
tissues to highly abundance before stimulation did not mean to harm 
other hosts. Then, the existence of VAR3 in human parasites and not 
others may indicate that from this point the virulence increased, as seen 
in newer isolates. Especially, considering that VAR3 is associated with 
SM. There might a recombining role of VAR3 especially because it exists 
in up to three different copies in a single parasite genotype (Gardner et 
al., 2002).  
The limited available isolates representing the variety of classifications 
covered in this chapter is a weakness for drawing conclusions from these 
experiments. An extra nine isolates obtained from Copenhagen’s groups 
were obtained but none of them grew in our lab. However, the need of 
performing limited cloning dilution become apparent at the end of the 
study, and it is known that it costs really long time to have the required 
PfEMP1 type.  
In conclusion, it seems that is that long PfEMP1 adapted to bind more 
than the short, but this may merely be due to the lack of variety of DBLs 
for adhesion. Therefore, it is suggested that it is the domain constitution 
rather than size that seems to be important.  
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5. General discussion:  
Malaria is still a major concern for global health, infecting about 128 
million in 2013 (WHO, 2014). Malaria infections vary from asymptomatic, 
mild and in some cases the disease becomes severe and fatal. The vast 
majority of malaria cases are chronic infections which cause a major 
concern for malaria elimination programmes by facilitating continuous 
transmission by the mosquitoes. One of the major concerns in the field is 
the shifting of malaria burden from the typical susceptible populations of 
young children and pregnant women to older children and adults (Cotter 
et al., 2013).  
Malaria pathogenesis is developed during the asexual intraerythrocytic 
stage where P. falciparum modifies the host erythrocytes by exporting 
repertoires of parasite proteins on surface of IEs. PfEMP1 is one of these 
proteins that mediate different functions including sequestration. 
Cytoadhesion is one of the sequestration forms which can be lethal 
through the obstruction of blood flow, mediating inflammatory responses, 
and/ or causing endothelial activation and dysfunction. However, 
sequestration is also considered to be a strategy to ensure transmission 
and not to harm the hosts.  
Different adhesion phenotypes to ECs can be observed in vitro and can 
be quantified and categorised based on the avidities between ligands 
and receptors. However, some isolates did not bind to ECs, suggesting 
that the parasites might bind to other host cells during the absence of the 
vectors. It is known that another complexity of the life cycle is the 
‘suspended’ transmission in the time of the year with little or no rain, 
particularly in low transmission settings. The complexity of the parasite’s 
life cycle is demonstrated by the explosive numbers of mosquitos just in 
three days following the rains when an adult mosquito needs at least 
eight days to grow following their hatching (Sohn, 2014). Thus, it is not 
only complicated to understand the sudden appearance of the vector 
during dry seasons, but it may also be complicated to discover the impact 
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of the ‘hidden’ parasites during the absence of the vector in chronic 
infections. 
Chronic infections have been associated with the expression of upsC and 
some upsB PfEMP1 variants. Theoretically, most upsC or small 
PfEMP1s could bind to CD36. The association between CD36 and 
chronic malaria was mainly drawn from the finding that the majority of 
PfEMP1 variants encodes CIDR1 sub-domains that encode the binding 
motif of CD36 in the head structure of PfEMP1 (Robinson et al., 2003, 
Baruch et al., 1997, Smith et al., 1998). Also, several reports showed that 
CD36 adhesion phenotypes in the field are associated with 
uncomplicated cases and not in SM (Newbold et al., 1997, Ochola et al., 
2011). However, others have demonstrated a correlation between CD36 
adhesion with SM (Almelli et al., 2014). In this study, adhesion 
phenotypes of IEs with variable PfEMP1s have been characterised. 
However, seven PfEMP1 variants of each genotype IT4 and HB3 have 
shown extremely variable binding adhesion phenotypes based on the 
parasite’s genotype. It was not surprised to find all IT4 isolates can bind 
to CD36 and HDMEC. But, surprisingly, none of HB3 isolates in this 
study bound to CD36 or ICAM-1 regardless their variant type.  
Previous studies also observed that HB3 isolates bind to ECs with lower 
avidities prior to any selection effects, suggesting other sites for binding. 
The lack of binding to ECs, or at least minimal binding capacities, does 
not exclude the adaption to bind elsewhere that might induce the 
immunomodulation to ensure chronic infections. It is possible that there 
are some parasites that have adapted not to induce high binding that 
could harm the host. Interestingly, in the late 1990s, Urban and 
colleagues studied the binding of IEs to leukocytes. It was shown that 
binding to dendritic cells modulated the immune responses and delayed 
parasite killing. This was shown through the finding that some parasites 
able to produce intimate contact with leukocytes prevented their 
maturation. In contrast, there were some parasites not able to mediate 
leukocyte adhesion phenotypes that completed their maturation normally. 
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The authors reported some evidence that not all parasites bind to the 
endothelium in their hosts despite their ability to express variant antigens 
associated with this phenotype (Urban et al., 1999).  
It was concluded that not all upsC encoded PfEMP1 proteins can bind to 
CD36. It seems there are some other factors that play an unknown role 
to enhance the transmission of the parasite. Importantly, group C 
expressing parasites have been found to be more tolerant to several 
environmental stress conditions (Rosenberg et al., 2009). Recent work 
has suggested the epigenetic dysregulation of virulence gene expression 
in SM (Merrick et al., 2012). There might be some epigenetic regulation 
for chronic infection that controls the adhesion.  
On the other hand, several reports have associated SM with upsA 
PfEMP1 variants. The associations between particular gene expression, 
malaria outcomes, ups-classifications, and host factors are not fully 
understood. However, the correlation of specific P. falciparum adhesion 
phenotypes with malaria outcomes has been partially improved. Up to 
date, three common endothelial adhesion phenotypes have been 
observed in different outcomes. It seems there is an overlap between the 
human receptors usage and disease severity and PfEMP1 variants. 
Recent findings suggest that EPCR interactions with conserved PfEMP1 
are associated with SM more than CD36 and ICAM-1 (Figure 5.1). The 
figure illustrates that upsA variants and EPCR binders are more 
conserved to be associated with SM. However, the figure has implicated 
ICAM-1 adhesion phenotypes more towards SM but not excluded from 
mild malaria, making the upsB PfEMP1 variants shared between SM and 
mild malaria AM. In contrast, binding to CD36 is more linked to mild 
malaria but, also, is not excluded from SM. This might be a reasonable 
theoretical demonstration of the diversity of common endothelial 
adhesion receptors and different PfEMP1 variants and disease severity.  
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Figure 5.1: diversity of adhesion phenotypes and possibilities of involvements of 
all PfEMP1 groups and their associations with disease severity.  
 
ICAM-1 has received more attention during this study to improve our 
current understanding of PfEMP1::ICAM-1 interactions. ICAM-1 plays an 
essential role in capturing leukocytes in inflammatory responses. It also 
mediates binding to HRV and P. falciparum IEs. The binding site of 
ICAM-1 to PfEMP1 has been studied using alanine replacement 
mutagenesis and ICAM-1-specific mAbs.  The binding region on ICAM-1 
for P. falciparum IEs was revealed to involve the BED face of ICAM-1 
which is three β-strands of ICAM-1 named B, D, and E, including the DE 
loop (Tse et al., 2004). In the current study, recently lab-adapted patient 
isolates selected on ICAM-1 were used to expand the number of isolates 
compared to the original work. Essentially, similar findings have 
emphasized the original thoughts about the significant role of L42 as a 
conserved residue for all ICAM-1-binding genetically distinct isolates 
despite high variable use of different contact residues in the DE loop of 
ICAM-1 (Madkhali et al., 2014). Thus, therapeutic approaches might be 
encouraged targeting the conserved residues of ICAM-1 as an adjunctive 
treatment of malaria SM symptoms.  
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Despite the concern of malaria drug resistance, rapid and effective 
parasite-killing drugs are available, particularly in Africa. However, 
malaria still causes death among children with SM syndromes. Several 
strategies have been highlighted to enhance survival in malaria, one of 
which is targeting the binding of parasite to the endothelial cells (Miller et 
al., 2013). The key outcome of host-parasites interaction studies is the 
identification of vital targets mediating the interaction between parasite 
ligands and host receptors and using this for the development of 
inhibitors that block IE sequestration. Anti-adhesion therapeutics is an 
encouraging project in the discovery of novel treatments. For example, 
levamisole, an available drug, disturbs CD36 dephosphorylation, which 
causes an inhibition of CD36-dependent binding. Based on the studies of 
the DE loop of ICAM-1, 36 anti-cytoadhesion mimeotopes were identified 
in silico to provide novel effective therapeutics. One of these compounds 
is (+)-EGCG that showed a significant inhibition effect ranging from 40%–
80%, including by the new ICAM-1-binding isolates used in the present 
study (Patil et al., 2011). It is thought that variable contact residues on 
PfEMP-1 of different isolates cause the variation of inhibition by the 
inhibitor. The mode of action of (+)-EGCG is assumed to be its structural 
simulation of part of the ICAM 1 binding site for IE based on the L42 loop. 
More recently, the core of (+)-EGCG was successfully replaced with 
tetrahydroisoquinoline ring. This has enabled the production of a small 
library of compounds targeting the DE-loop of ICAM-1. Thus, a novel 
cytoadhesion inhibitor was identified as a hit compound to encourage the 
anti-adhesion development. It is thought that it is chemically accessible 
and designed to interfere with PfEMP1::ICAM-1 interaction (Gemma et 
al., 2014).  
The isolates used here have shown high diversity of ICAM-1 binding. On 
the PfEMP1 side, only some DBLβ domains have proved to bind to 
ICAM-1. Recent studies have explored ICAM-1-DBLβ binding using 
different approaches, including structure modelling and biophysical 
analysis, especially for IT4 isolates. These efforts have provided useful 
hints to understand PfEMP1::ICAM-1 interactions. However, none of the 
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previous studies characterised the binding of the used isolates on ICAM-
1 using standard binding assays including the binding to primary ECs. 
Thus, it was attempted to examine the binding of IT4-ICAM-1 isolates to 
understand the binding phenotypes and compare it with available 
biophysical data. Two major differences between this part and the 
previous one are IT4-ICAM-1 are genetically identical and expressing 
known PfEMP1 confirmed by q-RT-PCR. IT4-ICAM-1 isolates have also 
shown diverse contacts of ICAM-1 residues but have also confirmed the 
use of the conserved L42 residue in the DE loop. This diversity of ICAM-
1 usage has led to some varying thoughts about ICAM-1 involvement in 
SM, which is more often associated with upsA PfEMP1s, whereas many 
of the IT4 variants are upsB. Even where there are known groups of 
DBLβ variants showing ICAM-1 binding it would be difficult to target the 
DBLβ domains in these groups due to their extensive sequence diversity. 
This is seen particularly in approaches to discriminate ICAM-1 binding 
DBLβ domains from non-binding ones, which has only been partially 
successful. There are ICAM-1 binders among the group A PfEMP-1 that 
contain a definable DC4 cassette, but this work is still at a very 
preliminary stage and needs more investigation to see if it could provide 
a starting point for the development of a vaccine targeting CM by 
inhibiting IE sequestration via ICAM-1 in the brain. The variability in the 
binding characteristics between IE and ICAM-1 suggests that it could be 
a difficult problem to find a cross-blocking therapy, although the central 
role of the L42 residue and anti-DC4 blocking antibodies provide some 
support for this approach. 
Limitations and future studies:  
It should be admitted that doing cytoadhesion assays in vitro for large 
number of isolates is not simple nor convenient due to the variation of the 
results occurring due to technical issues largely inherent with the assay. 
For example, static assays need very careful handling during the 
incubation and washing, and if the performance during these shaking 
steps is not appropriate, the whole assay can be dismissed. Also, in the 
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cell-based adhesion assay, if the control isolates did not demonstrate the 
sort of expected binding level to ECs, then it would not be worth carrying 
out the assay on that day. This caused the necessity of repeating the 
assays several times to reduce the SE.  
Another issue is that the limited available isolates represent a restricted 
variety of classifications which could be a weakness for the whole picture 
drawn from the experiments. It was tried to grow an extra nine isolates 
obtained from Copenhagen groups, but none of them grew in our lab. 
The need for performing limited cloning dilution to extend the available 
clones become apparent at the end of the study, and it is known that it 
costs really a long time to have the required PfEMP1 types, and so could 
not be included here.  
In future, one of the aims is extending the number of isolates from HB3 
genotype. The target isolates are HB3var03 (among DC13 isolates), 
HB3var10, HB3var17, HB3var21 and HB3var48. All these are long form 
PfEMP1 variants representing different ups groups, which should give 
useful hints about the findings of this study about the adhesion 
capabilities of upsC HB3 isolates to different host receptors. Also, ICAM-
1 selection on beads looking for HB3-ICAM-1 isolates that either express 
DBLβ3 or DBLβ5 such as HB3var02 (among DC4 isolates) and 
HB3var34, which is a central upsC but has six domains including DBLβ5, 
could be carried out to maximise the chance of obtaining other interesting 
isolates.  
Also, evidence has demonstrated that blocking the activity of Plasmepsin 
V which is essential for PfEMP1 exportation reduced the display of 
PfEMP1 and consequently cytoadhesion. It could be speculated that 
some parasites that maintain chronic infection regulate their PfEMP1 
expression through regulation Plasmepsin V (Sleebs et al., 2014).  
Future work will investigate the expression of Plasmepsin V in upsC HB3 
isolates and compare it with different parasites. Others have proposed 
that PHIST domains interact with the ATS domain of PfEMP1 at a 
conserved epitope which might be disrupted and affecting the parasite 
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cytoadhesion (Mayer et al., 2012). These interactions in HB3 upsC 
isolates should be investigated to find a cause their impaired 
cytoadhesion.  
It would of interest to examine the binding of parasites to ECs that have 
been co-incubated with early ring stage IEs for 12 hours. Ideally, the 
adhesion assay should be carried using the same population that 
incubated with ECs. This would be followed by RNA extraction to study 
the effects that could occurr in response to the parasites stimulation even 
before adhesion of mature trophozoite stages. Then, flow adhesion 
assay will be conducted on the IEs stimulated ECs and non-infected 
erythrocyte stimulated ECs. 
Interestingly, A4 was associated with a signature that reflects isolates 
from SM cases (Ochola et al., 2011). In the current study, most of the 
lab-adpted patient isolates were low-avidity ICAM-1 binders similar to A4. 
It is thought that there might be other severity induction-cause rather than 
just the binding. For example, dual binding could occur between the 
leukocytes and the parasites stabilising a major complex in vivo. It is 
thought that a competition experiment between the binding of LFA-1 and 
parasites to ICAM-1 on ECs preliminary might discriminate between the 
high and low-avidity parasites.  
Another valuable addition to strengthening the part that compares the 
binding between HUVEC and HBMEC is including EPCR binders from 
IT4, 3D7 and HB3 isolates.  
Another future work should be carried out in the shared borders of the 
KSA and Yemen. The adhesion phenotypes from this region have not 
been studied previously. The study would look at the gene expression 
profiles, and the adhesion phenotypes on ECs, ideally under 
physiological flow conditions. It should also include markers of immune 
response and endothelial activation and dysfunction. Also, measuring 
PfHRP2 will be done to relate the adhesion phenotypes with the 
sequestered biomass in the infected people. Also, citizens in Jazan suffer 
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from several genetic disorders such as sickle cell anaemia and 
thalassemia; it would of interest to understand, whether individuals have 
developed a protection against the disease such as by acquiring EPCR 
polymorphisms. 
In brief, sequestration might not be the only mediator of the SM. There 
are many studies that have compared concentrations of inflammatory 
mediators and shown that they are higher in malaria infected individuals 
than non-infected people. Nowadays, vascular endothelium dysfunction 
is thought to play an essential role to SM pathogenesis. The activation of 
the ECs can be stimulated by the adhesion of IEs or the inflammatory 
response mediators. This may well disturb microvascular blood flow. 
Thus, sequestration, inflammation, and endothelial dysfunction are 
perhaps closely related; vascular endothelial activation may be caused 
by the sequestered IEs and inflammation whereas activation of vascular 
endothelium can increase IEs binding to human receptors (Storm and 
Craig, 2014). A comment was published in the Nature in December 2014 
that discussed the thought that microbiologists are paying attention to the 
microbes’ virulence factors variables and usually ignoring the host 
variables. It was stated that a microbe is not able to cause illness without 
a host response. Several potential consequences resulting from 
interactions between the microbe and the host cause sickness. It was 
thought that scientists should focus on the interactions between a 
microbe and a host rather than the pathogen alone (Casadevall and 
Pirofski, 2014). 
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Appendices:  
Appendix 1:  
Static adhesion of new ICAM-1 binding isolates to CD36: 
Parasites Mean IE 
binding/mm2 
SD 
ItG 1321.4 427.0 
A4 1153.0 379.7 
8146 1462.2 1020.3 
P069 2308.6 419.2 
PCM7 363.3 171.9 
6392 606.0 330.4 
8131 923.7 485.2 
BC12 326.2 133.0 
8206 NA NA 
BC31 5818.9 1837.7 
J1 916.8 96.1 
GL6 1321.4 427.0 
Static adhesion of IEs with selected ICAM-1 binding isolates to CD36. The table 
presents the means of IE binding/mm2 and the standard deviation. 
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